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ABSTRACT 
Travelling wave ion mobility spectrometry (TWIMS) in combination with ultra-high 
performance liquid chromatography (UHPLC) and mass spectrometry (MS) has been 
applied successfully for the untargeted, global metabolic profiling of biofluids such as 
mouse plasma and saliva. Methods based on UHPLC-MS alone and in combination with 
ion mobility spectrometry (UHPLC-IM-MS) have been developed and validated for the 
untargeted metabolite profiling of saliva, obtained non-invasively by passive drool. 
Three separate metabolic profiling studies have been carried out in conjunction with 
bioinformatics strategies to identify potential metabolomic biomarker ions that are 
associated with efficacy of rice bran in colorectal cancer, physiological stress and that 
have the potential for the diagnosis of asthma.  
The advantages offered by the utility of ion mobility in UHPLC-MS based metabolic 
profiling studies, including the increased analytical space, mass spectral clean-up of 
contaminants such as PEG post-UHPLC-IM-MS analysis, enhancement of the selectivity 
of targeted metabolites as well as the potential for the identification of metabolites by 
comparison of ion mobility drift times have been highlighted. 
Ten potential metabolic biomarker ions of asthma have been identified from the 
moderate asthmatics from untargeted metabolite profiling of saliva by UHPLC-MS. A 
predictive model based on partial least squares – discriminant analysis (PLS-DA) has 
been constructed using these ten discriminant ions, which demonstrates good predictive 
capability for moderate asthmatics and controls. 
Potential metabolic biomarker ions of physiological stress have been identified through 
untargeted metabolite profiling analysis of saliva samples collected before and after 
exercise by UHPLC-IM-MS. Valerolactam has been identified as a potential biomarker 
of physiological stress from saliva by comparison of retention time, ion mobility drift 
time and MS/MS spectra with a standard of δ-valerolactam. 
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GLOSSARY OF TERMS 
%RSD % Relative standard deviation 
ACN Acetonitrile 
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1.1 MASS SPECTROMETRY AND ION MOBILITY SPECTROMETRY 
The year was 1912 when J. J. Thomson conducted experiments that would mark the 
beginning of mass spectrometry. Since then the technique has seen numerous 
improvements culminating into modern day mass spectrometry. The coupling of mass 
spectrometry with electron and chemical ionisation enabled the analysis of volatile 
compounds. The discoveries of electrospray ionisation by Dole et al. and Fenn et al. and 
matrix-assisted laser desorption ionisation by Karas et al. in the 1980s paved the way for 
analysis of non-volatile high molecular mass compounds such as synthetic polymers, 
proteins, glycans, polynucleotides etc. by mass spectrometry(Dole 1968; Fenn et al. 
1989; Karasek 1974). The coupling of mass spectrometers with separation techniques 
such as gas chromatography, liquid chromatography (LC), capillary electrophoresis 
(CE), ion mobility spectrometry (IMS) and field asymmetric waveform ion mobility 
spectrometry (FAIMS) have opened up new avenues in the world of analytical chemistry 
allowing mass spectrometry to become an important and a very powerful tool. 
Along with developments in mass spectrometry, the past decade has seen the coming of 
age of ion mobility spectrometry (IMS). IMS was developed initially as a method for 
detecting and identifying volatile and semi-volatile compounds, principally for security 
and military applications. The early years of ion mobility spectrometry saw the 
development of stand-alone IMS devices employed for the detection of volatile 
explosives and chemical warfare agents. IMS is a gas phase separation technique, so the 
development of mass spectrometric ion sources such as electrospray (ESI) and matrix 
assisted laser desorption ionisation (MALDI) amongst others, has equally benefited both 
ion mobility and mass spectrometry. The use of these sources originally developed for 
MS, have enabled the analysis of not only volatile species but also condensed phase and 
solid state analytes by IMS. Recently, IMS has found use in the rapid analysis and 
characterisation of drugs, pharmaceuticals and small biomolecules etc. (Weston et al. 
2005; Borsdorf & Eiceman 2006). 
Ion mobility spectrometry when coupled with mass spectrometry becomes a powerful 
analytical tool for the analysis of complex samples and thus can explore avenues in the 
fields of proteomics, genomics and metabolomics (Kanu et al. 2008). 
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1.1.1 Principles of mass spectrometry 
Mass spectrometry is a technique which measures the mass of a molecule based on the 
motion of a charged particle i.e. an ion, in an electric or magnetic field. The gaseous ions 
formed from the molecules or atoms of a sample are separated in space and time and are 
detected according to their mass-to-charge ratio i.e. m/z. The output from a mass 
spectrometer is a mass spectrum, which constitutes of the number of ions of each 
detected mass. Typically, a mass spectrometer consists of a sample introduction system, 
ionisation source, mass analyser and a detector, which are maintained under vacuum. 
The vacuum allows the minimisation of ion-molecule reactions, scattering, collisions and 
neutralisation of the ions as these would interfere with the mass spectral analysis.  
 
Figure 1.1 Simplified schematic of components of a mass spectrometer. 
The sample is introduced into the ionisation region where gas phase ions are generated 
from the analyte. These ions are then accelerated towards the mass analyser by the use of 
ion optics, and electric and/or magnetic fields, which separate the ions, based on their 
m/z ratio. These separated ions strike the detector and produce an ion current, which is 
converted into a mass spectrum by the use of computers.  
There are several different types of sources and mass analysers available, which function 
on various principles, but carry out the same function of producing ions and separation of 
ions respectively. Ionisation sources and mass analysers used in the work described in 
this thesis are described in the following sections. 
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1.1.1.1 Ionisation techniques 
The samples introduced into a mass spectrometer are ionised in the ion source prior to 
analysis in the mass analyser. Ion source is the region where gas phase analyte ions are 
formed from the sample molecules. 
A variety of ionisation techniques have been developed for mass spectrometry including 
electron ionisation, chemical ionisation, matrix assisted laser desorption ionisation 
(MALDI), atmospheric pressure chemical ionisation (APCI), thermospray ionisation, 
electrospray ionisation (ESI) etc. (de Hoffmann & Stroobant 2007). The selection of 
ionisation technique depends on the sample and the sample matrix; however, the function 
of all these ionisation techniques is the same, which is facilitating the introduction of 
sample into a mass analyser in a suitable form. The research presented in this thesis used 
electrospray ionisation, which is discussed in Section 1.1.1.2. 
1.1.1.2 Electrospray ionisation (ESI) 
The concept of electrospray was introduced by Dole et al. in 1968 (Dole 1968). 
However, the true potential of ESI was realised only in the late 1980s when Fenn et 
al.(Fenn et al. 1989) developed ESI as a true interface for mass spectrometry. Fenn 
demonstrated that multiply charged ions were obtained from large biomolecules, such as 
proteins, directly from solution enabling their mass spectrometric analysis at low m/z. 
ESI also enabled the hyphenation of liquid chromatography (LC) with mass 
spectrometry.  
The development of electrospray has been significant for modern mass spectrometry as it 
enables the generation of singly and multiply charged ions from semi-volatile 
biologically significant species e.g. protein and metabolites.(Gaskell 1997) 
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Figure 1.2 Droplet formation in electrospray ionisation (Banerjee & Mazumdar 2012) 
The ESI interface Figure 1.2 functions at atmospheric pressure. Ions are produced in ESI 
by spraying a solution of the analyte through a capillary maintained under a strong 
electric field. A large potential difference of 3-6 kV is applied between the capillary and 
a counter electrode over a small distance to produce an electric field of the order of 10
6
 
V.m
-1
. The high electric field induces charge separation at the tip of the capillary. In the 
absence of a potential applied to the liquid, the droplets fall off under the influence of 
gravity and no electrospray is achieved. However, with the increase in potential, at the 
onset voltage, which is specific to the surface tension of the solvent being used, the shape 
of the liquid emanating from the capillary tip starts to deform giving rise to a Taylor 
cone (Rohner et al. 2004)  which produces the electrospray. On increasing the potential 
further, the accumulation of charge on the surface of the electrospray droplets coupled 
with evaporation of the solvent which is aided by a coaxial gas flow, causes the droplets 
to reduce in size until the Raleigh limit is reached (Rohner et al. 2004). At the Raleigh 
limit, the force of coulombic repulsion between the ions is equal to the surface tension of 
the solvent. The stability of these charged droplets is therefore governed by the 
competition between coulomb repulsion and surface tension.(Kebarle & Peschke 2000) 
As a result of this, the droplets break-up producing a number of smaller droplets. The 
coaxial gas flow also limits the dispersion of the spray in space resulting in more 
efficient transfer of ions to the mass spectrometer.  
Two main theories have been proposed which describe the probable mechanism of 
production of gas phase ions from charged droplets – the charge residue model (CRM) 
and the ion evaporation model (IEM) (Kebarle & Peschke 2000). The charge residue 
6 
 
model (CRM) proposes sufficient dispersion of solvent droplets into smaller droplets 
until there is only one ion left in the droplet. At this stage it is believed to undergo 
complete solvent evaporation to produce a gas phase ion.(Dole et al. 1968) The other 
model, the ion evaporation model (IEM), predicts that before a droplet reached the final 
stages proposed by the CRM, the increased charge density in the droplet causes the 
coulombic forces to exceed the surface tension to expel an ion from the droplet into 
gaseous phase (Iribarne 1976). 
The condensed phase electrospray ionisation process has advantages over early gas phase 
ionisation processes, such as it readily allows hyphenation with high-performance liquid 
chromatography (HPLC) systems. This allows separation of complex samples by HPLC 
prior to mass spectral analysis consequently improving the sensitivity of the platform. 
1.1.1.3 Mass analysers  
Following ionisation of the analyte molecules, the gaseous phase ions move to a mass 
analyser for separation and detection. This movement of the ions is based on a series of 
electrical potentials. The analyser region of the mass spectrometer separates the gas 
phase ions according to their mass-to-charge ratio (m/z). The separation on the basis of 
m/z ratio can be carried out by several different ways and, as a result there exist a variety 
of mass analysers each with its advantages and limitations. The types of mass analysers 
commonly used include magnetic sector (B), quadrupole (Q), ion trap (IT), time-of-flight 
(ToF), Fourier transform-ion cyclotron resonance (FT-ICR) and Orbitrap (OT) 
(summarised in Table 1-1).  Two types of mass analysers were used in the work 
presented in this thesis, a ToF and an Orbitrap and are described in detail in the 
following sections. 
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Table 1-1 Types of mass analysers used in mass spectrometry 
Mass Analyser Annotation Principle of ion separation 
Magnetic sector B Momentum 
Quadrupole Q (m/z) Mass selective instability 
Ion trap IT (m/z) Resonance frequency 
Time-of-flight ToF Flight time of ions 
Fourier transform ion cyclotron resonance FTICR (m/z) Resonance frequency 
Orbitrap OT (m/z) Resonance frequency 
 
1.1.1.3.1 Time-of-flight (ToF) 
The Cincinnati Division of the Bendix Aviation Corporation introduced the first time-of-
flight (ToF) mass spectrometer in the late 1950s. Since its first introduction, there have 
been many revisions of the design of ToF mass analyser as described elsewhere 
(Guilhaus 1995; Cotter 1992; Ioanoviciu 2001). In a time-of-flight instrument, pulses of 
ions formed in the ion source are accelerated from the ion source by the application of a 
voltage into a field free region termed the flight tube. In the flight tube the ions are 
separated based on the differences in the time taken to reach the detector. Since, all the 
ions are accelerated by the same voltage; each ion possesses, at least in principle, the 
same kinetic energy. As a result, the velocity of each ion is a direct function of its mass. 
In other words, heavier ions will have a lower velocity than lighter ions and consequently 
will take longer (measured in terms of flight time t) to traverse the length of the flight 
tube. The m/z ratio of an ion is calculated from its flight time (de Hoffmann & Stroobant 
2007).  
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The kinetic energy of an ion is equal to its potential energy following acceleration from 
the source, and can be described as:  
          
   
 
 
Where z is the charge on the ion, e is the fundamental unit of charge (1.602 x 10
-19
 C), 
Vacc is the accelerating voltage, m is the mass of the ion and v is the velocity of the ion. 
Hence, the velocity of the ion in the flight tube can be represented by: 
  √
       
 
 
The velocity of the ion can also be represented based on its flight time (t) and the length 
(d) of the flight tube: 
  
 
 
 
The m/z can then be calculated by rearrangement of the equations and substituting for v 
as follows: 
 
 ⁄  
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However, most instruments are equipped with reflectrons to effectively increase the 
length of the flight tube without increasing the length of the instrumentation as shown in 
Figure 1.3. As a result, the calculation of m/z becomes difficult. Hence, in practice, the 
following equation is used to determine m/z ratios from measured flight times: 
          
Where, ‘a’ and ‘b’ are pre-determined constant values obtained from reference 
compounds of known molecular weights for given instrumental conditions. 
Theoretically, ToF mass analysers have an unlimited mass range due to the principles of 
operation. However, in reality very large molecules do not hit the detector plate with 
enough energy to produce a large enough current to be registered as a signal. As a result 
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ToF mass analysers have a limit to the mass range that can be measured. Nonetheless, 
ToF mass analysers are capable of functioning to the range in excess of 300kDa and the 
limits are constantly being pushed by instrumental developments (de Hoffmann & 
Stroobant 2007). 
Historically, the limitation of ToF mass analysers was poor resolution which was due to 
the variation in the flight times of ions of the same m/z. This obstacle was overcome by 
the use of reflectrons in the ToF design. A reflectron is a series of rings or grids to which 
an increasing potential is applied (Alikhanov 1957). The reflectron acts as an ‘ion-
mirror’ to reflect and focus ions of the same m/z. Ions with higher kinetic energies will 
arrive at the reflectron before those with lower kinetic energies; however they will also 
penetrate further into the electrostatic field of the relfectron as compared to the ions with 
lower kinetic energies. This arrangement allows the ions of the same m/z, but different 
kinetic energies, to arrive at the detector at the same time (Mamyrin et al. 1973). A 
schematic of a time-of-flight mass analyser with a reflectron is depicted in Figure 1.3. 
 
Figure 1.3 Schematic of a time-of-flight mass analyser with a reflectron (Rodrigues 
et al. 2007). 
The introduction of a reflectron in a ToF setup increases the resolution to the range of 
>10000 (FWHM) as compared to that of mere 1000 obtained using a linear ToF. 
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1.1.1.3.2 Orbitrap 
The orbitrap is a relatively new type of mass analyser which was proposed first in 1996 
in a patent by Alexander Makarov (Makarov 1996) and introduced in 2000 (Makarov 
2000). The design of this mass analyzer is based on the concept of orbital trapping, 
which was first introduced by Kingdon (Kingdon 1923). 
 
Figure 1.4 A schematic diagram of an Orbitrap mass analyser (de Hoffmann & 
Stroobant 2007). 
The orbitrap is essentially an electrostatic trap that uses a Fourier transform to obtain 
mass spectra. The mass analyser design consists of a central electrode that is spindle 
shaped which in turn is enclosed in a barrel shaped outer electrode consisting of two 
equal parts with a small gap between them (Figure 1.4). The ions are injected 
tangentially (i.e. along the axis r as depicted in Figure 1.4) through the space between 
the two parts of the external electrode with a kinetic energy of some keV. An opposing 
electrostatic voltage to the ions, of the order of several kilovolts (typically ~3.2 kV) is 
applied to the central spindle shaped electrode while the outer electrode is at ground 
potential. The electrostatic attraction of the ions towards the central electrode is 
compensated by the centrifugal force; as a result the ions start to oscillate in the trap in 
complex spiral patterns around the central electrode (in the direction of z-axis as shown 
in Figure 1.4) under the influence of an electrostatic field. The frequency of oscillations 
is inversely proportional to the square root of the m/z. The oscillating frequency of the 
ions is measured and Fourier transformed to obtain a mass spectrum (de Hoffmann & 
Stroobant 2007). 
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The main advantage offered by the orbitrap mass analyser is very high resolution rivalled 
only by an FTICR mass analyser. The resolving power of the orbitrap is proportional to 
the number of oscillations of the ion around the central electrode. An orbitrap offers 
dramatic increase in resolution and mass accuracy, compared to a time-of-flight (ToF) 
mass analyser. The orbitrap also provides high mass accuracy and increased dynamic 
range (Makarov 2000; Hu et al. 2005). In the studies described in this thesis an Orbitrap 
Exactive mass spectrometer (Thermo Scientific, UK) was used to obtain accurate mass 
data (as shown in Figure 1.5). 
 
Figure 1.5 Schematic of the Thermo Exactive Orbitrap mass spectrometer (Thermo 
Scientific 2013). 
Charged analytes are transferred from the ion source to the orbitrap mass analyser 
through a series of ion optics that use a combination of voltages and a vacuum gradient. 
The ions can be held in the analyser for a selected duration of time and detected by the 
outer electrodes, which surround the orbitrap analyser. 
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1.1.1.4 Detectors 
A detector is the final component of the mass spectrometer setup and it facilitates the 
transformation of the ions separated by the mass analyser into a usable signal i.e. a mass 
spectrum. The signal generated by the detector is proportional to the abundance of the 
incident ions. There are two major types of detectors used in modern day mass 
spectrometry electron multiplier or a multichannel plate detector. The detectors used in 
mass spectrometry have been reviewed elsewhere (Koppenaal et al. 2005).  
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1.1.2 Ion mobility spectrometry 
1.1.2.1 Overview of ion mobility spectrometry 
Modern day Ion mobility spectrometry (IMS) originated as plasma chromatography 
(Carr 1984; Karasek 1974). IMS is a gas phase electrophoretic technique which separates 
ions based on their relative mobilities in the presence of an external electric field and 
opposing drift gas (McDaniel & Mason 1973; Mason & McDaniel 1988). The electric 
field facilitates the acceleration of the ions, whereas collisions with the buffer gas 
decelerates them, giving rise to a constant drift velocity (Clemmer & Jarrold 1997). The 
mobility of an ion is a function of the collisional cross section (Ω) (i.e. its size and 
shape), ionic charge and its reduced mass (Creaser et al. 2004). The mobility is 
determined by measuring the drift velocity of the ion under the influence of an electric 
field gradient and in the presence of a buffer gas in a drift tube. Hence, ion mobility of a 
particular analyte ion is characteristic of the analyte and the given buffer gas; and as a 
result it can be used as a detection technique for a single specific component from a 
mixture. 
Modern day ion mobility spectrometry is subdivided into two main classes; drift tube ion 
mobility spectrometry (IMS) and differential mobility spectrometry (DMS) or field 
asymmetric waveform ion mobility spectrometry (FAIMS). Conventional IMS employs 
a constant, time-independent electric field applied to a drift tube and ions are separated 
on the basis of their interaction with opposing drift gas flow. In DMS or FAIMS, a time-
dependent electric field is used to influence the ion transport properties of ions. 
The development of IMS occurred over the past few decades, primarily as a method for 
detecting volatile and semi-volatile organic compounds in fields such as security and the 
military. This technique has found widespread application as a detector for chemical 
warfare agents in battlefields and for narcotics and explosives at airport security. IMS 
has been successfully employed for the detection and analysis of a wide array of 
chemical species such as semi-volatile compounds, carbon and silicon clusters, synthetic 
polymers and biomolecules (von Helden et al. 1993). 
Conventional drift tube ion mobility spectrometry was not used in the work described in 
this thesis; however, the fundamental concepts of ion mobility are essential to understand 
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the mechanisms of separation by ion mobility and have been highlighted in the following 
sections. 
1.1.2.2 Principles of ion mobility spectrometry 
Ion mobility spectrometry (IMS) determines the drift velocities (νd) of the ionised 
analyte molecules in the weak electric field of the drift tube in the presence of a drift gas. 
The velocity of an ion in this setup can be determined from the equation: 
      
Where, νd is the ion’s drift velocity (cm s
-1
), K is the mobility of the ion (cm
2
 V
-1
 s
-1
) and 
E is the electric field strength (V cm
-1
). Hence, the drift velocity of the ion is directly 
proportional to its mobility. 
The mobility (K) of an ion within any given drift cell can be defined by the Mason-
Schamp equation: 
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Where, q represents the charge state of the ion, N is the number density of the drift gas, k 
is the Boltzman’s gas constant (1.380x10-23 m2 kg s-2 K-1), µ=(mM)/(m+M) is the 
reduced mass (kg) for the ion (m) and drift gas molecule (M), Teff is the effective 
temperature, Ω is the collisional cross section of the ion (cm2) and α is the electric field 
correction factor. Thus, the mobility of an ion at a given temperature and gas pressure is 
determined by the mass, charge and the collisional cross section of the ion. However, this 
relationship holds true only in low electric fields i.e. where the ratio of E/N is ≤ 2 
Townsend (Td). At higher values of E/N the mobility of the ion becomes dependent on 
the field strength, which forms the basic principle of DMS or FAIMS.  
It is clear that the mobility measurements are dependent on the instrumentation and the 
parameters such as temperature and electric field strength used for the analysis. Any 
changes to the instrumentation or the parameters will affect the mobility of the ion. 
Changes to the temperature will alter the velocity of the ions. The number density of the 
drift gas will also affect the ion velocity, as increased number density of the drift gas will 
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cause increased collisions with the analyte ions, thus reducing the velocity of the analyte 
ions. As a result for comparison of ion mobility data, standardisation is required. Thus, 
for comparison of mobility measurements obtained under differing conditions and 
instrumentation, mobility is reported as reduced mobility (Ko), which normalises and 
scales the data to normal conditions of temperature (T in Kelvin) and pressure (P in Torr) 
of the drift gas. 
    (
   
 
) (
 
   
) 
Where, Ko is the reduced mobility, K is the mobility, T is temperature (Kelvin) and P 
pressure (Torr). 
1.1.2.3 Travelling wave ion mobility spectrometry (TWIMS) 
The Waters Synapt HDMS mass spectrometer (Waters Corporation, Manchester, UK) 
was the first commercially available mass spectrometer capable of performing ion 
mobility measurements. A schematic of the instrument is depicted in Figure 1.6. The 
Synapt implements a new ion mobility method termed as the travelling wave ion 
mobility spectrometry (TWIMS).  
 
Figure 1.6 Schematic of Waters Synapt HDMS mass spectrometer with tri-wave ion 
mobility drift cell (Waters Corporation 2007). 
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Unlike the conventional ion mobility devices, which employ a constant electric field for 
the propulsion of ions through a drift tube, travelling wave ion mobility spectrometers 
use a series of stacked ring ion guides (SRIG) in the presence of a neutral buffer gas. In a 
SRIG a sequence of ring-shaped electrodes is coaxially arranged as shown in Figure 1.7. 
Ions are transported through the SRIG in a manner similar to that of a quadrupole mass 
analyser, by the application of radio frequency (RF) voltages applied to the electrodes. 
Alternate ring electrodes have opposite phases of RF applied to them which radially 
confine the ions within the device causing them to travel along the axis.  
 
Figure 1.7 Schematic of a stacked ring ion guide (SRIG) in a T-wave device (Waters 
Corporation 2012). 
A direct current (DC) voltage is applied to a pair of adjacent ring electrodes. This 
superimposed DC voltage produces a barrier, which the ions cannot cross. If this DC 
voltage is stepped up to the next adjacent set of ring electrodes, it effectively moves the 
barrier forward a short distance and hence the superimposed moving DC potential is 
termed as ‘travelling wave’. This causes any ions, which are in front of the barrier to 
move forward (Figure 1.8). Sequential stepping up the ion barrier from one end of the 
device to the other end produces a travelling wave which drives the ions through the 
device (Giles et al. 2004; Shvartsburg & Smith 2008). 
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Figure 1.8 Illustration of propulsion of ions through a T-wave device by application 
of a moving DC voltage barrier (Pringle et al. 2007). 
The application of the DC voltage to a pair of ring electrodes is grouped and this pattern 
is repeated throughout the SRIG such that at any given instance, there are multiple 
travelling waves passing through the device (Figure 1.9).  
 
Figure 1.9 A depiction of multiple travelling waves moving through the T-wave 
device and movement of ions (Giles et al. 2004). 
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In the presence of a neutral gas in the TWIMS device, the transport of ions in the SRIG 
region is dependent on the travelling wave height (V), velocity of the travelling wave 
(m/s) and gas pressure (mbar). These factors influence the dwell time of the ion in the 
SRIG and careful manipulation of these factors can be used for separation of ions of 
different collisional cross section.  Out of these three, the travelling wave height (V) is an 
important consideration. A large wave height causes ions to ‘surf’ the travelling wave 
and exit the SRIG, but with a lower wave height, the ions move along the decreasing 
potential gradient, whilst the interactions with the neutral buffer gas will cause ‘drag’ 
resulting in the ions rolling over the top of the wave to interact with the following 
travelling wave. Ions with high mobility with respect to the travelling wave will be 
propelled at the base of the travelling wave, whereas ions with lower mobility will roll 
over the top of the wave more frequently and will be transported through the SRIG at a 
lower velocity by subsequent travelling waves. Hence, the separation of the ions in the 
device is based on the interaction of the structural characteristics (i.e. size, shape) of the 
ions with the neutral buffer gas and the travelling wave (Pringle et al. 2007; Waters 
Corporation 2012). This process of interaction of the ions with the travelling wave 
provides mobility based separation of the ions in the SRIG forming the basis of 
travelling wave ion mobility spectrometry (TWIMS).  
The travelling wave device in the Synapt HDMS (Waters Corporation, Manchester, UK) 
can be operated in a variable wave height mode i.e. the wave height can be gradually 
altered as the wave traverses the length of the SRIG region. This effectively increases the 
length of the drift tube providing better separation of the ions. Manipulation of the wave 
in such a manner imparts greater control over mobility based separations in TWIMS. 
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1.1.3 Ultra-high performance liquid chromatography (UHPLC) 
The complex nature of biological samples demands pre-separation prior to mass 
spectrometric analysis. Chromatographic techniques essentially form the foundation of 
the separation sciences and hence are at the core of analytical chemistry. In recent years, 
high-performance liquid chromatography (HPLC) has become the method of choice for 
separations and analysis of complex mixtures in various fields such as general chemistry, 
pharmaceuticals, natural products, food safety, forensic analysis and ‘-omic’ sciences 
(McMaster 2007). The need for separation of complex mixtures with varying physical 
and chemical properties along with technological advancements has led to the origins of 
a number of variants of liquid chromatographic techniques such as high-performance, 
ultra-pressure, supercritical fluid, hydrophilic interaction (HILIC) and ion 
chromatography. The versatility offered by liquid chromatographic techniques for the 
analysis of chemically diverse compounds is due to the customisation of LC through a 
choice of stationary phases along with additives such as buffers. Consequently, it offers 
greater control over separations. Selectivity for analytes is achieved in liquid 
chromatography by choice of columns in conjunction with modification of composition 
of mobile phases (Ardrey 2003). The core fundamental concepts of liquid 
chromatography have been extensively reviewed elsewhere (Ardrey 2003; McMaster 
2007). Liquid chromatography is commonly combined with MS for high-throughput 
analysis of complex samples due to its high resolving power, robustness and easy 
hyphenation using electrospray ionisation (ESI).  
Reversed phase liquid chromatography is the most commonly used form of LC 
separations and is based on the principle of hydrophobic interactions between analytes 
and a stationary phase. A non-polar stationary phase is employed which is typically a 
straight chain alkyl group (such as C18H37, known as C18 or ODS) linked covalently to a 
silica particle through a covalent siloxane bond. An aqueous, moderately polar mobile 
phase such as water combined with an organic solvent (methanol, acetonitrile etc.) is 
employed to separate analytes based on their hydrophobicity (Kellner et al. 2004). This 
results in the fast elution of polar molecules whilst less polar molecules are retained. A 
gradient elution can be applied to this system wherein the percentage of organic solvent 
in the eluent is gradually increased; the affinity of hydrophobic analytes towards the 
stationary phase is thus reduced resulting in faster elution times for such analytes. The 
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optimisation of the percentage of the organic solvent and the gradient profile is critical 
for ensuring maximum separation of analytes from any complex mixture prior to mass 
spectral analysis. 
Recent years have seen evolution of traditional HPLC through technical advances giving 
rise to ultra-high performance liquid chromatography (UHPLC). UHPLC utilises smaller 
particle sizes (typically sub ~2 µm) or superficially porous particles for increased 
efficiency of chromatographic separation. The back-pressure generated by UHPLC 
columns is inversely related to the particle size of the media used to pack the column. 
Over the years the trend in liquid chromatography has been the development of efficient 
media (i.e. stationary phases) to improve chromatographic performance and reduce 
analysis times. This is achieved by building high performance pumps and 
instrumentation which can withstand high back-pressures generated by LC columns with 
smaller particle sizes or by using high efficiency particles such as core-shell stationary 
phases. These two technologies have been used in the research presented in this thesis 
and are outlined in the following sections: 
1.1.3.1 UPLC 
In HPLC columns, as the particle size decreases to less than 2.5 µm there is a significant 
increase in chromatographic efficiency which does not diminish even at increased mobile 
phase flow rates (Swartz 2005). As a result of using smaller particle size, speed and peak 
capacity can be increased. Ultra performance liquid chromatography employs sub 2 µm 
particles of materials such as bridged ethylene hybrid (BEH) C18 as a packing material 
(Waters Corporation, Manchester, UK).  This has been termed UHPLC or UPLC™ 
(Waters Corporation, Manchester, UK). UPLC takes advantage of advancements in 
particle chemistry combined with instrumentation which is capable of operating at higher 
pressures as compared to that used in HPLC systems. 
1.1.3.2 Poroshell  
Porous silica is widely used as a column packing material in analytical and preparative 
LC systems. Porous silica particles have proved useful for the analysis of 
macromolecules such as proteins, polypeptides and nucleic acids (Kirkland et al. 2000). 
The concept of pellicular particles was first proposed by Horvath et al. in late 1960s and 
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were initially intended for analysis of macromolecules (Horvath & Lipsky 1969). The 
evolution of porous silica particles over the years has led to the development of 
superficially porous silica microspheres as a packaging material for HPLC (Cohen et al. 
2011). These have been termed core-shell or poroshell particles (Kirkland et al. 2000). 
 
 
Figure 1.10 Schematic depicting the structure of core-shell particles (Agilent 
Technologies 2013). 
Poroshell particles consist of an impermeable solid inner core surrounded by a uniform 
porous silica layer and thus are significantly different to conventional porous silica 
particles (Kirkland et al. 2000). These particles typically have a solid core of ~1.7 µm 
coated by a porous layer of 0.5 ~µm thickness. These stationary phases have been 
claimed to offer 80-90% of the efficiency at reduced system back-pressures of the order 
of ~40-50% compared to that offered by sub 2µm particles (Eddinger-Anderson et al. 
2010). Poroshell particles provide increased column performance comparable with 
UHPLC systems without generating excessive back-pressure; as a result these can be 
used using conventional HPLC setup without the loss of chromatographic efficiency.  
However, the nature and design of these particles render them difficult for 
manufacturing. The preparation of thin porous shells (of the order of 0.25 to 0.5 µm) 
around spherical non-porous silica cores (of 1.2 to 1.7 µm diameters) is an expensive 
process. Along with the difficulties in manufacturing of core-shell particles, the efficient 
packing of the narrow bore columns with these particles presents further challenges in 
production of poroshell columns (Cohen et al. 2011). 
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The use of poroshell columns has not been limited to macromolecules and with 
technological advancement in the manufacturing of stationary phases, poroshell particles 
with smaller pore sizes which are well suited for small molecule analysis (of the order of 
120 Å as opposed to 300 Å for macromolecule analysis) have been made possible, 
extending the analytical range of this technique (Agilent Technologies 2013). 
In the research described in this thesis, both UPLC systems and Poroshell C18 particle 
columns have been used in separate metabolite profiling studies providing comparable 
chromatographic performance. 
1.1.4 Hyphenation of LC-MS with IM 
Gas chromatography (GC) due to the nature of the technique functions with gaseous 
phase ions for the separation and thus can be easily interfaced with a mass spectrometer 
(MS). However, the interfacing of liquid chromatographic (LC) systems with a MS 
presents greater challenges as the analytes are dissolved in LC mobile phase and the 
molecular weights and chemical nature of the species separated and analysed by LC vary 
to a larger extent than the volatile and semi-volatile species analysed by GC. The 
problem of LC-MS interfacing was addressed with the introduction of the technique of 
electrospray ionisation (ESI), which facilitated the generation of gaseous phase ions from 
the condensed phase. This enables the 2-dimensional separation of components of a 
complex mixture based first on retention time (tR) and then by the mass-to-charge ratio 
(m/z). 
In the past few decades, the most significant advancement in the field of ion mobility as 
a valuable analytical technique has been its hyphenation with mass spectrometry (IM-
MS). The hyphenation of IM with MS presents the opportunity to obtain valuable data 
which is not possible from IMS or MS alone. McDaniel et al. were the first to couple 
low-field ion mobility drift cells with magnetic sector MS (McDaniel et al. 1962). The 
hyphenation of IM with time-of-flight (ToF) and quadrupole (Q) mass spectrometers 
followed shortly after making MS the detector of choice for IM separations. A historical 
account and a review of hyphenation of various types of ion mobility such as IMS, DMS, 
FAIMS and TWIMS with mass spectrometry is presented by Kanu et al. (Kanu et al. 
2008). 
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Both hyphenated techniques described here i.e. LC-MS and IM-MS have been 
immensely successful with widespread applications, the reason for this being the 
orthogonality of the separation techniques involved. However, there are frequent cases 
where compounds which co-elute by LC-MS are not resolved by the separating ability of 
mass spectrometry and similarly cases involving the analysis of challenging, complex 
mixtures which require pre-separation prior to analysis with IM-MS (Varesio et al. 
2011). A solution would be the combination of all three techniques of separation. 
Modern day ion mobility systems, such as travelling wave devices are capable of coping 
with short dwell time of ions in the ion mobility drift cells and thus can easily keep up 
with rapid separation offered by UHPLC coupled with a fast scanning mass 
spectrometer. Along with these advantages, ion mobility spectrometry, being a gas phase 
separation technique, is orthogonal in nature to mass spectrometry and can easily be 
combined with UHPLC. This hyphenation of UHPLC-IM-MS has been explored for 
analysis of complex mixtures such as detection of trace impurities in drug products 
(Eckers et al. 2007) and targeted analysis of multiple compounds from a urine sample 
(Varesio et al. 2011). 
The combination of ultra-high performance liquid chromatography, ion mobility and 
mass spectrometry presents itself as a powerful technique for the analysis of complex 
mixtures such as metabolomic samples derived from biofluids. The hyphenation of ion 
mobility with UHPLC-MS for metabolite profiling of biofluids is explored in the 
research presented in this thesis.  
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1.2 METABOLOMICS 
Metabolism is the sum total of all the chemical processes occurring in the body of a 
living organism or within a cell that are necessary for the maintenance of life. 
Metabolites are the molecules which partake in the process of metabolism and include a 
range of chemically diverse species including molecules such as amino acids, sugars, 
vitamins, organic acids, as well as macromolecules such as nucleic acids and proteins. 
Metabolism encompasses: anabolism – the assembly of small molecules to produce 
larger compounds, catabolism – the breakdown of larger molecules into smaller 
molecules and biotransformation – the conversion and elimination of endogenous or 
exogenous compounds through excretion. All exogenous and endogenous compounds 
are subject to these processes and thus form an intricate network of metabolic pathways. 
The entire complement of small molecular weight metabolites (< 1500 Da) is termed the 
metabolome, and the term was first introduced by Oliver et al. (Oliver et al. 1998). It 
also includes interactions with metabolite products and substrates such as lipids, small 
peptides, vitamins, nucleic acids and other protein factors (Krastanov 2010). 
The idea that changes in biological fluids or tissues are indicative of the physiological 
state of an organism or a diseased state, dates as far back as ancient Greece. The efforts 
for exploring biochemical systems enclosed within the human body have been ongoing 
for centuries. ‘Urine charts’ which linked colours, smells and tastes of urine to various 
conditions were widely used in ancient times as diagnostic indicators of diseased states.  
Modern day metabolomics explores the same basic principle of relating chemical 
fingerprint of biofluids or tissues to the biological state of the organisms (Nicholson & 
Lindon 2008).  
Since the Human Genome Project in 1990s, there has been a revolution in the approaches 
and techniques used in molecular biology and biochemistry. The interest and 
advancement over the years in these related fields has led to a better understanding of the 
human biochemistry (National Institutes of Health 2013). The outcomes from early 
stages of the Human Genome Project suggested that genetic differences might be able to 
account for various disease processes. This led to the discipline of transcriptomics. 
Research in the recent years has highlighted the complex relationship between 
environmental interactions and genetic make-up and its impact on the phenotype of 
living organisms. A full understanding of these complex interactions cannot be achieved 
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only at genomic, transcriptomic or proteomic level alone. Even the combination of 
genomics and proteomics does not provide a full understanding of the cellular functions 
of living systems. This is due to the fact that both these techniques ignore the dynamic 
metabolic state of the organism (Fiehn 2002).   
1.2.1 ‘Omics’ sciences 
The word ‘omics’ is derived from the Greek suffix, ‘ome’ which means whole or 
complete and refers to scientific areas in systems biology. The sciences which come 
under the umbrella of ‘omics’ e.g. genomics, proteomics, transciptomics, lipidomics and 
metabolomics aim to provide a global perspective on the biological functions in order to 
better understand life.  
 
Figure 1.11 Coverage of '-omic' sciences and place of metabolomics as the most 
predictive phenotype 
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1.2.2 Overview of metabolomics 
The science of investigating the metabolome started in the late 1960s, when Dalgliesh et 
al. combined GC with flame ionisation detection (FID) for investigations on metabolism 
(Dalgliesh et al. 1966), although the term ‘metabolomics’ was not used (Griffiths et al. 
2010). Metabolomics arose from the work carried out in the 1980s. The field grew at a 
rapid pace with its coupling with advanced pattern recognition and multivariate statistical 
techniques (Nicholson et al. 1983). The term metabonomics was coined in 1999 by 
Nicholson et al. and was defined as “the quantitative measurement of the dynamic, 
multiparametric metabolic response of living systems to pathophysiological stimuli or 
genetic modification” (Nicholson et al. 1999). It is the systematic study of the unique 
chemical fingerprints of low molecular weight endogenous metabolites or metabolite 
profiles in biological samples (Zhang, Sun & Wang 2012).  
The field of metabolomics has witnessed the parallel development of closely related 
fields of metabonomics and metabolic profiling.  
1.2.3 Metabonomics, metabolomics and metabolic profiling 
The terms metabonomics and metabolomics have separate origins, however, they have 
been used interchangeably throughout the literature. One description suggests that the 
term metabolomics applies to plant studies, whereas metabonomics was reserved for 
studies involving animals. A second approach inferred that the choice of terms was based 
on the analytical technique used, with metabolomics referring to studies utilising LCMS 
and metabonomics using NMR (Mishur & Rea 2011). Nicholson et al. describe the 
difference between metabolomics and metabonomics as ‘philosophical rather than 
technical’. Metabonomics has been described to measure the global metabolic response 
of living systems to biological stimuli or genetic modification; the focus of which is to 
understand systematic change through time. Whereas, metabolomics aims to characterise 
and quantify all small molecules in given samples. However, these terms are used 
interchangeably in literature and the analytical methods and statistical procedures used 
are the same (Mishur & Rea 2011; Nicholson & Lindon 2008). 
The terms metabolomics, metabonomics and metabolite profiling will be used 
interchangeably in the context of this thesis. 
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1.2.4 Approaches in metabolomics 
Regardless of the analytical technique utilised for analysis, metabolomic studies can be 
divided into two distinct approaches; targeted analysis of specific metabolites and the 
more challenging non-targeted methods. 
Targeted metabolomic studies focus on a single metabolite or a sub-set of a particular 
class of metabolites which are representative of a particular metabolic pathway. The 
strategy of analysis by this approach is to evaluate metabolic target compounds identified 
from the study of metabolic pathways. Hence, targeted metabolomics approach is 
referred to as a ‘hypothesis-testing’ approach. This approach proves to be inefficient at 
detecting previously uncharacterised compounds as only selected analytes are evaluated. 
Analytical methods routinely employed for targeted metabolomics include LC-MS 
operated in selected ion recording (SIR) or multiple reaction monitoring (MRM) modes. 
An account of analytical strategies utilised in targeted metabolomics is given later in this 
thesis and is discussed elsewhere (W. Lu et al. 2008). 
Non-targeted metabolomic analysis refers to the comprehensive global metabolic 
profiling of all measurable analytes in a sample. In the non-targeted approach, no prior 
knowledge of the samples is assumed and hence is recognised as ‘hypothesis-generating’ 
approach. 
A significant portion of modern metabonomics research is focussed on metabolic 
profiling to measure the entire metabolic content within a biological system. The 
reasoning behind the ambition to study the entire metabolic content was the recent 
advances in whole genome sequencing (genomics) and comprehensive proteome 
profiling (proteomics). Comprehensive profiling of the metabolome in similar fashion to 
that of genome and proteome will provide insight into biochemistry, which connects the 
genome and the proteome with a particular phenotype, while accounting for 
physiological development and interactions with environment, i.e. nutrients, diurnal 
variations etc. This will provide a more complete picture of the biochemistry for 
integrating the knowledge with systems biology.  As unbiased monitoring of all the 
analytes is expected, the data generated from global metabonomic profiling by any 
analytical method is vast; and thus complex data interpretation strategies such as 
multivariate analysis and chemometrics are required. Also the number of metabolites 
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present in a particular system cannot be predicted. Metabolites have a diverse variety of 
chemical structures and properties and thus extraction, enrichment, separation and 
analysis steps are difficult. 
1.2.5 Biofluids in metabolomics 
Recent metabolomic studies of biomedical significance show a growing trend of the use 
of biofluids, cell or tissue extracts. These include plasma, whole blood, urine, 
cerebrospinal fluid, synovial fluid, semen, serum, tissue homogenate etc. Metabolomic 
studies have also investigated biofluids such as seminal fluid, amniotic fluid, lung 
aspirate as well as digestive fluids. However, biofluids such as urine and plasma are 
routinely used for various disease diagnosis and in clinical trial settings as they are easily 
obtainable and established procedures and protocols exist for their collection (Zhang, 
Sun, Wang, et al. 2012).  
Various metabolomic studies have shown the potential of mapping and analysing the 
perturbations in biological systems through biofluid analysis for disease diagnosis and 
biomarker discovery (Claudino et al. 2012). The goal of modern day metabolomics is to 
identify novel and specific biomarkers for early disease diagnosis and to better 
understand disease mechanism than traditional biochemistry and histopathological 
methods. At the same time the emphasis is on non-invasive biomarkers and thus patient 
comfort. Hence, non-invasively collected biofluids such as saliva and urine are gaining 
precedence as compared to traditionally used diagnostic biofluids such as plasma 
(Zhang, Sun, Wang, et al. 2012). 
1.2.6 Analytical techniques in metabolomic analyses 
Metabolomics investigations particularly those involving global metabolite profiling 
consist of two keys steps; data collection of metabolite fingerprints and information 
mining. To facilitate this, there is a requirement for analytical platforms capable of 
producing global metabolite profiles from complex biological samples. An ideal 
analytical technique should enable the analysis to be performed directly on the sample, 
with minimal sample pre-treatment, high throughput, no bias towards particular classes 
of metabolites and should be both highly and equally sensitive to all the components in 
the sample. Realistically, there is no single analytical technique, which provides all the 
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desired properties. Hence, there is a general trend towards carrying out metabolite 
profiling using multiple analytical platforms to maximise the coverage of the metabolic 
profiles. The metabolites are present in large number, diversity, concentration, dynamic 
range and complexity in biological samples; and thus separation science forms an 
essential part of the study of all metabolites in these samples. 
An overview of the key analytical techniques, which have been used for metabonomic 
studies, is given below. Particular emphasis is given to liquid chromatography-mass 
spectrometry (LC-MS) and ion mobility-mass spectrometry (IM-MS). 
1.2.6.1 Overview of analytical techniques in metabolomics 
Nicholson and co-workers pioneered the metabonomics approach using nuclear magnetic 
resonance (NMR) spectroscopy in 1999 (Nicholson et al. 1999); and since then NMR has 
been the predominantly used technique in metabonomic investigations along with mass 
spectrometry (MS). The hyphenation of MS with separation-based techniques such as 
gas, liquid and thin-layer chromatography (GC, LC and TLC) or capillary 
electrophoresis (CE) have been used as a means of detection and identification of 
metabolomic biomarkers (Wilson et al. 2005; An et al. 2010; Ciborowski et al. 2010; N. 
Li et al. 2010; Varghese et al. 2010; Jansson et al. 2009; Sreekumar et al. 2009; Issaq et 
al. 2008; Want et al. 2010; Kaddurah-Daouk 2006). There have been a limited number of 
reports of the use of techniques such as fourier transform infra-red (FT-IR) spectroscopy, 
fourier transform-ion cyclotron resonance-mass spectrometry (FT-ICR-MS) and other 
electrophoretic techniques for metabolome-related studies (Jansson et al. 2009). 
Numerous researchers have debated the advantages and disadvantages of 
chromatographic and other analytical techniques in combination with mass spectrometry 
(Pasikanti et al. 2008; Xiayan & Legido-Quigley 2008; Theodoridis et al. 2008; Issaq et 
al. 2008; Zhou et al. 2012; X. Lu et al. 2008; Dunn & Ellis 2005). 
The main advantage of NMR spectroscopy is its non-destructive nature wherein the 
sample can be further analysed using a different analytical technique. Apart from being a 
rapid, cost-effective, high-throughput method; its minimal sample pre-treatment 
requirement is ideal for global metabolomic profiling research. It is a powerful technique 
for obtaining structural information on small organic molecules and thus has been 
employed for metabolomic studies of various biofluids such as urine, cerebrospinal fluid, 
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plasma, saliva etc. and has been effectively used to identify and quantify their 
components (Tang et al. 2009; Dunn & Ellis 2005; Nicholson et al. 1985; Nicholson et 
al. 1983). However, the drawback of this method is its low sensitivity, despite the use of 
higher magnetic field instruments for increasing the resolution, compared to other 
techniques such as mass spectrometry (MS). The sample volume requirements for the 
method are also high in comparison with other techniques. Biofluid samples contain 
large proportion of water in them, which causes peak broadening in NMR spectra and 
thus may mask detection of other metabolites of interest. In addition, some classes of 
analytes such as sulphates cannot be detected by NMR spectroscopy. Thus, although 
NMR has been the analytical workhorse for metabonomics research, the improved 
sensitivity and low sample volume requirements offered by hyphenated mass 
spectrometric (MS) methods (mainly liquid chromatographic) has invoked growing 
interest for metabolic profiling investigations.  
Gas chromatography (GC) combined with mass spectrometry (MS) provides a very 
powerful method for the analysis of volatile organic compounds. With improvements in 
technology and fused-silica columns, it provides high resolution, high efficiency, better 
reproducibility and requires a small sample volume. With advancements such as two-
dimensional GC (GCxGC) coupled with time-of-flight mass spectrometry (ToFMS), the 
analysis time is significantly reduced and detection of large number of metabolites is 
possible in a single analysis. A major prerequisite for GC-MS analysis is that the 
analytes should be volatile and thermally stable. However, most of the metabolites from 
biological fluids are polar and non-volatile in nature; thus these cannot be directly 
analysed using GC-MS and require derivatisation. This along with long chromatographic 
run times reduces the throughput of the method. Despite its shortcomings, gas 
chromatography coupled with mass spectrometry (GC-MS) provides a valuable tool for 
analysis of volatile components of biofluids in metabonomic studies (Pasikanti et al. 
2008; Dalgliesh et al. 1966) and has been implemented for metabolite profiling studies of 
biofluids such as urine and plasma (Zhang, Sun, Wang, et al. 2012). 
Capillary electrophoresis (CE) methods which separate analytes based on their size-to-
charge ratio, have also been used with limited success for characterising the metabolome 
(Sugimoto et al. 2010; Ramautar et al. 2008). Recent advances in technology have 
enabled the hyphenation of CE with mass spectrometry using an electrospray ionisation 
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source, however with limited success. The main advantage of CE is its applicability to 
hydrophilic metabolites and its suitability for analysis of ionic and polar compounds, 
which may not be retained by reversed-phase liquid chromatographic columns. Although 
CE exhibits good sensitivity, selectivity and fast analysis times; the main shortfall of this 
method is difficulty in interfacing with mass spectrometry. Since the volume of sample 
used for this technique is in the nano-litre range, detection of low abundance metabolites 
is difficult to achieve. Most of the applications of this method in metabolomics involve 
targeted approach rather than comprehensive profiling of the metabolome. CE-MS is 
considered as a complementary method to liquid chromatography.  
Along with hyphenating mass spectrometry and chromatographic methods, MS is also 
used as a high-throughput screening tool by direct infusion mass spectrometry (DIMS). 
In this method, biological sample extracts are directly injected or infused into an 
electrospray ionisation mass spectrometer. A single mass spectrum is acquired per 
sample and thus has high complexity. Comprehensive analysis of the metabolome is not 
possible using this method, and is thus used as a screening tool in metabolomics. 
Applications of DIMS are mainly concerned with microbial and plant metabolomics. 
1.2.6.2 LC-MS in metabolomics 
Liquid chromatography in tandem with mass spectrometry is widely used in many 
biochemical and chemical analyses especially in ‘-omics’ sciences to analyse the 
composition of complex samples. The use of chromatographic technique such as LC 
prior to MS detection decreases the complexity of data by imparting the separation of 
analyte species. This has proved to be invaluable for the analysis of complex samples 
such as biofluids, plant and microbial extracts as well as tissue homogenates encountered 
in metabolomic studies (Theodoridis et al. 2008; X. Lu et al. 2008; Zhou et al. 2012). 
The application of LC-MS to metabolomic studies is relatively recent, but has shown 
rapid and continuing increase in number of publications based on this approach. MS is 
already a well-established technique in drug-metabolite and small molecule analysis. MS 
combined with a separation technique such as LC shows potential for comprehensive 
metabolite profiling studies. 
Most commonly used ionisation technique for interfacing LC-MS is with electrospray 
ionisation, which is capable of producing gas-phase ions from the liquid phase. ESI has 
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advantages such as excellent quantitative response, reproducibility, high sensitivity and 
simple sample preparation. ESI is a soft-ionisation technique and is suitable for global 
profiling of metabolites.  
Like all the analytical techniques, LC has benefited from the advancement in technology. 
The use of UHPLC (Section 4.1.2) has resulted in higher chromatographic efficiencies 
and shorter analysis times and the advantages of UHPLC-MS for metabolic profiling 
studies are evident. LC-MS methods have already been successfully used for 
metabonomic profiling studies pertaining to biofluids such as urine and plasma for 
applications including nutritional studies and biomarker detection. 
1.2.7 Application of ion mobility spectrometry (IM-MS) in metabolomics 
Ion mobility spectrometry (IMS) complements traditional mass spectrometric (MS) 
separations as IM separates ions based on shape and collisional cross sections (CCS) of 
the analyte ions. The implication of this being structural isomers that share the same m/z 
and are unresolved by mass spectrometry can be separated by ion mobility (Lapthorn et 
al. 2012). Dwivedi et al. have shown the applications of combination of ion mobility 
with mass spectrometry (IM-MS) for detection and separation of isomers of complex 
carbohydrates (Dwivedi, Bendiak, et al. 2007) as well as enantiomeric separation of 
chiral compounds (Dwivedi et al. 2006). In addition, IMS is a rapid separation technique 
with typical scan times in the order of milliseconds. Qualities such as the speed of 
analysis and the orthogonal nature to mass spectrometry have demonstrated the potential 
of this technique to be used as a second-dimension of separation following GC or LC to 
provide enhanced coverage of complex samples without compromising the high 
throughput nature of chromatography-mass spectrometry based techniques (Bedair & 
Sumner 2008). 
Despite these advantages, the applications of IM-MS in metabolomic investigations, 
especially for metabolite profiling studies remain limited in number, although the interest 
in the use of this technique is growing. Dwivedi et al. investigated and characterised the 
potential of ESI-IM-MS for separation, detection and identification of components from 
complex metabolic mixtures (Dwivedi, Wu, et al. 2007). Bacterial cultures of E. coli 
were analysed for metabolites in this study and over 500 metabolites were separated and 
detected. The potential advantages offered by ESI-IM-MS and MALDI-IM-MS were 
33 
 
highlighted for the analysis of complex samples such as bacterial metabolome of E. coli 
(Dwivedi, Puzon, et al. 2010). Ambient pressure ion mobility mass spectrometry has 
been used for global and targeted studies on neuronal metabolome of rats (Kaplan et al. 
2013). This study focussed on probing the metabolome from a rat brain tissue after acute 
cocaine dosing to demonstrate the potential of using high throughput IM-MS separations 
for metabolomic studies for pharmacological investigations in drug abuse.  
Harry et al. have explored an approach for enhancing coverage of urinary metabolome 
by LC-IM-MS (Harry et al. 2008). Drift tube ion mobility spectrometry combined with 
HPLC and MS was evaluated for profiling of urinary metabolome using rat urine and 
strategies for data mining were demonstrated. Other applications include metabolite 
profiling of human blood by high resolution ion mobility mass spectrometry (IM-MS) 
(Dwivedi, Schultz, et al. 2010) and analysis of breath using differential mobility 
spectrometry (Basanta et al. 2010) amongst a growing trend of metabolomic studies 
utilising IM for increased selectivity and enhanced coverage of the metabolome. 
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1.3 INTRODUCTION TO DATA MINING METHODS IN METABOLOMICS 
Metabolic profiling experiments generate vast amounts of data that can be overwhelming 
in terms of size and complexity and the complexity of the generated dataset only 
increases with advancements in the sophisticated analytical technologies used to acquire 
the data. Hyphenated chromatography and mass spectrometry platforms can generate 
extended datasets, which need data mining and deconvolution before conclusions that 
address the biological question under scrutiny can be drawn (i.e. obtaining results which 
are ‘fit-for-purpose’). Due to the size and the complexity of the data produced, the use of 
univariate statistical techniques is not suitable. Thus, data mining methods based on 
pattern recognition and multivariate statistics are an essential analytical tool for 
scrutinising metabolomic data, especially data obtained from non-targeted global 
metabolomic analyses (Jansen & Westerhuis 2012). The primary aim of the data mining 
in metabolomics is to reduce the complexity of the data whilst maintaining all the 
relevant information contained in the huge quantity of the data generated. In the case of 
metabolomic experiments focussed on non-hypothesis driven, untargeted metabolite 
profiling studies, the data handling and statistical data processing needs to be done with 
utmost care to avoid false discoveries of biomarkers (Broadhurst & Kell 2006). 
Mass spectrometry has been hailed as the gold standard for the study of the wide 
chemical diversity and range of concentrations of the metabolome. There has been 
significant research into various methodologies for processing of the data obtained from 
mass spectrometric techniques. These data processing techniques  have been reviewed 
extensively by Boccard et al. (Boccard et al. 2010) and Goodacre et al. (Goodacre et al. 
2004), including techniques to combine data from different analytical sources, such as 
LC-MS and 
1
H-NMR, to obtain comprehensive coverage of the metabolome (Forshed et 
al. 2007).  
1.3.1 Data pre-treatment 
Typically, metabolomic raw data generated from chromatographic and mass 
spectrometric techniques consists of several hundred to several thousand 
chromatographic peaks and their associated mass spectra arising from multiple 
components in the metabolic profile. However, the dataset is also contaminated with 
noise and peak areas of different metabolites usually differ. Thus, to extract relevant 
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information from such a large and heterogeneous and contaminated dataset, several data 
pre-treatment steps followed by powerful regression and projection methods are 
required.  
A crucial step prior to data mining is to assemble a primary dataset from which noise and 
missing data-points are removed. The datasets obtained from hyphenated 
chromatography-mass spectrometry platforms often require extensive pre-processing 
before being subjected to statistical analysis. Over a course of the analysis of an 
analytical sample batch, chromatographic peaks may demonstrate retention time shifts or 
intensity variations due to instrumental and other factors such as temperature, pH, 
column contamination etc. (Want et al. 2010). Hence, chromatographic peak detection, 
noise filtering, retention time alignment, normalisation etc. are required to achieve good 
quality data matrix prior to subsequent statistical analysis.  
The first stage is to generate a data matrix table containing retention time & m/z pairs (or 
features) and peak areas (or peak heights in some cases). Once a data matrix has been 
constructed, the data needs to be further treated in order to concentrate on the features 
associated with biological variation in the data. LC-MS or GC-MS data generated from 
metabolomics profiling studies inherently possess several properties that make data 
analysis difficult without proper pre-treatment. For example, there are large differences 
in abundances, peak areas and intensities, which need to be compensated for as a 
detectable biological effect is usually related to the variation in concentration rather than 
the absolute concentration of a metabolite. The variation induced due to the biological 
change of interest is mixed with other types of variation such as systematic, random and 
arising from other technical sources. This variation of interest needs to be distilled from 
other sources of variation.  
1.3.2 Normalisation 
Normalisation is the first data transformation process, which aims to compensate for 
instrumental and systematic errors arising in the metabolic profiling workflow. These 
errors commonly arise during chromatography or mass spectrometry, such as variation in 
the intensities of the metabolites between different samples due to loss of sensitivity etc. 
(Redestig et al. 2009). A metabolic profiling experiment usually involves the analysis of 
a number of samples and even with modern high-throughput methods this requires 
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extended run times. As a result, during the course of the analysis of the samples, 
variations arise in the characteristics of the data, such as chromatographic retention times 
and mass spectral peak intensities. A solution to this problem is to introduce an internal 
standard, such that the intensity of the endogenous metabolite can be related to that of 
the internal standard. Stable-isotope labelled counterparts of the metabolites of interest 
are ideal candidates to be used as internal standards in targeted metabolite profiling, 
where normalisation of the data to the intensity of the internal standard is rapidly 
becoming the method of choice. The other option for non-targeted metabolic profiling is 
to normalise the data to the intensity of the total ion current (TIC) for that particular 
sample. This method of normalisation serves to avoid additional steps in sample pre-
treatment, as well as avoiding the possibility of interaction of the added internal standard 
with endogenous molecules, such as ion suppression, or chemical interactions with other 
endogenous metabolites in the sample of interest. Normalisation is a critical step in data 
pre-treatment as it serves as means of circumventing systematic errors and removal of 
between sample variations for detection of biological differences in intensities of 
metabolites of interest. 
1.3.3 Multivariate statistical approaches 
Multivariate statistical approaches are well suited to the extraction of valuable significant 
information from the vast amount of data generated from ‘–omics’ techniques in systems 
biology. Two multivariate statistical analysis methods are most commonly used in 
metabolomics profiling studies viz. principal component analysis (PCA) and partial least 
squares discriminant analysis (PLS-DA). These are projection-based methods where 
latent or artificial variables are constructed through modelling from observed variables 
i.e. a data matrix consisting of m/z and retention time pairs. Techniques which have 
evolved from these two basic approaches, such as orthogonal projection to latent 
structures (O-PLS) and O2-PLS, are also gaining popularity and have been reviewed 
elsewhere (Fonville et al. 2010). Depending on the aim of the analysis, unsupervised or 
supervised approaches are employed for data processing, for example observing trends in 
the data, group classification and obtaining an overview of the data. 
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1.3.3.1 Principal component analysis (PCA) 
Principal component analysis (PCA) is the first and simplest method used in metabolic 
profiling. It assumes no prior knowledge of the samples and hence is called an 
‘unsupervised’ method. PCA is a multivariate statistical analysis approach that facilitates 
the identification of differences and similarities between groups of samples. PCA was 
first conceived by Pearson in the year 1901, who defined it mathematically as an 
orthogonal linear transformation (Pearson 1901). 
PCA forms the basis of modern day multivariate data analysis and the fundamentals of 
the method have been described in detail by Wold (Wold 1987). It attempts to reduce the 
dimensionality of the data while retaining the original variability in the data. PCA 
transforms a number of correlated variables into smaller number of uncorrelated 
variables called ‘principal components’. Principal components are assigned so that the 
first component (PC1) explains/accounts for most of the variation in the dataset, the 
second (PC2) accounts for the next largest variation and so on. A PCA analysis proceeds 
in this manner with each component accounting for progressively smaller amounts of 
variance. Variance is a measure of the spread of the dataset. Consequently it can be used 
to assess groupings, outliers, trends and homogeneity in datasets. PCA can also be used 
to determine if the analytical system remained within acceptible control limits by the 
measurement of quality control (QC) samples spread throughout the analytical sample 
sequence and by assessing the clustering of the samples from this group. 
1.3.3.2 Partial least squares discriminant analysis (PLS-DA) 
Partial least squares (PLS) regression is a multivariate method of assessing a relationship 
between a descriptor matrix X and a response matrix Y. However, unlike PCA, PLS 
regression is a ‘supervised’ method and is directed by the response matrix Y to derive 
components from the descriptor matrix X to maximise the covariance in the data. In 
other words, the response matrix drives out the discriminant components from the dataset 
to maximise separation. PLS in its simplest form is a method for relating two data 
matrices and building predictive models based on the same (Wold 2001). 
PLS regression can be used for discrimination analysis in the form of PLS-DA. This 
variant of the regression method is commonly used in metabolic profiling studies for 
classification or class-separation purposes. PLS and other derived supervised approaches 
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are used to tackle subtle problems in  which relationships within datasets  are buried in 
the background of other large multiplexed effects allowing the smaller features to be 
uncovered. For example, in the case of biological systems, a variety of factors such as 
age, gender, environment, metabolic rate etc. contribute to the composition of the 
metabolic profile of different individuals. Not all of these factors are relevant to the 
understanding of a biological variation of interest and the main source of variation in the 
data may not address the biological question being interrogated. As a result, these should 
be down-weighted during the analysis and importance should be given to the relevant 
source of variation in the data. This can be achieved through the supervised approaches 
and these have proved useful in modern day metabolic profiling (Fonville et al. 2010). 
However, one drawback of the PLS-DA method is that it can suffer from overfitting. 
This usually occurs because the number of samples used in metabolic profiling 
experiments is usually much smaller than the number of variables extracted from the 
analytical data. 
1.3.4 Scaling and transformations 
The validity and accuracy of the supervised and unsupervised models can be improved 
by the correct use of scaling and centering. Three types of scaling are predominantly 
used in multivariate statistics involving metabolic profiling viz unit variance (UV), 
centering with no scaling (Ctr) and Pareto scaling (Par). The UV scaling assigns each 
variable a weighting of one and as a result provides equal chance to all the variables of 
being expressed in the model with equal importance. In terms of mass spectrometric 
data, this means ions with high intensity will be compressed while those with low 
intensity will be magnified and, as a result, metabolites from both the ends of the 
dynamic range in terms of their concentration will be given equal importance. In Ctr 
method of scaling, the importance given to a variable is related to its signal, i.e ions with 
low amplitude will have less influence on the model as compared to those with high 
signal amplitude. The drawback of this method is that metabolites which are present in 
lower concentrations in the samples, even if important, will not influence the model thus 
causing loss of potentially important sources of variation. The compromise between UV 
and Ctr is the Par scaling. This method of scaling allows spectral regions with low 
amplitude to influence the model, but only if they show variation. This is the most 
popularly used method for scaling in metabonomic applications.   
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1.4 SALIVA 
Saliva is often regarded as the ‘mirror of the body’. It’s a perfect surrogate medium to be 
applied for clinical diagnostic purposes. It has an old history of being studied but its 
physiological importance has only been recognized recently. In the past 50 years the 
pace of salivary research has accelerated with the advent of new techniques and 
approaches such as metabolomics, genomics, proteomics etc. The research has 
illuminated the biochemical and physicochemical properties of saliva, comprising the 
multifunctional roles it has in speech, lubrication, digestion of food and maintaining oral 
and general health (Mandel 1993). The interest in saliva has grown exponentially in the 
last decade with the finding that saliva was filled with hundreds of components that may 
serve to detect systemic disease or evidence of exposure to various harmful substances as 
well as provide biomarkers of health and diseased states (Schipper et al. 2007). 
 
Figure 1.12 Location of the major salivary glands in the oral cavity. 
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1.4.1 Physiology and secretion 
Human saliva is a complex bio-fluid consisting of secretions from a number of glands. 
These salivary glands are divided into three major salivary glands – the paired parotid 
glands, the submandibular glands and the sublingual glands which contribute to the 
largest percentage volume of saliva produced. The paired parotid glands are located 
opposite the maxillary first molars whereas the submandibular and the sublingual glands 
are situated on the floor of the mouth under the tongue Figure 1.12. The major salivary 
glands are aided by minor salivary glands located throughout the oral cavity (Carpenter 
2013).  
1.4.2 Composition of saliva 
Saliva consists of secretions from major and minor salivary glands, gingival crevicular 
fluid, oral bacteria, their metabolites and food debris. Whole saliva consists of a variety 
of biologically relevant compounds including hormones, nucleic acids, peptides, 
proteins, metabolites, immunoglobulins, enzymes (lysozymes, lingual lipase, α-amylase 
etc.), mucins, electrolytes (Na, K, Ca, Mg, carbonates, phosphates etc.) and nitrogenous 
products such as urea and ammonia (Humphrey & Williamson 2001). Despite the 
complexity, it is a very dilute fluid comprising of 99% water.  
Saliva is a highly variable and individualised fluid and it’s chemical composition and 
flow is affected by various factors including age, gender, circadian rhythm, circannual 
cycle, psycho-emotional state, physical exercise, hydration, systemic diseases, 
medication, substance abuse and nutrition (De Almeida et al. 2008; Carpenter 2013).  
1.4.3 Functions of saliva 
Saliva performs a wide array of roles within the oral cavity, and its importance is not 
fully appreciated until it is absent or its quality or quantity is diminished (Humphrey & 
Williamson 2001). Saliva is responsible for a number of functions involving 
maintenance of oral health and homeostasis. It aids in the production of food bolus 
during mastication, aids in the digestive process (through enzymes such as amylase and 
lipase), protects the oral cavity against mechanical damage by lubrication as well as 
provides first line of defence against pathogens. The lubrication of oral tissue also aids in 
swallowing of food and speech. It forms an integral part of the sense of taste by acting as 
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a solvent for ions while maintaining a balanced pH in the oral cavity by acting as a buffer 
(Walsh 2007). Another important function of saliva is the maintenance of the health of 
the oral mucosa through growth factors which promote wound healing in the oral cavity 
and curtailing destructive enzymes. Saliva ensures the stability in the oral cavity and aids 
in maintaining integrity of tooth enamel (Pedersen et al. 2002). 
1.4.4 Saliva as a diagnostic bio-fluid and its clinical applications 
In the past, saliva or oral fluid has been neglected as a diagnostic medium and preference 
has been given to other more invasively collected biofluids such as blood, serum and 
plasma. Saliva, however has the advantage of allowing non-invasive sample collection 
and substances present in saliva are in their biologically active form (Pink et al. 2009). A 
good correlation between levels of compounds in saliva as compared to plasma has been 
reported, which makes saliva an attractive alternative to invasively obtained matrices 
such as whole blood, plasma and CSF. 
Saliva has been used in clinical diagnosis for more than a century. Ancient traditional 
Chinese medicine believed saliva to be ‘sibling’ biofluid of blood and that these two 
share a common origin. It was believed that changes in saliva were indicative of the 
wellness of an individual. The viscosity, odour, taste as well as patient’s gustatory 
sensation of their saliva were considered as symptoms of diseased states e.g. over-
secretion of saliva was linked with heartburn. These theories were earliest marks of use 
of saliva as a diagnostic biofluid (Zhang et al. 2009a).  
The pace of research into saliva as a diagnostic medium has accelerated in recent years 
with the advent of new techniques, which have provided a wealth of information 
regarding the biochemical and physicochemical properties of saliva. Significant 
advancements have been made in the development of salivary diagnostic tools (Wong 
2012). The potential for early detection of systemic diseases or exposure to harmful 
substances has been demonstrated (Pink et al. 2009; Walsh 2007). Saliva has been used 
as a tool for monitoring steroid, peptide and immune markers in sport and exercise 
science (Papacosta & Nassis 2011). It has also been utilised as a  non-invasive biomatrix 
in pharmacokinetic studies (Raju et al. 2013). Salivary biomarkers have found 
applications in occupational and environmental medicine (Soo-Quee Koh & Choon-Huat 
Koh 2007) as well as proving valuable in clinical applications (Zhang et al. 2009b). 
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Salivary α-amylase has been identified as a stress-related biomarker for autonomic 
nervous system activity (DeCaro 2008). Measurement of late evening salivary cortisol 
concentrations by tandem LC-MS has been used as a screening test for Cushing’s 
syndrome (Raff 2011). Effects of aerobic exercise have also been investigated using a 
variety of analytical platforms using saliva (González et al. 2008; Papacosta & Nassis 
2011). The majority of the applications listed here have utilised LC-MS or NMR as the 
method of choice for analysis, which highlights the trend of instrumentation utilised in 
salivary analysis.  
The complexity, biological significance of saliva and the advancements in analytical 
technology combined with modern day bioinformatics strategies (Ai et al. 2012) have 
shown the immense potential of this matrix in metabolite profiling. The non-invasive 
nature of the sampling and good-correlation with levels of compounds present in blood 
suggests that saliva maybe a valuable alternative to blood or urine profiling for screening 
of biomarkers (Chiappin et al. 2007; Williamson et al. 2012). 
The following table highlights some of the metabolomics/biomarker studies which have 
been published with saliva as the biofluid. 
Technique Application Author/Publication Year 
NMR 
Metabonomic analysis of 
periodontis 
(Aimetti et al. 2011) 
NMR 
Diurnal analysis of salivary 
profiles 
(Bertram et al. 2009) 
NMR 
Effect of dietary standardisation 
on metabolomic profiles 
(Walsh et al. 2006) 
CE/MS 
Pancreatic, breast, oral cancer 
profiles 
(Sugimoto et al. 2010) 
Assays 
Biomarkers in blood and saliva 
comparison 
(Williamson et al. 2012) 
LC/MS 
Signatures of oral cancer and 
leukoplakia 
(Wei et al. 2010) 
LC/MS 
Saliva sample preparation for 
metabolomics 
(Álvarez-Sánchez et al. 2012) 
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1.4.5 Metabolite profiling of saliva 
The utility of saliva for metabolite profiling has been demonstrated in a variety of 
applications. The term ‘Salivaomics’ was coined in 2008 suggesting the vast amount of 
interest and applications related to saliva based ‘–omic’ research including metabolomic, 
proteomic, transcriptomic and genomic research (Wong 2012).  
A wide range of analytical platforms have been explored for the metabolite profiling 
studies on saliva.  Bertram et al. demonstrated the ability of 
1
H nuclear magnetic 
resonance (NMR) for metabolite profiling of saliva. The diurnal effect on salivary 
metabolite profile, as well as differences between morning and night saliva samples, 
were also evaluated using NMR (Bertram et al. 2009). A holistic approach was employed 
by Takeda et al. for understanding the salivary metabolome using NMR (Takeda et al. 
2009). There have been examples of comparative studies between salivary, plasma and 
urinary metabolite profiles following an acute dietary standardisation using NMR (Walsh 
et al. 2006). NMR has also been used for investigating salivary metabolomic signatures 
of chronic periodontal disease (Aimetti et al. 2011). Techniques such as capillary 
electrophoresis coupled with mass spectrometry (CE-MS) have been used to identify 
oral, breast and pancreatic cancer specific profiles from salivary metabolite profiling 
(Sugimoto et al. 2010). Salivary metabolome has been successfully utilised for diagnosis 
of oral squamous cell carcinoma (OSCC) or oral cancer and leukoplakia by untargeted 
metabolite profiling using LC-MS (Wei et al. 2010). LC-MS is rapidly becoming the 
method of choice for untargeted metabolite profiling studies, however, the applications 
of this technique for profiling of saliva are limited in number. 
1.4.6 Sampling of saliva 
The complex nature of biochemical and physico-chemical properties presents challenges 
for the use of saliva as a research material (Schipper et al. 2007). The composition of 
saliva is highly variable both intra- and inter-participants and is also dependent on time 
of the day. Hence, standardisation of the saliva collection is an important consideration 
of salivary research. 
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1.4.6.1 Collection devices 
There exists a large number of commercially available sample collection devices for 
saliva sampling, such as synthetic swabs, micro-sponges, cotton pledgets etc. Most of 
these are optimised for particular assays or for specific class of compounds, such as 
steroids or measuring specific analytes such as DHEA-S (Whetzel & Klein 2010), 
cortisol (Poll et al. 2007). These devices vary in size, shape and the materials out of 
which they are made. Some devices are equipped with salivary stimulant materials to aid 
in production of saliva to obtain desirable volume of sample specimen. Most of the 
commercially available devices are made in such a way that they can be used to collect 
saliva for general-purpose analysis.  
However, not all saliva sample collection devices perform the same (Smolders et al. 
2009; Donzella et al. 2008). Saliva is a mixture of oral fluids secreted by different source 
glands e.g. submandibular gland which is situated in the lower area of the mouth 
between cheek and jaw. Thus, a saliva collection device, such as an adsorbent swab, 
which is placed in this region will have a higher concentration of analytes secreted from 
the submandibular gland. Hence, in such cases the saliva sample obtained will not be a 
representative sample of the whole saliva. Therefore, although these commercially 
available saliva sampling devices can be used for a variety of applications and targeted 
analyses, they are subject to producing interference or loss of analytes due to adsorption 
or reaction with the sample device material. All these factors prevent such collection 
devices from being a universal sample collection solution. 
1.4.6.2 Sample collection 
Passive drool is the most widely used technique for the collection of whole saliva. It is 
highly recommended as it is approved to be used with almost all analytes. Since it 
involves no adsorbent materials during sampling, interference caused by such materials 
can be avoided. Sampling methodology for passive drool is simple, efficient and very 
cost effective as no complicated sampling devices or salivary stimulants are utilised 
(Donzella et al. 2008; Navazesh & Christensen 1982).  
During the passive drool approach of saliva collection, the participants are  instructed to 
sit comfortably with their heads tilted forward and keep their eyes open (as this is a 
factor which influences salivary flow). Participants are handed a glass collection vial for 
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the saliva and asked to let saliva pool in front of their mouths; the saliva is then dribbled 
out between slightly parted lips into the glass collection vial held near the lips at regular 
intervals. Stimulated saliva generated by spitting is different in composition to 
unstimulated saliva obtained by passive drool method and hence spitting is to be 
discouraged during sample collection (Navazesh & Christensen 1982). 
1.4.6.3 Comparison of saliva collection approaches 
The methods for collection of saliva can be classified under two major groups viz. 
stimulated and unstimulated saliva collection (Navazesh 1993; Donzella et al. 2008). The 
stimulated methods of saliva collection include mastication, spitting or the use of 
salivary stimulants such as citric acid. The alternate approach of unstimulated saliva 
collection includes methods such as passive drool or draining wherein the participants 
allow saliva formed in the oral cavity to be dribbled off the lower lip into a collection 
vial. Metabolite concentrations have been reported to be higher in unstimulated saliva as 
compared to stimulated saliva (Takeda et al. 2009). Bacterial levels have been reported 
to be 14 fold higher in samples collected by stimulated method of spitting as compared to 
unstimulated samples obtained by passive drool approach (Chiappin et al. 2007). Saliva 
collected by mastication e.g. from chewing on a Salivette – a cotton roll, and then 
recovered by centrifugation of the cotton roll produces saliva with lesser viscosity, 
contamination with cotton wool as well as the possibility of loss of metabolites by 
adsorption onto the cottonwool (Poll et al. 2007). Hence, to minimise such effects, 
passive drool approach of saliva collection is commonly used in metabolomic research. 
1.4.6.4 Storage 
The procedures used for the storage of saliva are an important consideration while using 
saliva for analytical and metabolomic applications. The composition of the saliva sample 
is prone to change due to enzymatic or bacterial activity immediately after sample 
collection. The bacteria contained in saliva samples continue to metabolise components 
from saliva post sampling procedures, producing low levels of new components. If 
precautions are not taken during storage, saliva can also produce degradation products 
from the salivary components as many of them have short biological half-lives. There is 
also the risk of loss of compounds from saliva due to adsorption of compounds from 
saliva onto surfaces of storage containers of transfer mediums used. Many components 
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of saliva are thermally labile i.e. susceptible to temperature changes and are affected to a 
greater extent. 
1.4.7 Saliva sample preparation 
Pre-treatment of saliva prior to its analysis is often required to remove interferences or 
for concentration of analytes for optimum detection. A popular technique for pre-
treatment of saliva is the use of solid phase extraction (SPE) which facilitates the clean-
up of sample as well as concentration of the sample.  
The larger the number of steps in sample pre-treatment, the greater the likelihood of 
human error increases, which may result in loss of reproducibility of sample preparation. 
As a consequence the sample may not be an accurate representation of the metabolic 
composition of the sample. Hence, limiting the number of steps of sample pre-treatment 
is desirable. 
Human saliva contains a host of proteins representative of various biological activities 
such as food digestion (α-amylase, maltase, peptidases, phosphatises etc.) and protective 
functions in the gastrointestinal tract (immunoglobulins - IaG, lysozymes, lactoferrins, 
histatins, cystatins etc.); various proteins involved with cardiovascular (kallikrein, 
histamine, renin, tonin) and nervous system functions (neuroleukin, nerve growth factor 
etc.) are also present (Grigoriev et al. 2003). Other proteins are also present which have 
antibacterial and/or antiviral properties. Multifunctional glycoproteins in saliva, such as 
mucins provide protection against mechanical damage and prevention of dehydration 
(Turner & Sugiya 2002). Thus, it is clear that human saliva contains significant levels of 
proteins and thus sample pre-treatment for metabolomic applications should focus on 
removal of proteins from the samples to improve the selectivity of metabolites in saliva. 
With the growing interest in ‘salivaomics’, sample preparation protocols for the analysis 
of saliva by LC-MS are being established. Alvarez-Sanchez et al. compared a variety of 
sample preparations techniques for the metabolite profiling of saliva to obtain the 
maximum number of features by liquid chromatography-time-of-flight-mass 
spectrometry (LC-ToF-MS) (Álvarez-Sánchez et al. 2012). An investigation carried out 
by Polson et al. dealt with the optimisation of protein precipitation from biofluids. This 
involved the evaluation of various protein precipitation techniques, such as addition of 
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variety of organic solvents, acids, salts and metal ions. The effectiveness of protein 
precipitation by employing various ratios of organic solvents was also evaluated. 
Acetonitrile in the ratio of 2:1 to biofluid sample was found to be most efficient with 
protein removal efficiency of >96% (Polson et al. 2003). Theodoridis et al. suggested a 
minimal sample pre-treatment methodology based on the removal of particulate matter 
from biofluids, followed by protein precipitation using solvents such as acetonitrile for 
LC-MS based metabolomics (Theodoridis et al. 2008). This approach of protein 
precipitation combined with ultrasonication for homogenising the viscous saliva samples 
was utilised in the research presented in this thesis. 
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1.5 RATIONALE BEHIND THE RESEARCH 
Metabolomics is a technologically driven science. In recent times, mass spectrometry 
(MS) has occupied a central role in metabolomics which is growing along with the 
development and improvements in MS technologies (Bedair & Sumner 2008). The 
advent of new technologies such as IMS and FAIMS, as well as the continuous 
advancements in instrumentation and data processing methodologies, has shown promise 
for metabolomics. Although technologies such as travelling wave ion mobility 
spectrometry (TWIMS) and FAIMS have existed for over a decade, their use in 
combination with mass spectrometry for metabolomic studies on biofluids remains 
largely under explored (Kanu & Hill 2004; Dwivedi, Wu, et al. 2007).  
Modern day metabolomics has seen a trend towards the use of non-invasively obtained 
biofluids such as saliva, urine and breath etc. for applications such as biomarker 
discovery and disease diagnosis (Smolders et al. 2009). The utility of saliva as an 
analytical tool in metabolomics has already been demonstrated with a variety of 
applications (Esteban & Castaño 2009). Good correlation between saliva and the 
compounds present in blood have been established. These factors coupled with the non-
invasive sampling of saliva makes it an attractive alternative to invasively obtained 
biofluids for metabolomic studies. However, there are limiting factors to the collection of 
saliva as mentioned in section 1.4.6, which highlight the need for establishing protocols 
for the collection, storage and pre-treatment of saliva prior to its effective use in 
metabolomic setting.  
Thus, the work presented in this thesis aims to evaluate the use of ion mobility in 
metabolic profiling studies involving plasma and saliva, develop and validate methods 
using the combination of UHPLC-IM-MS as well as establish standard protocols for the 
collection, storage and pre-treatment of a valuable biofluid - saliva. 
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1.6 AIMS AND OBJECTIVES 
The objective of the research described in this thesis was the development of novel 
methods based on mass spectrometry and ion mobility spectrometry for metabolite 
profiling and the detection of diagnostic and prognostic biomarkers of diseases. The 
remainder of this thesis is divided into four chapters as described below: 
1. Chapter 2 describes the development and evaluation of a method based on 
UHPLC-IM-MS for detection of biomarkers of chemopreventive efficacy of rice 
bran in colorectal cancer as evaluated from a APC
min
 mouse model of colon 
carcinogenesis. It highlights the advantages of using ion mobility for the clean-up 
of contaminants from mass spectrometric data post analysis. 
2. Chapter 3 describes the potential of non-invasively obtained biofluid – saliva, for 
metabolite profiling analysis. Untargeted global metabolite profiling analysis of 
saliva was carried out on samples obtained from healthy controls and individuals 
with asthma to identify potential metabolomic biomarkers of the disease. 
3. Chapter 4 describes the development and validation of a method for metabolite 
profiling of saliva based on UHPLC-IM-MS. The advantages of the developed 
method for the targeted and untargeted metabolite profiling analysis of saliva 
have been highlighted. The developed method was used for untargeted metabolite 
profiling of samples obtained after induced physiological stress to identify the 
metabolomic biomarkers. The advantages offered by ion mobility towards 
increasing the analytical space and the identification of the discriminant 
metabolites by comparison with standards have been presented. 
4. Chapter 5 presents a conclusion to the thesis and details further work. 
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2 CHAPTER TWO:  
METABOLOMIC ANALYSIS OF THE 
CHEMOPREVENTIVE EFFICACY OF RICE 
BRAN IN COLORECTAL CANCER BY 
UHPLC-IM-MS. 
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2.1 INTRODUCTION 
Colorectal cancer is the third most common cancer in the world accounting for over 9% 
of all cancer incidences (Haggar & Boushey 2009). It is the fourth most common cause 
of cancer related deaths worldwide. There is a wide variation in frequency of 
occurrences of colorectal cancer across the world due to factors such as differences in 
diet, consumption of red and processed meat, fibre intake, alcohol, body weight and 
physical activity. (Cancer Research UK 2011). Countries with the highest incidence rates 
include Australia, New Zealand, Canada, the United States, and parts of Europe. The 
countries with the lowest risk include China, India, and parts of Africa and South 
America (Haggar & Boushey 2009). Food and nutrition have a highly important role in 
the causation and prevention of colorectal cancers. There has been a significant amount 
of research into the chemo-preventive role of dietary fibre in protecting against benign 
and malignant colorectal cancers according to the WCRF, AICR report of 2007 
(WCRF/AICR 2007).  
Several studies linking colorectal cancer with dietary factors have been published. These 
include the impact of intake of polycylic aromatic hydrocarbons (PAH’s) (Obayashi et 
al. 2009), dietary flavonoids (Cooke et al. 2006) etc. 
In 1971 Burkitt highlighted low dietary fibre intake as a risk factor for colorectal cancer 
for the first time (Burkitt 1993). According to the WCRF/AICR report, there have been 
at least sixteen cohort studies and ninety-one case-control studies investigating the effect 
of dietary fibre on colon carcinogenesis. Most of these studies concluded that increase in 
dietary fibre reduced the risk of colorectal cancer (WCRF/AICR 2007). Conflicting point 
of views on the relationship between dietary fibre intake and colorectal cancer have been 
presented in reviews elsewhere (Obrador 2007; Peters et al. 2003; Sengupta et al. 2001). 
Despite extensive research, there has not been a definitive conclusion on the role of 
dietary fibre in protecting against colorectal cancer. 
A study carried out by Verschoyle et al. showed that rice bran supplementation in diet at 
a concentration of 30% w/w interfered with adenoma development in a preclinical model 
of colon carcinogenesis based on the APC
min
 mice (Figure 2.1) (Verschoyle et al. 2007). 
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2.1.1 APCmin mice 
 
Figure 2.1 APC
min
 mouse 
In 1989, Moser et al. discovered a mutation in the mouse genome that led to multiple 
intestinal neoplasia (Moser et al. 1989). The mutation was observed in progeny, which 
were derived from mice treated with ethylnitrosourea (Figure 2.2), which is a mutagen. 
These mice developed numerous adenomas throughout the intestinal tract. This 
phenomenon has been referred to as multiple intestinal neoplasia (MIN) and the gene 
responsible for the mutation was determined to be adenomatous polyposis coli (APC). 
Hence this model of colon carcinogenesis derived the name APC
min
. This model is well 
characterised and has shown phenotypic and histopathological similarities with man. 
Thus it has been widely used as a pre-clinical model of colorectal cancer and 
consequently to test the therapeutic efficacy of new drugs and cancer preventive 
strategies (Leclerc et al. 2004). 
 
Figure 2.2 Ethylnitrosourea - a highly potent mutagen 
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2.1.2 Fibre and its role 
Fibre exerts several effects in the gastrointestinal tract. In principle, there are three main 
mechanisms by which dietary fibre is believed to interfere with colorectal 
carcinogenesis. Firstly, fibre is thought to exert ‘physical’ effects such as increasing the 
faecal bulk and thus hastening faecal transit and binding potentially co-carcinogenic bile 
salts. Secondly, fibre can cause changes in the intestinal microflora. Lastly, 
carbohydrates can undergo fermentation and produce short chain fatty acids such as 
butyric acid, which are believed to exert anti-carcinogenic effects. The anti-cancer 
properties of fibre can be due to any of these mechanisms or a combination of two or 
more; but precise mechanisms for its probable protective role towards colorectal cancer 
are still not clearly understood. 
The analytical methods used for the metabolite profiling of colorectal cancer have been 
critically reviewed elsewhere (Williams et al. 2013). In contrast to already published 
works, this study presents the first instance of the use of ion mobility spectrometry in 
combination with UHPLC-MS for metabolite profiling of mouse plasma. 
The aim of the current study was to develop statistical models based on plasma 
metabolite profiling and to identify potential metabolomic biomarker ions of the efficacy 
of rice bran in colorectal cancer using ultra-high performance liquid chromatography-ion 
mobility-mass spectrometry (UHPLC-IM-MS).  
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2.2 CHAPTER TWO AIMS AND OBJECTIVES 
The purpose of the work presented in this chapter was to explore novel methods for the 
metabolic profiling of plasma obtained from APC
min
 mice using travelling wave ion 
mobility spectrometry (TWIMS) as an added dimension of separation in conjunction 
with UHPLC-MS. The particular objectives were: 
 To develop a method based on UHPLC-IM-MS for metabolic profiling of 
plasma obtained from APC
min
 mice. 
 To explore the potential of ion mobility spectrometry for the improvement of 
mass spectral quality by selective removal of contamination such as PEG from 
the sample. 
 To employ the developed method for the metabolomic analysis of the 
chemopreventive efficacy of rice bran in colorectal cancer. 
 To identify potential metabolomic biomarker ions of the efficacy of rice bran in 
preventing colorectal cancer. 
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2.3 EXPERIMENTAL 
2.3.1 Chemicals and reagents 
Acetonitrile (analytical grade), water (analytical grade) and formic acid (>99.9%) were 
obtained from ThermoFisher Scientific (Loughborough, UK). L-carnitine (>99%) and 
hydrocortisone (>99%) were obtained from Sigma-Aldrich (Gillingham, UK). A 400 
ng/mL stock solution of leucine enkephalin was obtained from Waters Corporation 
(Manchester, UK) and used to prepare a 2 ng/ml working solution of leucine enkephalin 
in water:acetonitrile (50:50) (v/v) to be used as a LockMass (m/z 556.2771) solution. A 
standard mixture of 0.01 mg/mL L-carnitine and hydrocortisone was prepared in 
water:acetonitrile (95:05) (v/v) with 0.1% formic acid. 
2.3.2 APCmin mice bran supplementation and plasma collection 
The animal studies were carried out by the academic staff at the Department of Cancer 
Studies and Molecular Medicine (CSMM) at the University of Leicester. The animal 
studies included rice bran supplementation of mice, plasma collection, and assessment of 
intestinal neoplasia along with proteomic studies on mice plasma.  
A mixed population of male and female APC
min
 mice (n=35) were administered with 
rodent feed supplemented with rice bran at concentrations of 0%, 5%, 15% and 30% 
w/w. Based on the percentage of bran supplemented the mice were classified into groups 
starting with Group A for 0% rice bran supplemented (control group) to group D which 
had 30% rice bran supplemented in their diet respectively Table 2-1. These mice were 
administered with the supplemented rodent feed from the age of 4 weeks till the 
termination of the study at the end of 16 weeks. At the end of this period the mice were 
culled by cardiac exsanguination and whole blood was collected. Blood was processed 
into plasma and immediately stored at -80
o
C. The gastrointestinal tracts were extracted 
and washed with phosphate buffered saline (PBS) to remove food content and then were 
opened longitudinally to reveal adenomas. These adenomas were counted and their sizes 
were measured using digital callipers to determine the total tumour burden. 
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Table 2-1 Summary of demographic of the study 
Group Supplemented 
Bran (%) 
Total (n) Male Female 
Group A 0 7 4 3 
Group B 5 4 4 0 
Group C 15 16 9 7 
Group D 30 8 4 4 
Total  35 21 14 
2.3.3 Plasma sample pre-treatment 
Mouse plasma sample pre-treatment, method development and metabolomic profiling 
analysis by UHPLC-IM-MS and subsequent data processing was carried out at Centre 
for Analytical Science, Loughborough University by the author (Aditya Malkar). Mice 
plasma samples stored at -80°C were thawed at room temperature prior to sample clean-
up by protein precipitation. Each thawed plasma sample was vortexed for 30 seconds 
followed by ultra-sonication for 1 minute to improve homogeneity. Protein precipitation 
was achieved by the addition of 200 µL acetonitrile to 100 μL of plasma i.e. 2:1 ratio of 
precipitant to plasma (Polson et al. 2003). The mixture was vortexed for 30 seconds 
followed by ultra-sonication for 1 minute and then subjected to centrifugation at 10,000 
g for 10 minutes at ambient temperature. Precipitated proteins from the sample were 
discarded as a pellet at the bottom of the microcentrifuge tube. The supernatant was 
transferred to a fresh microcentrifuge tube and was subjected to concentration by 
evaporation using Turbovap LV concentration workstation (Caliper Life Sciences, 
Hopkinton, MA, USA). The supernatant was evaporated to near dryness prior to being 
reconstituted in 50 μL water/acetonitrile (95:05) (v/v) with 0.1% formic acid. The 
reconstituted plasma extract was placed in a 200 μL polypropylene micro-insert 
(Supelco, UK) in an autosampler vial (2 mL) for UPLC-MS analysis. An overview of the 
sample pre-treatment procedure is outlined in Figure 2.3. 
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Figure 2.3 Overview of sample pre-treatment for mice plasma 
2.3.4 Instrumentation 
The liquid chromatographic separations for the metabolomic analysis of mice plasma 
were performed on a Waters AQUITY UPLC chromatograph with an in-built auto-
sampler (Waters Corporation, Manchester, UK) fitted with a Waters AQUITY BEH 
(bridged ethylene hybrid) C18 column (2.1 mm x 100 mm, 1.7 μm; Waters Corporation, 
Manchester, UK) maintained at 40°C. A VanGuard BEH C18 pre-column (Waters 
Corporation, Manchester, UK) was attached prior to the analytical column. The UPLC 
system was coupled with a Waters Synapt HDMS ion-mobility mass spectrometer 
(Waters Corporation, Manchester, UK) equipped with an electrospray interface. 
MassLynx v4.1 (Waters Corporation, Manchester, UK) was used for controlling the 
setup and for data acquisition. 
2.3.4.1 UPLC conditions 
Mobile phase A consisted of 0.1% aqueous formic acid (v/v) and mobile phase B was 
0.1% formic acid in acetonitrile (v/v) with the flow rate set to 0.5 ml/min. The mouse 
plasma extract (10 μL injected) was analysed by the chromatographic gradient: 5% B (0-
1 min), increased to 35% B (1-10 min). This was followed by a column clean-up phase 
built into the method to reduce carry over and condition the column for analysis of 
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subsequent samples, in which the mobile phase was increased to 95% B (10-11 min) and 
maintained at 95% B (11-12 min) before returning to initial conditions (13-15 min). 
2.3.4.2 MS conditions 
Electrospray ionisation conditions for the MS, with the ion source operated in positive 
ion mode were: capillary voltage 3.0 kV; cone voltage 30 V; source temperature 120°C; 
desolvation temperature 300°C; desolvation gas, N2 gas flow 600 L/hr; cone gas flow 30 
L/hr. Data was acquired in centroid mode from 50 – 1200 Da with an inter-scan delay of 
0.02 sec.  
2.3.4.3 Ion mobility conditions 
The tri-wave (TWIMS) drift cell conditions were set at 30 mL/min drift gas (N2) with a 
variable travelling wave height ramp of 6.0 – 13.0 V and wave velocity of 300 m/s. The 
mass spectrum acquisition rate was 0.065 ms/scan.  
2.3.5 Method development 
The chromatographic gradient programme was optimised for the analysis of mice plasma 
samples using 0.01 mg/mL mixture solution of L-carnitine and hydrocortisone in 
acetonitrile/water (05:95%) with 0.1% formic acid. The TWIMS conditions were 
optimised online by infusing a 2 ng/mL solution of leucine enkephalin. The optimisation 
of ion mobility parameters is discussed in depth in chapter 4. The starting volume of 
mouse plasma used for sample pre-treatment was optimised by evaluating varying 
volumes in the range of 50 µL – 400 µL. Sample pre-treatment was carried out as 
outlined in Section 2.3.3 with an UHPLC injection volume of 10 µL. Based on the signal 
intensity and to avoid the overloading of the detector, 100 µL volume was chosen for 
analysis. 
2.3.6 Quality control of the methodology 
A quality control (QC) sample was prepared from equal-volume sub-aliquots of all the 
samples from all the sample groups of the study (Group A to D). A series of 5 
consecutive extracts derived from the QC samples were analysed prior to the sample run 
for conditioning of the chromatographic column. Randomisation of the sample list was 
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carried out prior to analysis to remove bias. A pooled mice plasma extract was analysed 
after every 5 samples as a quality control sample (QC). Blanks were analysed after every 
sample to ensure no-carryover between samples runs. 
2.3.7 Data processing and statistical analysis 
Data mining was carried out using MarkerLynx XS (Waters Corporation, Manchester, 
UK). The parameters used for peak alignment were: retention time range 0-10 min, 
retention time tolerance was set to 0.1 min; mass range was limited to 50-500 Da and 
isotopic peaks were excluded from the analysis. The data matrix generated by the 
MarkerLynx software was normalised to the summed total ion intensity per 
chromatogram. The data were pareto scaled prior to subjecting the data matrix to 
multivariate statistical analysis. Multivariate statistical analysis including PCA and PLS-
DA was carried out using SIMCA-P + (Umetrics, Sweden). Ion mobility data was 
visualised and processed using Driftscope v2.1 (Waters Corporation, Manchester, UK). 
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2.4 RESULTS AND DISCUSSION 
2.4.1 Physiological data from the mice 
 
 
Figure 2.4 Small intestine and colon of APCmin mice from Group A (0% bran 
supplemented control population) and Group D (30% bran supplemented 
population) 
An example of a small intestine and colon of an APC
min
 mouse from Group A (control 
population) and another from Group D (30% bran supplemented) population is shown in 
Figure 2.4. A significant reduction in the number and size of the adenomas can be 
observed in Group D (Figure 2.4 b) when compared with Group A (Figure 2.4 a). The 
number and burden of adenomas was evaluated from the intestines and colons of mice 
from all the groups.  
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Figure 2.5 Effect of lifetime dietary fibre administration on the burden and number 
of adenomas for APCmin mice 
Figure 2.5 shows that there is a dose related gradual decrease in the number and burden 
of adenomas from 0% to 30% bran supplementation. The group D population shows 
statistically significant decrease both in number and burden of the adenomas compared 
with the group A population, supporting the evidence that fibre at 30% concentration in 
the diet interferes with adenoma development in the APC
min
 mouse model. Hence, for 
subsequent multivariate analysis on the metabolomic data obtained, Group A and Group 
D were focussed upon. 
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2.4.2 Metabolite profiling of mice plasma by UHPLC-IM-MS 
Protein precipitation was the only step carried out in preparation of plasma samples for 
metabolomic analysis by UHPLC-IM-MS. This was achieved by the addition of 
acetonitrile in the ratio 2:1 with plasma (Polson et al. 2003). The main aim of the sample 
pre-treatment performed was to extract small-molecular-mass compounds while 
removing large amount of proteins from plasma, which would otherwise interfere with 
the metabolomic analysis. Mass spectrometric data acquisition was carried out in 
positive ionisation mode (ESI+). A typical total ion current (TIC) obtained from the 
analysis of mice plasma extract is shown in Figure 2.6 (a). 
 
Figure 2.6 Fig 1. UPLC-IM-MS metabonomic analysis of mice plasma extract. (a) 
UHPLC total ion chromatogram, (b) total ion mobility drift time plot summed over 
the entire chromatographic run, (c) retention time vs ion mobility drift time 
heatmap. (Data produced on Synapt HDMS) 
The UHPLC-IM-MS analysis of mice plasma generated a complex dataset consisting of 
mass-to-charge ratio, ion mobility drift time and chromatographic retention time. Figure 
2.6 shows an example profile of UHPLC-IM-MS analysis of mice plasma extract. The 
complexity of the three dimensional dataset obtained from the analysis within a short 
time frame of 10 minutes is illustrated (excluding the column clean-up and re-
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equilibration phase). It is clear that the manual interrogation of the data and comparison 
of profiles obtained from different groups of samples would be tedious, time consuming 
and unfruitful. Hence, the need for using multivariate statistics to find discriminating 
metabolites between the sample groups is evident. 
A three dimensional illustration of the structure of the data is depicted in Figure 2.7, 
generated by Waters DriftScope v2.1 (Waters Corporation, Manchester, UK). The 
orthogonal nature of the ion mobility domain of separation can be seen with respect to 
the chromatographic retention time (tR). The two dimensional retention time vs ion 
mobility drift time plot (Figure 2.6 c) shows examples of multiple species contributing 
to single chromatographic peak, which are separated by ion mobility. This demonstrates 
the enhanced separation of the complex plasma samples achieved by the use of ion 
mobility spectrometry within the same timeframe as a UHPLC-MS run. 
 
Figure 2.7 UHPLC-IM-MS analysis of mice plasma extract, a 3-dimensional 
representation illustrating the orthogonal structure of the ion mobility domain 
(drift time) with respect to chromatographic retention time (tR). (Data produced on 
Synapt HDMS) 
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2.4.3 Improvement of mass spectral quality using ion mobility 
Polyethylene glycols (PEG) are widely used in pharmaceutical and biological analyses 
for various purposes such as stabilisation of proteins for separation, storage and 
purification (Zhao & O’Connor 2007). However, they are also a common source of 
contamination in mass spectrometric systems, which cause significant challenges in the 
analysis of analytes of interest. Common sources of PEG are volumetric and storage 
equipment contaminated with PEG, laboratory glassware cleaning products such as 
Neutracon, Triton-X, Tween etc. and plastics utilised in analytical laboratory 
environments. 
PEG, if present in samples, generates significant interference with mass spectrometric 
experiments causing loss of signal and by obscuring the signal from analytes of interest. 
PEG can be spotted in a mass spectrum as it shows a common repeat of 44 Da with a 
characteristic Gaussian profile (Fenn et al. 1989). Removal of PEG from samples 
containing small molecules is a difficult task by traditional methods of sample cleanup 
such as solid-phase extraction, dialysis, ion exchange catridges and titanium dioxide 
addition. Such methods of sample clean-up would also require additional steps of sample 
pre-treatment for metabolomic analysis and would affect the holistic extraction of 
metabolites from samples (Eckers et al. 2007; Castro-Perez et al. 2007). 
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Figure 2.8 Visualisation and selection of PEG series by ion mobility drift time 
demonstrating charge state separation of singly and doubly charged PEGs 
obscuring the metabolomic information by suppression of signal .  
The contamination of samples with PEGs was suspected in the mice plasma samples 
used in this study. A possible source of contamination was thought to be plastic micro-
centrifuge tubes used for the storage and transport of mice plasma samples. The ion 
mobility heat map obtained from the UHPLC-IM-MS analysis of mice plasma extract 
facilitates easy detection and visualisation of the PEG contamination within the mice 
plasma extract samples as highlighted in Figure 2.8. The charged state separation of the 
PEG present in the mice plasma samples can be seen in the circled regions of Figure 2.8. 
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Figure 2.9 UHPLC-IM-MS analysis of mice plasma extract showing post-analysis 
selective extraction of PEG using ion mobility drift time. (Data produced on Synapt 
HDMS) 
A specific region of the chromatographic retention time (tR) vs ion mobility drift time 
(bins) can easily be selected from the generated heatmap and the mass spectra for that 
region extracted. Figure 2.9 shows the selection of the region of the heatmap containing 
a series of PEG ions displaying extracted mass spectrum for the region. The PEG ion 
distribution extends from approximately m/z 300 – 1000 with high peak intensity in the 
region around m/z 600. Low level metabolite ions in this region would therefore be 
obscured by the PEG ions. The selected regions shown in Figure 2.8 and Figure 2.9 can 
be removed from the dataset using DriftScope software (Waters Corporation, 
Manchester, UK) and the remnant dataset can be exported back to MassLynx (Waters 
Corporation, Manchester, UK) for further data interrogation. The removal of PEG signal 
by using the ion mobility drift time information enables access to lower-level 
components of the sample by the removal of PEG signals which would otherwise 
obscure the components in the given mass range. 
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Figure 2.10 Improvement of spectral quality by UHPLC-IM-MS: (a) UHPLC total 
ion current (TIC) for mice plasma extract without post analysis clean-up of PEG 
using drift time information, (b) mass spectrum associated with 0-10 min of the 
UHPLC chromatogram showing distribution of PEG series, (c) UHPLC total ion 
current (TIC) for mice plasma extract selectively cleaned up for PEG using drift 
time and (d) cleaned-up mass spectrum associated with 0-10 min of chromatogram 
using drift time to selectively remove PEG showing mass spectral improvement. 
(Data produced on Synapt HDMS) 
The improvement of the mass spectral quality by the use of ion mobility spectrometry 
can be seen from Figure 2.10. The total ion current (TIC) obtained by the UHPLC-IM-
MS analysis of mice plasma extract without subjecting to post-analysis ion mobility 
clean-up of the chromatogram is shown in Figure 2.10 (a), with its associated mass 
spectrum shown in Figure 2.10 (b). The series of PEGs present in the sample were 
selectively removed by post-analysis processing of the UHPLC-IM-MS data as described 
above. Figure 2.10 (c) shows the PEG cleaned-up TIC of the UHPLC-IM-MS analysis 
of mice plasma extract with its associated mass spectrum shown in Figure 2.10 (d). The 
mass spectral quality improvement can be seen with the reduction in the intensity of PEG 
series ions increasing the signal-to-noise for previously obscured components of the 
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mass spectrum in the region. Mass spectral clean-up with ion mobility by this method 
can prove to be a valuable tool for analysis of targeted metabolites from complex 
samples as well as for untargeted metabolite profiling experiments by improving the 
detection of smaller features from the UHPLC-IM-MS analysis. 
2.4.4 Software limitations 
Currently used software for mining the UHPLC-IM-MS metabolomic dataset e.g. 
MarkerLynx XS (Waters Corporation; used in the present study) were not equipped to 
deal with the ion mobility dimension of the dataset during multivariate statistical analysis 
step. As a result, the workaround used for this problem has been to collapse the ion 
mobility dimension during the first stage of data processing resulting in significant 
amount of potentially valuable unused data.  
Attempts were made to generate an in-house spreadsheet to convert the ion mobility data 
into numerical values to be included in the data matrix. However, this yielded 
insignificant results in the preliminary test and it was deemed that extensive specialist 
programming will be required for accurately and efficiently converting and incorporating 
the ion mobility data into the data matrix. 
A significant shortfall of the present data mining tools commercially available for 
metabolomic studies has been highlighted here.  
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2.4.5 Potential metabolomic biomarker ions of the chemopreventive efficacy of 
rice bran in colorectal cancer 
The multidimensional dataset generated by the UHPLC-IM-MS analysis (Figure 2.7) 
presented a challenge for the data analysis software (MarkerLynx XS, Waters 
Corporation, Manchester, UK in this case) traditionally used for metabolite profiling 
studies, as the software are equipped to deal only with two dimensional datasets e.g. 
chromatographic retention time and mass-to-charge ratio (m/z). The commercially 
available software are not capable of integrating the third dimension of separation - ion 
mobility, while generating the data matrix required for multivariate statistical analysis. 
As a result, ion mobility dimension was collapsed to reduce the complexity of the data 
with the intention to ‘open up’ the ion mobility dimension post multivariate statistics. 
 
Figure 2.11 Principal component analysis (PCA) of all mice plasma extracts (Group 
A, B, C, D and QC) samples. Component 1 (20.51%) and component 2 (13.46%). 
Model based on K=339 variables and N=44 observations. 
The quality of the data generated from chromatography-mass spectrometric techniques is 
of paramount importance in untargeted global metabolite profiling studies. It is important 
to establish that the data generated during metabolomic studies is of high quality if the 
studies are to yield valuable insights from a biological interpretation point of view. The 
data generated has to be acceptable in terms of chromatographic retention time 
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reproducibility and mass spectrometric sensitivity. As these studies aim to unravel small 
differences in the analysed samples, it is important to establish that the source of 
variation in the data is due to the biological question being asked and not due to 
instrumental variations or variable system performance.  
Principal component analysis (PCA), the most commonly employed unsupervised 
pattern recognition technique, enables the reduction of the dimensionality while 
maintaining the maximum variability of the data. Figure 2.11 shows the PCA plot of all 
the samples from the study (Group A – control to Group D – 30% bran fed mice 
population) and quality control (QC) samples. The QC samples were generated as 
described in Section 2.3.6, by pooling together aliquots from all the samples used in the 
analysis so as to provide a representative mean sample containing all the analytes which 
will be encountered during the analysis. The tight clustering of the QC samples towards 
the middle of the PCA plot (circled in Figure 2.11) provides evidence of reliable data 
quality, which is fit-for-purpose for metabolite profiling studies. The numbered QC 
samples showed no particular trend and were distributed in a random order within the 
cluster of samples indicating there was no significant drift in system performance which 
would cause a bias in the analysis. In case of a system performance drift, trailing of QC 
samples would have been observed in the PCA plot. 
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Figure 2.12 Principal component analysis (PCA) of all mice plasma extracts (Group 
A, B, C and D) samples. Component 1 (17.56%) and component 2 (16.44%). Model 
based on K=332 variables and N=35 observations. 
The QC samples were removed from the model after the initial inspection to establish 
reliable data quality and the rest of the samples (Groups A to D) were analysed by the 
unsupervised PCA approach (Figure 2.12). However, these showed no significant 
separation of the groups of samples in a model based on K=332 variables. Thus, from the 
data described in Section 2.4.1, it was decided to focus on the two extreme groups from 
the study i.e. Group A – the 0% bran supplement fed population (control group) and 
Group D – the 30% bran fed population which had shown statistical evidence of 
reduction in number of adenomas. 
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The comparison of Group A and Group D by PCA showed partial separation with 
clustering of Group D samples towards the middle of the PCA plot (Figure 2.13). 
 
Figure 2.13 Principal component analysis (PCA) of Group A and Group D samples. 
Component 1 (22.41%) and component 2 (19.18%). Model based on K=313 
variables and N=15 observations. 
Supervised pattern recognition approaches such as partial least squares – discriminant 
analysis (PLS-DA) and orthogonal partial least squares – discriminant analysis (OPLS-
DA) are often applied in metabolomic studies to tackle problems of subtle nature such as 
to uncover complex relationships buried in the background of larger multi-perplexed 
effects (Fonville et al. 2010).  
The current study involved plasma taken from a well-established APC
Min
 mice model of 
colon carcinogenesis. These mice were kept in a very controlled environment of a 
laboratory with the same age and maintained on the same diet, which would limit the 
factors responsible for metabolic variation. However, the population still had minor 
sources of variation such as gender, as the population was a mix of male and female 
mice, as well as individuality contributing to different rates of metabolism. As a result, a 
supervised OPLS-DA model was required to draw out the biological sources of variation 
in the data present in the cohort. 
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Figure 2.14 OPLS-DA analysis of Group A and Group D samples. Model based on 
K=315 variables and N=15 observations. Component 1 (18.79%) and component 2 
(7.76%). 
An OPLS-DA model based on K=315 variables produced a marked separation in the 
sample groups indicating that there were differences in the data between Group A and 
Group D populations. Group A i.e. the control population showed a wider within-
sample-group variation as can be seen from the spread of Group A samples across the 
principal component 2 in comparison to Group D samples which are restricted to a 
smaller range. Group D (30% bran supplemented) population shows tighter clustering as 
can be seen from Figure 2.14.  
Group A (N=7) consisted of 4 male and 3 female mice whereas Group D (N=8) 
contained 4 male and 4 female mice. The OPLS-DA plot does not show sub-clustering of 
the samples from either Group A or Group D, indicating that the effect due to bran 
supplementation is non-gender biased and affects male and female mice in the same 
respect. 
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Figure 2.15 S-plot generated from PLS-DA model showing distribution of the 
potential biomarker ions. 
A loadings S-plot was constructed using the OPLS-DA model shown in Figure 2.14, to 
segregate potential biomarker ions of efficacy. The S-plot is a statistical tool for 
visualisation of the distribution of the data from an OPLS-DA model of two classes. It is 
a popular method to filter out putative biomarker ions from the dataset as it is in essence 
a plot of the contribution of the variable towards class separation on the x-axis (modelled 
covariation i.e. p1) and the confidence or reliability of the variables on the y-axis 
(modelled correlation i.e. p(corr)1). 
The S-plot obtained from the OPLS-DA analysis of Group A and Group D samples is 
shown in Figure 2.15. The variables from Group D are shown in the positive first 
quadrant whereas those from Group A are shown in the third (negative) quadrant of the 
plot. A number of discriminant metabolite ions from either ends of the S-plot were 
selected and raw data was interrogated by analysing the extracted ion chromatograms 
(EIC) for the obtained individual ions. The chromatographic peak shapes of the EICs 
were analysed to ensure that only the ions, which produced valid chromatographic peaks 
with good peak symmetry and intensity, were retained for further processing and to 
narrow down the list of potential biomarker ions. Emphasis was given to scrutinising the 
raw data to verify the authenticity of the potential biomarker ions. The variables obtained 
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from either ends of the s-plot (highlighted in Figure 2.15) were systematically tested for 
their trend-plots and chromatographic peak shapes to distil and reduce the number of 
potential biomarker ions. 
 
Figure 2.16 Trend plot showing relative intensities of the potential biomarker ion 
212.95±0.02 across samples from Group A and Group D. 
Figure 2.16 shows an example trend plot of one such discriminant metabolite ion 
obtained after careful scrutinising of the variables from the s-plot. A trend plot facilitates 
the easy visualisation and comparison of the normalised chromatographic peak areas of 
the selected variable’s distribution across the samples from the study. The Figure 2.16 
shows a plot of all the samples from Group A and Group D vs the normalised 
chromatographic peak areas for the variable (potential biomarker ion) with m/z 
212.95±0.02. The figure shows a clear distinction between the individual intensities for 
the ion between the two sample groups. The normalised chromatographic peak areas for 
the variable are lower in Group A as compared to Group D and hence it can be inferred 
that the ion is up-regulated in Group D samples due to bran supplementation. 
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Figure 2.17 Example extracted ion chromatogram (EIC) of potential biomarker ion 
212.95±0.02 showing up-regulation. (Data produced on Synapt HDMS) 
The raw data for the potential biomarker ion was inspected by using the extracted ion 
chromatogram for m/z 212.95±0.02. The Figure 2.17 shows comparison of example EIC 
from an example of a Group A sample and a Group D sample, providing evidence of up-
regulation of the ion in the latter Group of samples. The change in the chromatographic 
peak areas was statistically evaluated for all the samples from the study pertaining to 
Group A and Group D. A clear statistical difference was observed from the histogram 
with error bars (inserted image in Figure 2.17) thus confirming the variable as a 
potential biomarker ion of efficacy. 
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Other ions were similarly interrogated from the s-plot using their EICs and are 
summarised in Table 2-2.  
Table 2-2 Potential biomarker ions of efficacy obtained from OPLS-DA comparison 
of Group A and Group D mice plasma extract samples 
No. 
Retention Time 
(min) 
m/z 
±0.02 
Regulation 
1 2.52 148.99 Up-regulated 
2 7.71 189.02 Up-regulated 
3 2.54 212.95 Up-regulated 
4 3.19 218.01 Up-regulated 
5 2.54 218.97 Up-regulated 
6 0.92 160.07 Down-regulated 
7 4.48 226.97 Down-regulated 
 
The identification of the potential metabolomic biomarker ions listed in the table was 
beyond the scope of this research. Further work is required to identify the discriminant 
metabolite ions obtained from this study. A logical approach is to carry out MS/MS 
analysis on the individual ions obtained as an outcome of this work to understand the 
structure of individual molecules and to obtain a list of possible matches. Authentic 
standards of the shortlist of these candidate molecules could then be compared with the 
discriminant metabolites by LC-MS and LC-MS/MS to ascertain their identities. 
The biological significance of the discriminant metabolites obtained cannot be evaluated 
at this stage without the knowledge of the identities of the ions. 
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2.5 CONCLUSIONS 
The work presented here is the first application of combination of ion mobility (IM) with 
UHPLC-MS for metabolic profiling analysis of mouse plasma. This chapter also presents 
the first application of the developed methodology for the metabolomic analysis of 
chemopreventive efficacy of rice bran in colorectal cancer. The use of ion mobility 
spectrometry for post-analysis clean-up of contaminants such as PEG is also 
demonstrated. 
The combination of high resolution UHPLC, ion mobility, mass spectrometry and 
powerful bioinformatics tools allows metabolomic biomarkers of efficacy to be 
identified from complex bio-fluids such as plasma derived from pre-clinical animal 
studies. This approach may prove useful for other pre-clinical studies to identify new 
biomarkers of efficacy. The utility of untargeted global metabolite profiling analysis by 
rapid UHPLC-IM-MS analysis and bioinformatics modelling for such studies has been 
demonstrated. The presence of PEG or other contamination in mass spectrometric 
samples is a difficult problem to deal with especially with respect to untargeted 
metabolic profiling studies. This study has preliminarily identified a panel of potential 
biomarker ions of efficacy following administration of rice bran extract with the view to 
assessing, validating and ultimately extending to a human patient intervention study. 
This work demonstrates that inclusion of ion mobility separation in the UHPLC-MS 
analysis allows clean-up of samples post-UHPLC-IM-MS analysis using ion mobility 
drift time information. 
The existing established model of colon carcinogenesis based on APC
Min/+
 mice has 
provided valuable insight and preliminary results over the years on human colon cancer 
(Leclerc et al. 2004). The next step would be to carry out the study with a larger cohort 
of samples utilising the potential biomarker ions obtained from bioinformatics models 
generated in the current study and using a targeted instead of an untargeted profiling 
approach. However, for more advanced and significant research, sampling needs to be 
carried out on human volunteers with colorectal cancers.  
Plasma as a bio-fluid has been used in clinical and pre-clinical research. In recent times, 
the number of studies utilising plasma as a bio-fluid for the detection of proteomic and 
metabolomic biomarkers of diseases has seen a significant increase (Z.-Y. Li et al. 2010; 
87 
 
Pereira et al. 2009). However, the collection of plasma from human volunteers requires 
trained individuals to carry out sampling and sample handling. Plasma, being an 
invasively collected bio-fluid, also induces participant/patient discomfort and thus makes 
sampling difficult especially in participants with trypanophobia i.e. needle phobia. As a 
result, there is a growing trend in utilisation of non-invasively obtained bio-fluids such as 
saliva and urine (Raju et al. 2013). 
The complete elimination of contamination from samples would be desirable. As a 
result, stringent protocols for collection and storage of bio-fluid samples such as plasma 
and saliva need to be established. The contamination of bio-fluid samples with 
plasticisers, PEG and other contaminants can be controlled by careful selection of 
materials and containers used for handling of metabolomic samples during storage and 
pre-treatment. This has been explored in detail in Chapter 3 and Chapter 4.  
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3 CHAPTER THREE:  
UNTARGETED METABOLITE PROFILING OF 
SALIVA BY ULTRA HIGH PERFORMANCE 
LIQUID CHROMATOGRAPHY-MASS 
SPECTROMETRY (UHPLC-MS) FOR 
DISCOVERY OF POTENTIAL BIOMARKERS 
OF ASTHMA. 
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3.1 INTRODUCTION 
Asthma is one of the most common chronic inflammatory diseases of the respiratory 
tract. About 300 million people suffer from asthma worldwide. According to 2004 data 
an estimated 32 million people in Europe are affected by asthma out of which 6 million 
suffer from severe symptoms. In the UK, around 5.4 million people are currently 
receiving treatment for asthma which includes around 1.1 million children (1 in 11) and 
4.3 million adults (1 in 12). There were 1143 deaths in the UK due to asthma in the year 
2010. An estimated 75% of hospital admissions for asthma are avoidable and as many as 
90% of the deaths from asthma are preventable (Asthma UK 2013). Thus, there is the 
need to improve the understanding of asthma as well as to develop solutions for early 
detection of the disease. 
Asthma is a chronic respiratory condition in which a person’s airways become narrow 
making it difficult to breathe. Currently there is no cure for this disease. Asthma is 
typically characterised by coughing, wheezing or shortness of breath. When allergens or 
environmental factors cause a spike in these symptoms, it is referred to as an Asthma 
attack. During an attack, large airways called bronchi react to a trigger like an allergen 
with contracting spasms. The bronchi inflame and produce mucous further narrowing the 
airways and lead to the symptoms of asthma. Asthma attacks may last a few minutes or 
linger for a few days. Symptoms can usually be relieved using asthma medication. It is 
believed that there is a strong genetic component to predisposition to asthma (Mackay & 
Rosen 2001; Holgate 2008). 
Asthma is a complex syndrome, which is characterised by variable degree of airflow 
obstruction, bronchial hyper-responsiveness and airway inflammation (Anderson 2008). 
It is chronic in nature and both genetic (atopy) and environmental factors (Holgate 2008) 
contribute towards its onset and manifestation. Asthma is a heterogeneous disease with 
common inflammatory features, but with several different phenotypes. The heterogeneity 
of asthma is not only limited to the symptoms, but it also relates to different response to 
therapies (Holgate 2008). Theories on mechanism of asthma and its 
immunohistopathology have been reviewed (Mackay & Rosen 2001).  
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The diagnosis of asthma in primary care is based on the presence or absence of airflow 
limitation, and its reversibility to inhaled bronchodilators, as measured by peak 
expiratory flow or spirometry. According to the guidelines, using spirometric values or 
peak flow as the prime outcome of interest is of limited value in patients with normal or 
near normal pre-treatment lung function since there is little room for measurable 
improvement (British Thoracic Society & Scottish Intercollegiate Guidelines Network 
2012); furthermore it is estimated that 30% of patients with a diagnosis of asthma have 
no evidence of the disease (Shaw et al. 2012; Boulet 2003; Marklund et al. 1999). 
Biomarkers of airway inflammation and airway hyperresponsiveness obtained from 
various invasive and non-invasive physiological sources such as sputum, blood, serum, 
urine, and exhaled breath have been used to diagnose of asthma (Wadsworth et al. 2011). 
These tests differ in their sensitivity, specificity and patient acceptance. More 
importantly they cannot be used below certain lung function thresholds or ages, limiting 
their application and widespread adoption. Consequently there is a need for simple, non-
invasive procedure and biomarker for the accurate identification of asthma (Szefler et al. 
2012). 
Historically, the diagnosis of asthma was largely based on pulmonary function tests, 
spirometry and tissue biopsies. In recent times, biomarkers obtained from various 
invasive and non-invasive physiological sources such as sputum, blood, serum, urine, 
exhaled breath condensate etc. have been preferred for accurate diagnosis of various 
subtypes of asthma (Wadsworth et al. 2011). Diagnosis of asthma based on tissue 
biopsies, induced sputum tests, serum protein tests, methacholine challenge tests etc. are 
either too invasive and involve patient discomfort or require high level of expertise for 
sample collection and analysis. Consequently there is a need for simple, non-invasive 
procedures that yield biomarkers for the clinical diagnosis of asthma (Szefler et al. 
2012).  
Metabolic profiling is the systematic study of the chemical fingerprints of low molecular 
mass endogenous metabolites in biological samples. Changes in metabolite 
concentrations reflect the biochemical effects produced in an organism as a function of 
disease state or therapeutic intervention (Nicholson & Lindon 2008). As a result 
metabolic biomarkers of diseases can aid early detection of diseases and provide better 
understanding of both disease occurrence and progression. The application of metabolic 
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profiling to the discovery of biomarkers of asthma has been explored in various biofluids 
and is reviewed elsewhere (Adamko et al. 2012; Szefler et al. 2012).  
Previously carried out studies include the metabolomic analysis of asthma in urine by 
NMR (Saude et al. 2011) and childhood asthma by LC-MS (Mattarucchi et al. 2012).  
2-D gel electrophoresis has been applied for the identification of novel biomarkers of 
asthma and chronic obstructive pulmonary disorder (COPD) from plasma (Verrills et al. 
2011). Exhaled breath condensate has also been analysed by NMR to prospect for 
biomarkers of childhood asthma (Carraro et al. 2007). However, the use of saliva for the 
metabolomic analysis of asthma remains largely underexplored with rare applications 
such as the analysis of salivary cytokines and pathogens by PCR and ELISA (Wexler et 
al. 2009). 
The work described here is the first instance of the use of saliva and metabolite profiling 
by UHPLC-MS as a potential tool for asthma diagnosis. In the present study, non-
targeted metabolomic analysis of saliva samples from asthmatic and healthy control 
individuals was carried out by ultra-high performance liquid chromatography-mass 
spectrometry (UHPLC-MS). Data processing was performed using a commercially 
available software package for the discovery of potential metabolomic biomarker ions of 
asthma by comparing moderate asthmatic and healthy control saliva samples. Predictive 
models based on partial least squares-discriminant analysis (PLS-DA) were obtained 
from the analysis and employed for classification of saliva samples from mild/early stage 
asthmatic individuals. 
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3.2 CHAPTER THREE AIMS AND OBJECTIVES 
The purpose of the work presented in this chapter was to explore the potential of human 
saliva as a non-invasive medium for metabolomic study of asthma. The specific 
objectives were: 
 To investigate the potential of saliva as a biofluid for metabolomic study by 
UHPLC-MS. 
 To carry out a metabolomic investigation to distinguish moderate asthmatic 
population from healthy control population via the analysis of metabolic profiles 
obtained by UHPLC-MS. 
 To construct predictive models from moderate asthmatic and healthy control 
population and to test these models on mild asthmatic population. 
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3.3 EXPERIMENTAL 
3.3.1 Chemicals 
Acetonitrile (analytical grade), water (analytical grade) and formic acid (>99%) were 
purchased from Fisher Scientific (Loughborough, UK). L-carnitine (>99%) and 
hydrocortisone (>99%) were obtained from Sigma-Aldrich (Gillingham, UK). A 
standard mixture of 0.005 mg/mL L-carnitine and hydrocortisone was prepared in 
water:acetonitrile (95:05) (v/v) with 0.1% formic acid. A ToF Reference Mass Solution 
kit (Agilent Technologies, Santa Clara, CA, USA) consisting of purine (m/z 121.0509) 
and Hexakis(1H, 1H, 3H-tetrafluoropropoxy)phosphazine (m/z 922.0098) was used to 
prepare a reference mass solution for acquiring accurate mass data.   
3.3.2 Demographic for the metabolomic study 
Fifty-seven volunteers (male and female), aged between 21 and 76 participated in the 
study. The participants included 9 moderate asthmatic individuals (3 male and 6 female), 
27 mild asthmatic individuals (14 male and 13 female) and 21 healthy individuals (7 
male and 14 female) (summarised in Figure 3.1). The classification of moderate and 
mild asthmatics was based on established diagnostic tests for asthma viz. forced 
expiratory volume (FEV1%PRED), sputum eosinophil count (EOS) and methacholine 
challenge (PC20). These tests are explained in detail in Section 3.3.3. The participant 
information, including diagnostic data and medication regimes are outlined in Figure 3.1 
and Table 3-1.  
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Figure 3.1 Overview of demographic of the asthma metabolomic study. 
3.3.3 Overview of the tests for diagnosis of asthma 
The population used in the study was well characterised for asthma based on a range of 
diagnostic tests (Appendix 7.6) and clinical diagnosis carried out at the Respiratory 
Biomedical Research Unit (BRU) at the Nottingham City Hospital (Nottingham, UK). 
The sub-classification of asthmatics into mild asthmatics and moderate asthmatics was 
carried out based primarily on three tests as described below. 
3.3.3.1 FEV1%PRED 
Forced expiratory volume in 1 second (FEV1) is a measure of lung function. It is the 
volume exhaled during the first second of a forced expiratory manoeuvre started from a 
level of total lung capacity. Total lung capacity (TLC) being the maximum volume to 
which the lungs can be expanded with the greatest inspiratory effort. FEV1 is the most 
commonly used index for assessing airway obstruction, bronchoconstriction or 
bronchodilation. Vital capacity (VC) is the maximum amount of air that a person can 
expel from the lungs after first filling the lungs to the maximum extent. FEV1 expressed 
as a percentage of vital capacity i.e. FEV1%VC is the standard index for assessing and 
quantifying airflow limitation. Forced vital capacity (FVC) is the volume of air that can 
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forcibly be blown out after full inspiration, measured in litres. FVC is the most basic 
manoeuvre in spirometry tests. 
FEV1/FVC (FEV1%) is the ratio of FEV1 to FVC. In healthy adults this should be 
approximately 75–80%. In obstructive diseases (asthma, COPD, chronic bronchitis, 
emphysema) FEV1 is diminished because of increased airway resistance to expiratory 
flow; the FVC may be decreased as well, due to the premature closure of airway in 
expiration, just not in the same proportion as FEV1 (for instance, both FEV1 and FVC are 
reduced, but the former is more affected because of the increased airway resistance). 
This generates a reduced value (<80%, often ~45%). In restrictive diseases (such 
as pulmonary fibrosis) the FEV1 and FVC are both reduced proportionally and the value 
may be normal or even increased as a result of decreased lung compliance. 
A derived value of FEV1% is FEV1% predicted, which is defined as FEV1% of the 
patient divided by the average FEV1% in the population for any person of similar age, 
sex and body composition. If the FEV1%Pred value is >80%, the person in less likely to 
have asthma. If the value is less than 80% (<80%) then the person is more likely to have 
asthma. This is one of the three criteria used for segregation of asthmatic population into 
moderate and mild classes for this study. 
3.3.3.2 Blood Eosinophil Level (EOS) 
The blood eosinophil level (EOS) is a blood test which measures eosinophil or white 
blood cells count. Eosinophils become active in presence of allergic diseases, infections 
and other such medical conditions. Most common causes of increase in eosinophil count 
are allergic reaction of parasitosis (an infection caused or transmitted by a parasite). If 
the blood eosinophil level is <3% the person is less likely to have asthma and if the level 
is >3% the likelihood/severity of asthma is more.  
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3.3.3.3 Methacholine challenge (PC20)  
Methacholine challenge is a test for hyper-reactivity of the smooth muscles of the lungs, 
often used to determine the absence or presence and severity of asthma. Lung function 
drops as a result of inhaling the chemical methacholine, which constricts the muscles 
around the airways in the lungs. The participants are made to inhale nebulised 
methacholine to determine the responsiveness of the airways of the participant to 
determine lung function. In the outcomes of this test, false-positive results are common 
and often caused by cigarette smoking, viral infections and presence of allergies. False-
negative results are rare if the test is performed correctly, so a negative test can be used 
to reliably rule out the presence of asthma. If a participant can tolerate >8mg/ml of 
nebulised methacholine concentration, he/she is deemed less likely to have asthma; on 
the other hand a person responding to <8mg/ml of methacholine is more likely to have 
asthma. 
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Table 3-1 Patient diagnostic and medication data for moderate asthmatics and healthy control population 
 Condition Gender Age Height 
(cm) 
Weight 
(kg) 
FEV1%PRED EOS PC20 
(mg/ml) 
BDP 
Equiv 
(µg) 
V1 
BDP 
Daily 
Daily Medication 
Routine (1) 
Daily Medication 
Routine (2) 
1 Moderate Asthmatic Female 60 162 58 59 10.75 0.03 1000 1000 Seretide 125 1BD Serevent 25 1BD 
2 Moderate Asthmatic Female 66 158 62.3 67 N/A 2.3 400 400 Symbicort 100/6 1BD   
3 Moderate Asthmatic Male 60 174.5 90.5 67 6 2.52 200 200 Seretide 50 1OD Serevent 25 1OD 
4 Moderate Asthmatic Female 28 171 81 66 N/A 0.5 400 400 Clenil Modulite 50 2BD Serevent 25 2BD 
5 Moderate Asthmatic Male 52 163 63 65 4.75 0.59 400 400 Seretide 50 1BD Seretide 25 1BD 
6 Moderate Asthmatic Female 42 149 69.2 88 1.5 2 400 400 Clenil Modulite 50 2BD Serevent 25 2BD 
7 Moderate Asthmatic Female 62 173 80.6 63 0.75 1 400 400 QVAR 50 1BD Serevent 25 1BD 
8 Moderate Asthmatic Female 41 171 146.4 68 0.8 6.35 800 800 Symbicort 200 1BD Oxis 6 1BD 
9 Moderate Asthmatic Male 66 173 101 58 19.5 2 2000 2000 Seretide 125 2BD   
10 Control Female 47 167 47.6          
11 Control Male 27 181 75.4          
12 Control Female 65 NR NR          
13 Control Male 21 184 69          
14 Control Female 21 166 87.3          
15 Control Female 24 158 67.9          
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16 Control Female 37 NR NR          
17 Control Female 54 158 48          
18 Control Female NR NR NR          
19 Control Female 23 170 78.2          
20 Control Female 21 167 62.4          
21 Control Female 23 159 55.7          
22 Control Female 21 172 53.3          
23 Control Female NR NR NR          
24 Control Male 28 163 60          
25 Control Male NR NR NR          
26 Control Female 26 178 63          
27 Control Male 61 185 95          
28 Control Male 25 173 95          
29 Control Female 61 165 90          
30 Control Male 21 NR NR          
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3.3.4 Saliva sample collection 
This research followed the good clinical practices and protocols as approved by the 
Nottingham Research Ethics committee (REC reference number 10/H0408/34). Samples 
were collected by Emma Wilson, Wendy Gerrard-Tarpey and Glenn Hearson at the 
Respiratory BRU at the Nottingham City Hospital (Nottingham, UK) using the protocol 
described in (Appendix 7.1, 7.2 and 7.3). 
Participants were asked not to consume alcohol for 12 hours prior to the sampling of 
saliva; only unflavoured water was permitted to be consumed. Participants were also 
asked to refrain from brushing their teeth, chewing gum, having a large meal, drinking 
tea or coffee and smoking for an hour prior to the sample collection. 
Sampling of whole saliva was carried out by the passive drool approach (Chiappin et al. 
2007). Each participant was seated with his or her head tilted forward causing saliva to 
pool in front of his or her mouth. Saliva was dribbled out of the mouth and collected into 
a glass collection vial (30mL Screw Top Universal Storage Vials, Chromacol, UK) prior 
to transferring as 600 µL aliquots into micro-centrifuge tubes (2.0 mL, LoBind 
Eppendorf, UK) for storage. Equal volume sub-aliquots (600 μL) of saliva from all the 
participants were pooled together, mixed and re-aliquoted as 600 μL aliquots to be used 
for method development and quality control (QC). Samples were stored at -80ºC 
immediately after aliquoting to arrest biological activity. The sample collection and 
storage was carried out according to the sampling protocol (Appendix 7.2 and 7.3). 
Eppendorf LoBind microcentrifuge tubes were specifically chosen to be utilised for 
storage and processing of saliva as they can be stored at -80
o
C as well as offer minimum 
interference with the analysis in terms of leechables from the surface of the tubes or loss 
of sample/metabolites due to adsorption on the surface. 
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3.3.5 Sample pre-treatment 
The sample pre-treatment, method development and metabolic profiling analysis by 
UHPLC-MS and the metabolomic data processing was carried out at Centre for 
Analytical Science, Loughborough University, by the author (Aditya Malkar). 
Samples stored at -80ºC were thawed to room temperature before subjecting to sample 
clean-up by protein precipitation. Each thawed saliva sample was vortexed for 30 
seconds followed by ultra-sonication for 1 minute to breakdown mucous substances in 
saliva and to improve homogeneity. Protein precipitation was achieved by the addition of 
1.2 mL acetonitrile to 600 μL of saliva i.e. 2:1 ratio of precipitant to saliva (Polson et al. 
2003). The mixture was vortexed for 30 seconds followed by ultra-sonication for 1 
minute and then subjected to centrifugation at 10,000 g for 10 minutes at ambient 
temperature. Precipitated proteins from the sample were removed as a pellet at the 
bottom of the microcentrifuge tube. The supernatant was transferred to a fresh 
microcentrifuge tube and evaporated to near dryness (~5 μL) using Turbovap LV 
concentration workstation (Caliper Life Sciences, Hopkinton, MA, USA) prior to being 
reconstituted in 300 μL water/acetonitrile (95:05) (v/v) with 0.1% formic acid. The 
reconstituted saliva extract was placed in a polypropylene micro-insert (Supelco, UK) in 
an autosampler vial (2 mL) for UHPLC-MS analysis. The sample pre-treatment protocol 
was followed throughout the study (Appendix 7.4) 
3.3.6 Instrumentation 
UHPLC-MS analyses were carried out using an Agilent 1200 series UHPLC interfaced 
with an Agilent 6230 time-of-flight mass spectrometer fitted with a JetStream ESI source 
operated in positive ion mode (Agilent Technologies, Santa Clara, CA, USA). 
UHPLC separation was carried out using a Poroshell 120 EC-C18 column (2.1 x 75 mm, 
2.7 µm; Agilent Technologies, Santa Clara, CA, USA). Poroshell particles have a solid 
silica core (1.7 µm) and a porous silica outer layer (0.5 µm thickness), with an end 
capped C18 bonded phase coated onto the porous outer layer of the particle (Kirkland et 
al. 2000).  
Mobile phase A consisted of 0.1% aqueous formic acid (v/v) and mobile phase B was 
0.1% formic acid in acetonitrile (v/v). The chromatographic gradient programme was 
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optimised using a solution of L-carnitine and hydrocortisone (0.005 mg/mL). The mobile 
phase flow rate was set to 0.5 mL/min. Saliva extracts (10 μL injected) were analysed 
using an optimised chromatographic gradient: 5% B (0-1 min), increased to 30% B (1-10 
min). This was followed by a column clean-up phase, built into the method to reduce 
carry over and condition the column for analysis of subsequent samples, in which the 
mobile phase was increased to 95% B (10-11 min) and maintained at 95% B (11-12 min) 
before returning to initial conditions (13-15 min). 
MS data was acquired with the instrument mode set to extended dynamic range (2 GHz). 
Mass spectra were acquired in the range m/z 50-1200. The scan rate of the MS was 10 
scans/s. Source conditions for the UHPLC were: sheath gas temperature and flow, 350 
ºC and 12 L/min; drying gas temperature and flow, 150 ºC and 10 L/min; nebuliser 
pressure, 35 psig; transfer capillary, 4000 V; skimmer voltage, 65 V; fragmentor voltage, 
150 V. Continuous internal calibration was performed to achieve desired mass accuracy 
using signals from infused reference ion solution at m/z 121.0509 (protonated purine) 
and m/z 922.0098 [protonated hexakis(1H, 1H, 3H-tetrafluoropropoxy)phosphazine]. 
Mass Hunter Qualitative Analysis software version B.05.00 (Agilent Technologies, 
Santa Clara, CA, USA) was used for processing raw data. Metabonomic data analysis 
including multivariate statistical analysis was carried out using Mass Profiler 
Professional software (Agilent Technologies, Santa Clara, CA, USA). 
3.3.7 Method development and quality control 
Method blanks were prepared by subjecting 600 uL of water to the entire sample pre-
treatment process and were analysed to assess contamination arising from polypropylene 
microcentrifuge tubes (LoBind Ependorf, UK) and polypropylene micro-inserts used 
during storage and sample pre-treatment. The effect of injection volumes in the range of 
1-20 μL on chromatographic peak areas was analysed for the methodology using pooled 
saliva extract samples, which were analysed in triplicate. The chromatographic peak 
areas of the extracted endogenous metabolite ions were plotted against the injection 
volumes to determine the optimum injection volume for the analysis. The reproducibility 
of the retention times (tR) and chromatographic peak areas of extracted metabolite ions 
were assessed from replicate analyses of pooled saliva samples (n=6), using the 
optimised injection volume. 
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Figure 3.2 Schematic representation of the analytical protocol for analysis of saliva 
by UHPLC-MS. 
A series of five consecutive pooled saliva extracts were analysed prior to the analysis of 
control and asthmatic saliva samples for chromatographic column conditioning purpose. 
The metabolomic sample list was randomised prior to analysis. A quality control (QC) 
sample was batch processed and analysed after every 5 samples to monitor the stability 
of the system and data quality.  
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3.3.8 Data analysis 
Mass Hunter Qualitative Analysis software version B.05.00 (Agilent Technologies, 
Santa Clara, CA, USA) was used for processing raw data. Molecular feature extraction 
(MFE) algorithm was used to extract unknown molecular features (MF) and compile a 
data matrix for each sample. Molecular features were extracted using the following 
thresholds: m/z range 50-600 Da; retention time range 0.01-10.00 min and mass spectral 
peak height of ions (centroid data) 100 cps. The abundance value for each molecular 
feature was calculated by MassHunter software as the sum of intensities of 
corresponding isotopic and adducts peaks. 
The generated data matrix consisting of the molecular features from all the samples were 
exported into Mass Profiler Professional software Version 12.05 (Agilent Technologies, 
Santa Clara, CA, USA) for metabolomic data analysis including chromatographic peak 
alignment across multiple UHPLC-MS data files and multivariate statistical analysis. 
Data filtering and alignment was carried out using the following parameters: minimum 
absolute abundance of molecular features 7000 cps, mass alignment window 10 ppm and 
retention time alignment window 0.15 min.  
Stepwise reduction of the number of molecular features was performed based on their 
abundance values and frequency of occurrence in sample classes. Aligned molecular 
features were filtered to reduce the dimensionality of the dataset prior to principal 
component analysis (PCA). In the first instance, only the molecular features present in at 
least 85% of samples in only one condition (i.e. asthmatic or healthy control) were 
retained for further processing. In the next step, molecular features were filtered based 
on p-value calculated for each using a student’s T-test. Lower p-value signifies higher 
significant difference between the conditions and P ≤ 0.1 was chosen as the filtering 
criterion to ensure that only the molecular features, which differ in their respective 
conditions with a statistical significance of 90%, were retained. The final criterion for 
filtration of molecular features was the fold change (FC). Molecular features, which 
satisfied the threshold of FC≥2.0, were retained for further processing by PCA and to 
build predictive models. 
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3.4 RESULTS AND DISCUSSION 
The non-targeted analysis of salivary metabolome by UHPLC-MS was performed in this 
study on samples collected from moderate and mild asthmatics (n=16) and healthy 
controls (n=21). The resulting dataset were pre-processed and then compared using 
unsupervised multivariate statistical analysis using principal component analysis to 
identify discriminant molecular features. Initial investigations were directed towards the 
development of a reliable and reproducible method for the metabolic profiling of saliva. 
3.4.1 UHPLC-MS Analysis 
Saliva extracts were analysed by UHPLC-MS following a protein precipitation step. 
Protein precipitation was the only sample clean-up process employed in order to 
minimise the effects of discrimination and unpredictable behaviour of unknown 
metabolites during sample preparation (Álvarez-Sánchez et al. 2012). The 
chromatographic gradient was adjusted using a solution of L-carnitine and 
hydrocortisone (0.005 mg/mL) such that highly polar L-carnitine was slightly retained on 
the column whereas less polar hydrocortisone eluted towards the end of the 10 minute 
chromatographic gradient Figure 3.3. This enabled all the metabolites from saliva 
extract to be separated within 10 minutes; hence a cycle time of 15 minutes was achieved 
with column clean-up followed by equilibration, which is suitable for high throughput 
metabolomic studies.  
 
Figure 3.3 UHPLC-MS analysis of a mixture solution of L-carnitine and 
hydrocortisone (0.05 mg/ml). (Data produced on Agilent 6230) 
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The effect of injection volume was assessed for injection volumes in the range of 1-20 
µL. Chromatographic peak areas of five extracted metabolite ions, spread across the 
entire 10 min gradient were randomly chosen to assess the dynamic range of the 
analytical system. Chromatographic peak areas showed a good linear response for 
injection volumes in the entire range of 1-15 µL as shown in Figure 3.4.  
 
Figure 3.4 Effect of injection volume range analysis of the methodology. 
Chromatographic peak areas of a random selection of ions spread across the entire 
chromatographic range were plotted against the injection volumes. Samples were 
analysed in triplicates (n=3) denoted by the error. (Data produced on Agilent 6230) 
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An injection volume of 10µL was selected from these experiments to be used for the 
analysis of saliva extract, which ensured that the analytical method was capable of 
detecting small positive or negative changes in the metabolite concentrations. 
Endogenous metabolite ions were selected for the validation of the method, which 
ensured that the matrix effects were accounted for during data processing.  
Reproducibility of the retention times of the metabolite ions are important parameters. 
They influence the outcome of the data alignment performed across all the samples. 
Based on replicate measurements (n=6) of the same five endogenous metabolites, the 
reproducibility of the retention time was determined to be less than 0.4%, demonstrating 
excellent UHPLC reproducibility (Table 3-2). The reproducibility of the 
chromatographic peak areas is also important for the identification of up-regulated and 
down-regulated metabolite ions. Table 3-2 also shows an inter-day %RSD of less than 
4% for the peak areas of metabolite ions over the range m/z 267 (tR=1.96 min) to m/z 416 
(tR=9.21 min). Hence, it is demonstrated that relatively small variations in metabolite 
areas between control and asthmatic samples can be clearly distinguished. 
Table 3-2 Reproducibility analysis of retention time and chromatographic peak 
areas (n=6) 
Assignment 
m/z Retention Time Area 
(±0.02) Mean tR/min RSD%  Mean Area/A RSD% 
M1 267.13 1.96 0.32 2005909 3.73 
M2 195.09 3.15 0.18 12909485 2.09 
M3 716.39 5.80 0.10 5891274 3.58 
M4 652.42 7.02 0.08 590003 3.81 
M5 416.36 9.21 0.09 561820 2.76 
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A typical UHPLC-MS profile for a saliva extract overlaid with a method blank is shown 
in Figure 3.5, depicting the complexity of the dataset. Method blanks demonstrated no 
contamination due to the polypropylene micro-centrifuge tubes and UHPLC micro-
inserts used for storage, pre-treatment and analysis. Employing the optimised gradient 
programme for the analysis enabled the elution of all detectable metabolites from the 
saliva sample in 10 minutes with a typical chromatographic peak base width of 9 
seconds. 
 
Figure 3.5 Example of a total ion chromatogram (TIC) of saliva extract (red trace) 
and a blank (black trace). (Data produced on Agilent 6230) 
3.4.2 Data reduction and multivariate analysis 
Visual inspection or manual processing of the data obtained from UHPLC-MS 
measurements would be time consuming and inefficient given the complexity of the data 
Figure 3.5. Hence, a molecular feature extractor (MFE) algorithm was employed, which 
enabled the automated extraction of ions corresponding to compounds present in saliva 
samples. This algorithm combines ion species such as multiply charged species, isotopes 
and adducts generated from a single compound into a single molecular feature (MF) to 
be utilised as a single variable in subsequent analysis. 
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Figure 3.6 A 3-D Principal component analysis (PCA) of saliva samples from the 
study coloured according to sample groups. X-Axis: Component 1 (20.07%), Y-
Axis: Component 2 (13.26%) and Z-Axis: Component 3 (6.44%). 
A total of 35011 molecular features were extracted from all the samples. Out of these, 
14267 were aligned across all the samples from the study. Principal component analysis 
(PCA) was carried out using these 14267 molecular features on all the sample groups 
from the study including conditioning runs and quality control (QC) samples. Clustering 
of QC samples (circled in Figure 3.6) provides evidence of consistent and reliable data 
quality across all the samples run, which is required for metabolic profiling studies. 
However, Figure 3.6 shows no clear separation of asthmatic and healthy population; 
hence, further data reduction was required to identify discriminant metabolites between 
control and asthmatic samples.  
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Figure 3.7 a) Summary of data reduction based on frequency of molecular features 
in samples, b) Volcano plot illustrating filtering of molecular features based on the 
results of T-test and fold change analysis (P value cut off 0.1 and fold change cut off 
2.0) 
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Moderate asthmatics (n=9) were compared against healthy individuals (n=21) in the first 
instance. The dimensionality of the dataset was reduced prior to PCA by filtering the 
data based on frequency of occurrence of molecular features and outcomes of t-test 
(summarised in a Venn diagram in Figure 3.7 a). In the first step, all molecular features 
which were present in at least 85% of samples of at least one group (i.e. moderate 
asthmatic or healthy) were retained. A high cut-off of 85% was chosen as a rigorous 
measure to account for the distribution of the individual groups’ population with respect 
to factors such as age, gender etc. A high cut-off ensures that the potential biomarker 
ions obtained at the end of the study would be independent of factors such as age or 
gender, and would be universally applicable to all the population. This reduced the 
number of MFs from 14627 to 188. In the next phase, the MFs were filtered based on 
their p-values obtained from a t-test and fold change analysis. MFs, which satisfied the 
p-value cut-off value of 0.1 and fold change value of FC≥2.0 were retained as illustrated 
from the volcano plot in Figure 3.7 b. This reduced the number of MFs from 188 to 10. 
A PCA plot was constructed based on the filtered 10 molecular features for moderate 
asthmatic and healthy control individuals (Figure 3.8). This unsupervised model shows 
clear separation of moderate asthmatics from healthy control samples, with the exception 
of a single asthma patient sample.  
 113 
 
 
Figure 3.8 A 3-D Principal component analysis (PCA) of saliva samples from 
moderate asthmatics (red) and healthy control samples (blue). X-Axis: Component 
1 (49.08%); Y-Axis: Component 2 (15.47%) and Z-Axis: Component 3 (12.02%). 
The moderate asthmatic patients were on different treatment regimens (Appendix 7.6) 
and therefore the ability to distinguish between moderate asthma and healthy controls is 
not treatment specific. Hence, it can be concluded that the molecular features responsible 
for the class separation are representative of the endogenous factors pertaining to asthma 
and not due to the effect of treatment. 
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The next step was to assess the contribution of the 10-discriminant features towards class 
separation. The correlation and covariance of the features was assessed from an s-plot 
(Figure 3.9). MFs characteristic of asthmatics (i.e. up-regulated) are represented in the 
first quadrant of the plot and the MFs characteristic of healthy control individuals (i.e. 
down-regulated) are shown in the third quadrant of the plot. 
 
Figure 3.9 A S-plot representing the correlation and covariance of the molecular 
features responsible for class separation. 
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Table 3-3 summarises the potential metabolic biomarker ions identified from this study. 
Accurate mass measurement data and isotopic ratio data on the discriminant metabolite 
ions were obtained by analysing a pooled saliva extract sample using high resolution 
mass spectrometry and utilised to obtain tentative elemental compositions on the 
discriminant metabolite ions with a mass error window of 3 ppm.   
Table 3-3 Discriminant molecular features (MFs) obtained from moderate 
asthmatics versus control samples 
Marker No. Retention 
Time (min) 
m/z 
(±0.02) 
Regulation Tentative 
Elemental 
Composition 
1 0.4 116.07 Up C5H9NO2 
2 2.2 261.14 Up C12H23N3O5 
3 1.1 290.17 Up C11H20N2O5 
4 3.6 316.22 Up C15H29N3O4 
5* 4.4 439.46 Up N/A 
6 3.4 227.13 Down C12H18O4 
7 4.7 573.26 Down C26H44N4O4S3 
8 0.5 596.33 Down C28H41N11O2S 
9 1.7 345.12 Down C22H17ClN2 
10 5.5 227.14 Down C11H18N2O3 
*No elemental composition could be postulated within the set 3 ppm 
tolerance window 
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Figure 3.10 Extracted ion chromatogram (EIC) for selected potential biomarker ion 
m/z 316.22 ± 0.02 showing change in intensity between moderate asthmatic (purple 
trace) and healthy control individuals (red trace). (Data produced on Agilent 6230) 
An example of a potential biomarker ion (m/z 316.22 ± 0.02) is shown in Figure 3.10, 
which shows up-regulation of the ion. The change in the chromatographic peak areas can 
be observed from the two overlaid example EICs. The EIC shows the presence of two 
chromatographic peaks for a single species at tR=3.35 and tR=3.65; with both peaks 
depicting up-regulation. Box and whisker plots were constructed for all the potential 
biomarker ions to visualise the trend of the biomarker ions in the entire demographic of 
the study. Box and whisker plots from up-regulated ions Figure 3.11 and  
down-regulated ions Figure 3.12 show marked differences in their normalised 
chromatographic peak areas.  
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Figure 3.11 Box and Whisker plots for Up-regulated biomarker ions (clockwise 
from top left: m/z 116.07, 261.14, 290.17, 316.22 and 439.46). 
 
Figure 3.12 Box and Whisker plots for Down-regulated potential biomarker ions 
(clockwise from top left: m/z 227.13, 573.26, 596.33, 345.12 and 227.14). 
 
 
 118 
 
3.4.3 Predictive models 
The discrimination potential offered by the data was evaluated using a widely utilised 
supervised pattern recognition method of partial least squares discriminant analysis 
(PLS-DA). A statistical model based on PLS-DA was constructed and validated for 
classification of asthmatic samples. The results of sample classification are presented in 
Table 3-4 in terms of recognition and prediction abilities, representing the percentage of 
the samples correctly classified during model training and cross-validation. The overall 
recognition ability during training of the model was 80% and the prediction ability for 
model cross-validation was 96.7%. The model therefore shows high predictive 
capabilities for distinguishing between moderate asthmatics and healthy controls by non-
invasive sampling of saliva combined with UHPLC-MS metabolite profiling. 
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The model created using moderate asthmatic samples was used to classify mild (early 
stage) asthmatic samples. The success rate of detection of mild asthma was low (55.6 
%). However, this is not a true representation of the predictive capabilities as a model 
built on moderate asthmatics and healthy individuals was tested on mild asthmatics due 
to restricted patient numbers. Further refinement of the model is required to distinguish 
between healthy controls, mild and moderate asthmatics. 
Table 3-4 Overview of classification results obtained by PLS-DA model. 
 
Predicted 
Asthmatic 
Predicted 
Controls 
Accuracy 
(%) 
Model Training 
  
True Moderate 
Asthmatic 
8 1 88.9 
True Controls 5 16 76.2 
Recognition ability 
  
80.0 
Model cross-validation 
  
True Moderate 
Asthmatic 
9 0 100.0 
True Controls 1 20 95.2 
Recognition ability 
  
96.7 
Model testing using mild asthmatics 
  
True Mild Asthmatic 27 15 55.6 
True Controls 0 12 
 
Recognition ability 
  
55.6 
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3.5 CONCLUSIONS 
In this pilot study, the robust methodology developed, based on protein precipitation and 
UHPLC-MS has been used in combination with multivariate statistical analysis for the 
identification of potential metabolomic biomarkers of asthma from saliva. A predictive 
PLS-DA model was created based on the discriminant metabolites obtained from the 
comparison of moderate asthmatics versus healthy control samples which clearly 
distinguished between the two groups. This model was evaluated for the recognition of 
asthma in samples obtained from mild asthmatic population.  
The potential benefits of a simple, non-invasive sampling technique for asthma screening 
have been highlighted. The technique can be used in conjunction with or as a preliminary 
alternative to the existing diagnostic tests such as forced expiratory volume (FEV1%), 
sputum eosinophil count and methacholine challenge. The work presented here 
demonstrates the advantages and the potential of non-invasively obtained saliva as a 
biofluid to diagnose and monitor the response to treatment of asthma. 
To our knowledge, this is the first study to employ a passive drool saliva test combined 
with mass spectrometry as a potential diagnostic tool for asthma. We found this approach 
could discriminate between asthma and health controls; a model derived from these 10 
discriminant metabolite ions classified asthma with an accuracy of 80% and 96.7% for 
model training and cross-validation respectively. These figures compare favourably to 
current tests used for the diagnosis of asthma. Tests of airflow obstruction are 
widespread however suffer from limited sensitivity and specificity. One study found the 
sensitivities and specificities for FEV1/FVC ratio to be 61%, 60% respectively; 
bronchodilator response 49%, 70% and peak flow amplitude percent mean to be 43%, 
75%(Hunter et al. 2002). Due in part to the limited tests available, the diagnosis and 
assessment of treatment response is still based on symptoms with high rates of 
misdiagnosis(Luks et al. 2010). More invasive tests such as bronchial challenge or 
induced sputum are available but are limited by their invasive nature, cost and need for 
expertise. They also only reflect one aspect of the asthmatic process(Grainge et al. 2011). 
Despite these tests a proper diagnosis remains a challenge even in specialist asthma 
clinics(Robinson et al. 2003). 
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The benefits of a simple, non-invasive sampling technique for asthma diagnosis are 
obvious and a great deal of work has focussed on the development of breath sampling, 
including exhaled nitric oxide (Shaw et al. 2007) , measurement of volatile organic 
compounds(Montuschi et al. 2007; Ibrahim et al. 2011)  and the e-nose (Dragonieri et al. 
2009) . The discriminatory ability of these tests varies.  Importantly the passive drool 
technique can be used in conjunction with or as a preliminary alternative to the existing 
diagnostic tests such as FEV1%, has good discriminatory ability, and provides metabolic 
information on the status of the airway. The saliva sampling kit is inexpensive and the 
passive drool technique can be performed in the clinic by a wide range of patients, 
including children. Samples can also be stored and transported with no need for 
immediate analysis. The use of UHPLC-MS is increasing in clinical laboratories because 
of the high throughput and specificity of the technique and the development of mass 
spectrometry-based assays for the simultaneous determination of panels of biomarkers 
has been shown to offer a rapid and routine approach to clinical diagnosis.   
Our pilot study has similar limitations to others in the field being cross sectional with 
relatively few participants. We cannot fully exclude a treatment effect, however the 
patients with asthma were on different treatment regimens and drugs; hence the 
molecular features responsible for the class separation are most likely representative of 
the endogenous factors pertaining to asthma and not due to a drug signal. The 
identification, validation and the biological significance of the discriminant molecular 
features obtained from the samples were beyond the scope of this pilot but will form part 
of future work. The discriminant metabolic features identified in the study also need to 
be validated and quantified using a larger cohort (n>100) of moderate and/or severe 
asthmatics versus healthy control populations using a targeted metabolite analysis 
approach. 
In conclusion the passive drool technique combined with UHPLC-MS is a novel non-
invasive method of accurately differentiating patients with asthma from healthy controls. 
Further longitudinal work is required to fully assess the discriminatory ability of this test. 
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4 CHAPTER FOUR: 
 THE APPLICATION OF ULTRA 
PERFORMANCE LIQUID 
CHROMATOGRAPHY-ION MOBILITY-MASS 
SPECTROMETRY (UPLC-IM-MS) FOR 
GLOBAL METABOLITE PROFILING OF 
SALIVA. 
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4.1 INTRODUCTION 
The health benefits of aerobic exercise for humans are well known. Exercise produces a 
vast amount of salutary effects but the understanding of how these effects occur is 
limited. It is a well-established fact that exercise triggers changes in composition and 
concentration of numerous metabolites (Lewis et al. 2010). A number of important 
investigations on the effect of saliva on human biochemistry have been carried out using 
plasma and serum (González et al. 2008). As an alternative to such invasively collected 
bio-matrices, saliva presents itself as an attractive and effective medium to evaluate the 
effects of exercise or in other words, physiological stress. Exercise has been shown to 
affect the salivary levels of steroid hormones, immunoglobulins (such as SIgA, SIgM, 
SIgG etc.), antimicrobial proteins and enzymes such as α-amylase (DeCaro 2008), 
lysozyme and lactoferrin etc. Targeted analysis of cortisol as a biomarker of stress from 
saliva is carried out routinely using a variety of assays and analytical methods. Catabolic 
and anabolic effects of exercise on human body’s stress response have also been 
assessed from saliva by monitoring cortisol, testosterone and dehydroepiandrosterone 
(Papacosta & Nassis 2011). It is clear that the measurement of physiological biomarkers 
in whole saliva can provide a significant tool for assessing the immunological and 
endocrinological status associated with exercise (Pollard 1995; Perogamvros et al. 2009). 
A holistic approach to this by untargeted metabolite profiling can provide valuable 
information towards improving the understanding of biochemistry associated with 
exercise. 
The fundamentals of UHPLC-IM-MS and reviews of metabolite profiling of saliva have 
been covered in Chapter one. Ion mobility spectrometry is a technique which separates 
ionised molecules on the basis of their collision cross sections (i.e. size and shape) in the 
gas phase and has been extensively reviewed (Creaser et al. 2004; Kanu et al. 2008) as 
well as an account of the same is presented in Chapter One. The application of ion 
mobility spectrometry hyphenated with mass spectrometry (IM-MS) to metabolite 
profiling has been reported (Dwivedi, Wu, et al. 2007; Harry et al. 2008), but the use of 
ion mobility-mass spectrometry combined with ultra-high performance liquid 
chromatography (Swartz 2005) has not been explored.  
The routinely used combination of mass spectrometry (MS) with a chromatographic 
separation technique such as ultra-high performance liquid chromatography (UHPLC) 
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presents a powerful tool for the analysis of metabonome of complex biological systems. 
In modern metabolomic studies, UHPLC-MS is a favoured technique as three-
dimensional data i.e. retention time (tR), mass-to-charge ratio (m/z) and intensities (I) is 
obtained. As a result hyphenated techniques provide with better resolution of analyte 
metabolites. However, there is a potential for further improvement of the analytical space 
by the use of ion mobility (IM) hyphenated with chromatography-mass spectrometry 
systems. The combination of ion mobility with UHPLC-MS presents an opportunity for 
complex metabolomic samples to be separated on the basis of retention time, ion 
mobility drift time and mass-to-charge ratio in a single chromatographic run. The use of 
ion mobility dimension of separation does not demand any additional sample preparative 
steps nor does it affect the high throughput offered by UHPLC. Thus this combination 
provides a valuable opportunity for exploring complex biofluids such as saliva. 
There have been no previously reported studies for the metabolic profiling of saliva 
using hyphenated UHPLC-IM-MS. This study describes the first instance of the 
development and validation of a method for the targeted and untargeted metabolic 
profiling of saliva by ultra-high performance liquid chromatography-ion mobility-mass 
spectrometry (UHPLC-IM-MS). The method has been applied to the profiling of 
metabolites and the discovery of potential discriminating biomarker ions of exercise-
induced physiological stress. 
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4.2 CHAPTER FOUR AIMS AND OBJECTIVES 
The purpose of the work presented in this chapter was to explore novel methods for the 
metabolic profiling of human saliva employing the use of travelling wave ion mobility 
spectrometry (TWIMS) as an additional dimension of separation in conjugation with 
UHPLC-MS. The specific objectives were: 
 To explore the potential of travelling wave ion mobility spectrometry combined 
with ultra-high performance liquid chromatography and mass spectrometry for 
metabolite profiling analysis of saliva. 
 To evaluate the advantages offered by ion mobility for targeted and untargeted 
metabolite profiling analysis. 
 To carry out untargeted global metabolite profiling investigation for the 
discovery of potential discriminating biomarker ions of physiological stress using 
the developed method. 
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4.3 EXPERIMENTAL 
4.3.1 Materials and samples 
4.3.1.1 Chemicals 
Acetonitrile (analytical grade), water (analytical grade) and formic acid (>99.9%) were 
obtained from ThermoFisher Scientific (Loughborough, UK). L-carnitine (>99%) and 
hydrocortisone (>99%) were obtained from Sigma-Aldrich (Gillingham, UK). A 400 
ng/mL stock solution of leucine enkephalin was obtained from Waters Corporation 
(Manchester, UK) and used to prepare a 2 ng/mL working solution of leucine enkephalin 
in water:acetonitrile (50:50) (v/v) as a LockMass (m/z 556.2771) solution. A standard 
mixture of 0.01 mg/mL L-carnitine and hydrocortisone was prepared in 
water:acetonitrile (95:05) (v/v) with 0.1% formic acid. A standard solution of 0.01 
mg/mL L-phenylalanine was prepared in water:acetonitrile (95:05) (v/v) with 0.1% 
formic acid. 
4.3.1.2 Saliva sample collection and storage 
Sampling of saliva for this study was carried out under the ethical approval obtained 
from the local ethical advisory committee (Ethical Advisory Committee, Loughborough 
University, Loughborough, LE11 3TU) with reference number G10-P24. Participants 
were healthy, non-smoking males, aged 18-35 and were recruited from Loughborough 
University staff and students (n=10). Samples were collected in the exercise laboratories 
of the School of Sport, Health and Exercise Sciences (SSEHS) by PhD students and staff 
of the Department of Chemistry – Helen J. Martin, Matthew A. Turner and Pareen Patel 
and SSEHS – Phillip Watson. 
Saliva was collected by passive drool from participants after an overnight fast. 
Participants were seated with their head tilted forward, allowing saliva to pool in front of 
the mouth. Saliva was allowed to be dribbled out of the mouth into a glass collection vial 
(30 mL Chromacol, UK) at regular intervals. This process was repeated until a sufficient 
colume of saliva (i.e. 1 mL) was obtained (Chiappin et al. 2007). Saliva collected from 
all the participants was re-aliquoted as 500 μL aliquots into microcentrifuge tubes (2.0 
mL, LoBind Eppendorf, UK). 500 μL saliva from all the participants was pooled together 
and re-aliquoted as 500 μL aliquots to be used for method development and quality 
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control (QC). Samples were aliquoted prior to storage to minimise freeze-thaw cycles. 
The saliva samples were stored at -80°C immediately after aliquoting to arrest biological 
activity.  
4.3.1.3 Sample pre-treatment 
The sample pre-treatment, method development and metabolic profiling analysis by 
UHPLC-IM-MS and the data analysis was carried out by the author (Aditya Malkar). 
Saliva samples stored at -80°C were thawed at room temperature for 30 minutes prior to 
sample clean-up by protein precipitation. Each thawed saliva sample was vortexed for 30 
seconds followed by ultra-sonication for 1 minute to breakdown mucous substances in 
saliva and to improve homogeneity. Protein precipitation was achieved by the addition of 
1 mL acetonitrile to 500 μL of saliva i.e. 2:1 ratio of precipitant to saliva (Polson et al. 
2003). The mixture was vortexed for 30 seconds followed by ultra-sonication for 1 
minute and then subjected to centrifugation at 10,000 g for 10 minutes at ambient 
temperature. Precipitated proteins from the sample were removed as a pellet at the 
bottom of the microcentrifuge tube. The supernatant was transferred to a fresh 
microcentrifuge tube and evaporated to near dryness (~5 µL) using a Turbovap LV 
concentration workstation (Caliper Life Sciences, Hopkinton, MA, USA) prior to being 
reconstituted in 50 μL water/acetonitrile (95:05) (v/v) with 0.1% formic acid. The 
reconstituted saliva extract was placed in a 200 μL polypropylene micro-insert (Supelco, 
UK) in an autosampler vial (2 mL) for UHPLC-IM-MS analysis. 
4.3.2 Instrumentation 
The liquid chromatographic separations were performed on a Waters ACQUITY UPLC 
chromatograph with an in-built auto-sampler (Waters Corporation, Manchester, UK) 
fitted with a Waters ACQUITY BEH (bridged ethylene hybrid) C18 column (2.1 mm x 
100 mm, 1.7 μm; Waters Corporation, Manchester, UK) maintained at 40°C. A 
VanGuard BEH C18 pre-column (Waters Corporation, Manchester, UK) was attached in 
series with the analytical column. The UPLC system was coupled with a Waters Synapt 
HDMS ion-mobility mass spectrometer (Waters Corporation, Manchester, UK). 
MassLynx 4.1 (Waters Corporation, Manchester, UK) was used for controlling the setup 
and for data acquisition. A Waters ACQUITY UPLC chromatograph (Waters 
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Corporation, Manchester, UK) coupled with a LTQ Orbitrap Mass Spectrometer 
(ThermoFisher Scientific, UK) was used to acquire accurate mass measurements on 
discriminant metabolites. 
4.3.3 Method development 
4.3.3.1 UHPLC conditions 
Mobile phase A consisted of 0.1% aqueous formic acid (v/v) and mobile phase B was 
0.1% formic acid in acetonitrile (v/v). The chromatographic gradient programme was 
optimised using a solution of L-carnitine and hydrocortisone (0.01 mg/mL). The mobile 
phase flow rate was set to 0.5 mL/min. The saliva extract (10 μL injected) was analysed 
by the optimised chromatographic gradient: 5% B (0-1 min), increased to 35% B (1-10 
min). This was followed by a column clean-up phase built into the method to reduce 
carry over and condition the column for analysis of subsequent samples, in which the 
mobile phase was increased to 95% B (10-11 min) and maintained at 95% B (11-12 min) 
before returning to initial conditions (13-15 min). 
4.3.3.2 MS conditions 
Electrospray ionisation conditions for the Synapt HDMS, with the ion source operated in 
positive ion mode were: capillary voltage 3.0 kV; cone voltage 30 V; source temperature 
120°C; desolvation temperature 300°C; desolvation gas, N2 gas flow 600 L/hr; cone gas 
flow 30 L/hr. Mass spectra were acquired with a scan rate of 1 sec/scan with a 0.02 sec 
inter-scan delay. Conditions for LTQ-Orbitrap MS were: heated electrospray ionisation 
(HESI) source operated under positive polarity mode; source voltage 4.5 kV; capillary 
voltage 35V; capillary temperature 300ºC and sheath gas flow 45 L/hr. 
4.3.3.3 Optimisation of the ion-mobility separation 
The tri-wave (T-wave) drift cell conditions were set at 30 mL/min drift gas (N2) with a 
variable travelling wave height ramp of 7.0-15.0 V and wave velocity of 300 m/s. The 
mass spectrum acquisition rate was 0.065 ms/scan. Optimisation of tri-wave parameters 
was carried out on-line by directly infusing 2 ng/mL solution of Leucine Enkephalin. 
The optimised variable travelling wave height ramp was set to 6.0-13.0 V. Saliva extract 
was analysed prior to and after optimisation of ion-mobility separation.  
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4.3.3.4 Dynamic range determination and reproducibility 
Injection volumes (1-20 µL) of pooled saliva extract were analysed by UHPLC-IM-MS. 
Chromatographic peak areas of selected endogenous metabolite ions eluting at various 
retention times throughout the chromatogram were extracted and plotted against the 
injection volume of saliva.  
The reproducibility of the analytical method was assessed using the optimised injection 
volume (10 µL) determined from the dynamic range experiment. Six pooled saliva 
extract samples were analysed consecutively by UHPLC-IM-MS. Chromatographic 
retention times and chromatographic peak areas of extracted endogenous metabolite ions 
were used to establish the reproducibility of the analytical method. 
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4.4 ANALYSIS OF BEFORE-EXERCISE AND AFTER-EXERCISE SALIVA 
SAMPLES 
Participants exercised for 30 minutes on a cycle ergometer (Lode Corival, Groningen, 
The Netherlands) at a power output of 2 Watts/Kg of body mass of the participant. The 
exercise intervention and the sampling were carried out in an environmentally controlled 
chamber set at a temperature of 25
o
C with a relative humidity set to 50%. Two saliva 
samples were collected per participant, one before exercise and the other 30 minutes 
after the end of the exercise. 
 
Figure 4.1 Heart rate data depicting evidence of induced physiological stress 
(Reproduced with permission) (Malkar et al. 2012) 
Heart rate data of the participants was used as means to monitor the extent of 
physiological stress of the participants. Heart rate data was processed by Pareen Patel. 
Figure 4.1 provides evidence of physiological stress being induced in all the participants 
due to exercise on the cycle ergometer. 
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4.4.1 Analytical protocol 
The analytical protocol used for the analysis of samples is shown schematically in 
Section 3.3.7 - Figure 3.2. A series of five consecutive injections of a pooled saliva 
extract were run prior to the sample analysis to condition the chromatographic column. 
The analysis of replicate injections showed little retention time drift following this 
conditioning procedure. The sample list was randomised using Microsoft Excel prior to 
analysis and a pooled saliva extract was analysed after every 5 saliva samples as a 
quality control sample (QC). The sensitivity of the instrument was monitored on-line 
using the LockMass signal. A separate method blank study was carried out as a part of 
initial UHPLC-IM-MS method development for this work. Method blanks demonstrated 
no contamination due to polypropylene micro-centrifuge tubes or polypropylene micro-
inserts used for this study. Method blanks also demonstrated no carry-over between 
saliva sample runs. 
4.4.2 Data mining and multivariate statistical analysis 
Data mining was carried out using MarkerLynx XS (Waters Corporation, Manchester, 
UK). The parameters used were retention time range 0-10 minutes; retention time 
tolerance was set to 0.1 min; mass range 50-500 Da; mass tolerance 0.05 Da; isotopic 
peaks were excluded for analysis; minimum spectral peak intensity was set to 50 counts. 
The resulting three dimensional data matrix containing arbitrarily assigned peak index 
(consisting of m/z and retention time pairs), sample names (observations) and their 
normalised chromatographic peak areas (variables) was exported to SIMCA-P+ 
(Umetrics, Sweden) for further data processing. Data was normalised to the total ion 
intensity within the particular sample for each feature (i.e. m/z_retention-time pair) using 
MarkerLynx XS (Waters Corporation, Macnhester, UK) using chromatographic peak 
area. This method of normalisation adjusts all the ion intensities so that the sum of 
intensities within each sample is the same. Multivariate statistical analysis, principal 
component analysis (PCA) and orthogonal partial least squares discriminant analysis 
(OPLS-DA), were carried out on normalised data to identify discriminant metabolites in 
saliva between the two groups of samples i.e. before and after exercise. 
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4.5 RESULTS AND DISCUSSION 
4.5.1 Method development 
The UHPLC chromatographic gradient programme used for the analysis of saliva extract 
was optimised using 0.01 mg/mL solution of L-carnitine and hydrocortisone, such that 
the highly polar metabolite, L-carnitine, was just retained on the column (tR=0.52 min), 
whereas the low polarity hydrocortisone eluted towards the end of the 10 min 
chromatographic gradient (tR=8.48 min) as shown in Figure 4.2. This was followed by a 
column clean-up and re-equilibration phase (10-15 minutes). The total cycle time was 15 
minutes, which is suitable for high throughput global metabolic profiling workflows. 
 
Figure 4.2 Optimisation of UHPLC gradient based on L-carnitine and 
hydrocortisone solution (0.01 mg/mL). (Data produced on Synapt HDMS) 
Protein precipitation was the only sample clean-up procedure applied to the saliva prior 
to UHPLC-IM-MS analysis, in order to minimise the effect of discrimination and the 
unpredictable behaviour of unknown metabolites during sample preparation (Álvarez-
Sánchez et al. 2012). The selection of endogenous metabolites for validating the method 
ensured that the matrix effects were accounted for during data processing. 
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Figure 4.3 UPLC-IM-MS metabonomic analysis of saliva extract. (a) UHPLC total 
ion chromatogram, (b) total ion mobility drift time plot summed over the entire 
chromatographic run, (c) retention time vs ion mobility drift time heatmap. (Data 
produced on Synapt HDMS) 
A typical UHPLC-IM-MS profile for a saliva extract is shown in Figure 4.3 illustrating 
the complexity of the three-dimensional nested dataset obtained from the analysis. The 
two dimensional retention time vs ion mobility drift time plot shows multiple species 
contributing to single chromatographic peaks (Figure 4.3 c), demonstrating that the 
combination of ion mobility with UHPLC allows further separation of co-eluting species. 
Ion mobility spectrum is plotted as bins, where each bin represents an acquired mass 
spectrum (65 µs/scan), with 200 bins covering the drift time range of 0-13 ms. Spectra 
were accumulated to yield 200 mass spectra and one ion mobility spectrum per second 
giving 6-7 data points across a typical UHPLC peak.  
 136 
 
 
Figure 4.4 UPLC-IM-MS analysis of saliva extract before and after optimisation of 
the T-wave IM parameters. (a) total ion mobility drift time plot (bins) prior to 
optimisation of IM parameters, (b) total ion mobility drift time plot (bins) after 
optimisation of IM parameters. (Data produced on Synapt HDMS) 
The major parameters that affect the separation of ions in the T-wave drift cell are IMS 
gas pressure, IMS wave velocity and IMS wave height. The ion mobility separation 
shown in Figure 4.3 was improved by adjusting the variable wave height ramp as a wave 
gradient effectively increases the length of the IMS drift cell (Shvartsburg & Smith 
2008).  
Figure 4.4 (a) shows IM separation prior to optimisation, with a wave height ramp of 
7.0-15.0 V. The majority of the components of the saliva extract have a drift time in the 
first 100 bins/spectra, associated with IM drift times of <2.6 ms. Ideally, only the first 20 
bins/spectra and the last 20 bins/spectra should be empty with analytes distributed across 
the remaining bins/spectrum (0.13-11.7 ms) of an overall drift time plot for optimum 
separation. This can be seen in Figure 4.4 (b), with an optimised wave height ramp of 
6.0-13.0 V. Under the optimised UHPLC and ion mobility conditions, analytes that are 
unresolved and co-eluting in the retention time dimension may be resolved in the ion 
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mobility dimension as a result of the increased peak capacity of UHPLC-IM-MS as can 
be seen in Figure 4.5. 
 
Figure 4.5 Analysis of saliva extract before (a) and after optimisation (b) of ion 
mobility parameters shows improved separation of components in ion mobility 
dimension. (Data produced on Synapt HDMS) 
The effect of UHPLC injection volume was assessed for injection volumes in the range 
of 1-20 µL. Six randomly extracted metabolite ions, spread across the chromatographic 
range were selected to assess the dynamic range of the analytical system. 
Chromatographic peak areas showed a linear response for injection volumes in the range 
1μL to 10μL, with the response levelling out above 15 μL for some metabolite ions 
(Figure 4.6). Hence, a 10 μL injection volume of saliva extract was used for subsequent 
analysis and global metabolic profiling studies as it lies within the dynamic range of the 
analytical method.  
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Figure 4.6 Dynamic range analysis of the developed UPLC-IM-MS method. Injection volume vs chromatographic peak areas of six 
example endogenous metabolite ions with their HMDB assignments 
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The results of a UHPLC reproducibility study (n=6) of peak area and retention time are 
summarised in Table 4-1. Data show relative standard deviation (RSD) less than 9% for 
chromatographic peak areas and less than 1% RSD for retention times across the range 
of the chromatogram. The data show that the method is consistent and reliable, which is 
required for measuring small differences in concentration of detectable metabolites in 
metabolic profiling studies. 
Table 4-1 Summary of reproducibility study of retention time and peak areas. 
Tentative  
Assignment 
m/z Retention Time  
(tR)/min 
RSD%  
(Retention 
Time) 
RSD % 
(Area) 
Valeraldehyde 104.1 0.57 0 8.78 
N-Acetylcadaverine 125.1 1.92 0.85 4.13 
Caffeine* 195.08 3.29 0.24 0.57 
Aspartame 295.12 3.37 0 3.53 
18-Hydroxycortisol* 379.21 3.6 0.22 8.71 
HMDB07080 607.53 7.2 0 3.30 
*Verification of IDs was carried out by comparison with analytical standards. 
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4.5.2 Targeted metabolite identification 
 
Figure 4.7 UHPLC-IM-MS targeted analysis of L-phenylalanine (m/z 166.08) in a 
saliva extract (a) extracted ion chromatogram for L-phenylalanine (m/z 
166.08±0.05), (b) mass spectrum at 1.21±0.03 min, (c) selected ion mobility 
spectrum for L-phenylalanine (m/z 166.08±0.05, 1.21±0.03 min), (d) mass spectrum 
at 1.21±0.03 min with ion mobility bins 64-68 selected, showing spectral quality 
improvement. (Data produced on Synapt HDMS) 
The nested UHPLC-IM-MS dataset collected from a saliva sample maybe interrogated 
for the presence of a targeted analyte. Figure 4.7 shows an example of the extracted ion 
chromatogram (Figure 4.7 a) and ion mobility data (Figure 4.7 c) for a targeted analyte, 
L-phenylalanine present in saliva. Both ion mobility drift time and retention time showed 
a close match with a standard indicating positive identification of the L-phenylalanine 
and that matrix effects do not adversely affect retention times. The shape of the 
chromatographic and ion mobility peaks (Figure 4.7 a and c) indicates the presence of a 
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single species. Selection of the appropriate retention time and ion mobility region 
(retention time 1.21 min, ion mobility bin numbers 64-68) for L-phenylalanine enhances 
the relative mass spectral response of the protonated amino acid (Figure 4.7 b and d). 
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4.5.3 Global metabolite profiling analysis of before- and after-exercise saliva 
samples 
The UHPLC-IM-MS analysis of saliva extracts generates a complex dataset consisting of 
mass-to-charge ratio, chromatographic retention time and ion mobility drift time. IM 
separation being orthogonal to that of liquid chromatographic separation and mass-to-
charge ratio increases the peak capacity as a result of the separation of species of the 
same m/z or retention time in the mobility dimension. The resulting multidimensional 
UHPLC-IM-MS datasets present a challenge for the multivariate statistical techniques 
commonly employed for global metabolite profiling studies. The powerful software 
available for de-convoluting UHPLC-MS data is not equipped to account for ion-
mobility dimension while compiling data matrix for multivariate analysis. The 
complexity of the data was therefore reduced in the initial stages of the analysis by 
collapsing the IM dimension.  
Key factors in the analysis of complex biological metabolomic samples include 
chromatographic column conditioning, number of quality control samples and run order 
(Want et al. 2010). These factors were evaluated using pooled saliva samples collected 
from male volunteers before-exercise and after-exercise. Figure 4.8 shows unsupervised 
principal component analysis (PCA) of all the randomised before-exercise and after-
exercise saliva samples and replicates of quality control (QC) samples consisting of an 
extract of a pooled saliva sample, which was analysed with every batch of 5 samples. 
The model was based on a total of 4078 variables, which were normalised and Pareto 
scaled, such scaling being the preferred option while dealing with metabolomic data 
obtained by MS (van den Berg et al. 2006). Clustering of quality control (QC) samples 
(circled in Figure 4.8) provides evidence of consistent and reliable data quality adequate 
for metabolic profiling studies. 
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Figure 4.8 Principal component analysis (PCA) of all saliva samples from the study 
(before-exercise, after-exercise and QC samples) Component 1 (14.17%) & 
Component 2 (12.68%). 
The unsupervised PCA approach indicates partial separation between the two classes of 
samples (Figure 4.8) with before-exercise samples generally having lower or negative 
principle component 1 (PC1) and 2 (PC2) scores while after-exercise samples showing 
higher PC1 and PC2 scores. Supervised approaches, such as partial least squares (PLS) 
and orthogonal partial least squares discriminant analysis (OPLS-DA) models, are often 
applied in metabonomics to uncover relationships buried in the background of larger 
inherent effects (Fonville et al. 2010). In biological systems, for instance, it is often the 
case that several factors contribute to the metabolic state of an organism e.g. age, gender, 
nutrition, environment etc. Hence, to focus on the biological question of interest, 
physiological stress in this case, and to disregard other sources of variation an OPLS-DA 
model was used. A total of 3067 normalised, Pareto scaled variables were used to 
construct the model, which was able to distinguish between the two classes of samples 
(Figure 4.9). 
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Figure 4.9 A supervised orthogonal partial least squares – discriminant analysis 
(OPLS-DA) model, distinguishing between the two classes of samples (before-
exercise and after-exercise saliva samples) Component 1 (14.44%) & Component 2 
(8.26%). 
 
 
Figure 4.10 The loadings s-plot obtained from the OPLS-DA model for the 
metabolomic comparison between pre-exercise and post-exercise saliva samples. 
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A loadings S-plot was constructed using the OPLS-DA model to segregate discriminant 
metabolites (Figure 4.10). A number of variables were selected from extreme ends of the 
s-plot and their normalised trend plots were compared as initial screening for potential 
biomarker ions. Discriminant features were extracted from the S-plot and were verified 
by comparing their extracted ion chromatogram (EIC) from raw data. An overview of the 
top 6 discriminant metabolites obtained from the analysis is provided in Table 4-2. 
Table 4-2 A summary of top 6 discriminant metabolite ions. 
Retention 
time 
(t
R
)/min 
m/z* Regulation 
Tentative 
Elemental 
Composition(s)* 
ppm 
error 
Fold 
change 
RSD 
from 
QC 
samples 
(%) 
0.8 86.0962 Up-regulated C
5
H
11
N 2.9 2 8.3 
1.3 100.0755 Up-regulated C
5
H
9
ON 1.9 16 3.9 
0.7 213.1233 Up-regulated C
10
H
16
O
3
N
2
 0.6 2 3.4 
1.3 120.0033 Down-
regulated 
C
8
H
9
N 2.3 46 1.2 
1.8 185.0252 Down-
regulated 
C
9
H
16
O
2
N
2
 0.1 2 5.1 
1.4 217.1046 Down-
regulated 
C
6
H
12
O
3
N
6
 1.3 6 12.9 
*m/z and tentative elemental compositions obtained from UHPLC-Orbitrap-MS data 
analysed by XCalibur Software (ThermoFisher Scientific) 
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Figure 4.11 Box and whisker plot for potential biomarker ion m/z 100.07±0.02 
The box and whisker plot for one of the potential biomarker ions 100.07±0.02 in Figure 
4.11 showing clear statistical difference in the normalised chromatographic peak areas 
from samples obtained before and after exercise. 
 
Figure 4.12 Example raw data for selected potential biomarker ion m/z 100.07±0.02: 
(a) extracted ion chromatogram (EIC) showing change in intensity between before-
exercise and after-exercise samples. Black trace denotes before-exercise and grey 
trace denotes after-exercise EICs. (b) selected ion mobility spectrum for m/z 
100.07±0.02 showing a single sharp peak, indicating the presence of a single  
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m/z 100.07 species at retention time of 1.31 minutes. (Data produced on Synapt 
HDMS) 
Figure 4.12 (a) shows an example of the raw data for selected potential biomarker ion 
m/z 100.07 ± 0.02 showing up-regulation of this ion with a retention time of 1.31 min. 
The retention time and m/z data for this molecule were used to extract the selected ion 
mobility spectrum shown in Figure 4.12 (b). The single symmetrical IM spectrum peak 
indicates the presence of a single component. Identification of this component would 
therefore require the candidate molecule to match the ion mobility as well as the 
retention time and m/z characteristics. 
Accurate mass measurement data and isotopic ratio data on the discriminant metabolite 
ion were obtained by analysing a pooled saliva extract sample using high resolution mass 
spectrometry. The molecular formula, C5H9NO, was determined from the accurate mass 
and isotopic pattern. The generated molecular formula was used to search electronic 
sources including ChemSpider and the Human Metabolome Database (HMDB) (Wishart 
et al. 2013) for possible candidate metabolites. The number of candidate molecules was 
reduced by application of biological knowledge about the candidate metabolites, such as 
the biological availability of candidate metabolite in human saliva; δ-valerolactam and 
N-methyl-2-pyrrollidinone were shortlisted as possible matches. Authentic standards of 
the shortlist of candidate metabolites were analysed using UHPLC-IM-MS and by 
UHPLC-MS/MS. 
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Figure 4.13 Identification of discriminant metabolite (a) extracted ion 
chromatogram for m/z 100.07 in saliva, (b) MS/MS spectrum for m/z 100.07 in 
saliva, (c) extracted ion chromatogram for δ-valerolactam standard, (d) MS/MS 
spectrum of δ-valerolactam standard, (e) selected ion mobility spectrum for m/z 
100.07, (f) selected ion mobility spectrum for δ-valerolactam. (Data produced on 
Synapt HDMS) 
The retention time, MS/MS spectrum and ion mobility drift time of the biomarker ion 
m/z 100.07±0.02 in the pooled saliva samples matched that of δ-valerolactam (Figure 
4.13). This provides strong evidence for the assignment of this molecule as a potential 
biomarker of exercise induced physiological stress. δ-valerolactam is included in the 
human metabolome database (reference number HMDB11749) as a known metabolite 
present in saliva (Wishart et al. 2013). It has been shown in mouse models to result from 
the metabolism of cadaverine (Callery & Geelhaar 1984), which is known to be present 
at part per million levels in human saliva as a potential source of δ-valerolactam (Cooke 
et al. 2003). The physiological role of δ-valerolactam is not well understood and the 
effects of exercise and other stresses on its metabolism are at present unknown.  
 149 
 
4.6 CONCLUSIONS 
This study demonstrates proof of principle in a pilot study with a small number of 
participants that ion mobility data may be acquired within the timescale of an UHPLC-
MS experiment for metabonomic analysis of saliva. The combination of UHPLC with 
IM-MS provides an added dimension enabling enhanced separation of co-eluting 
components of complex metabonomic samples on the basis of retention time, ion 
mobility and mass-to-charge ratio in a single 10-minute chromatographic run.  
The results show the potential of the UHPLC-IM-MS technique for the targeted and the 
global metabolic profiling analysis of saliva and other biological fluids, and for the 
subsequent biomarker discovery process. In this study, δ-valerolactam has been 
identified as a potential biomarker in saliva of exercise-induced physiological stress on 
the basis of retention time, MS/MS spectrum and ion mobility drift time compared to a δ-
valerolactam standard. The advantages of ion mobility spectrometry with UHPLC-MS 
for discovery and identification of metabolites from metabolite profiling studies have 
been demonstrated. This work shows the potential of hyphenated ion mobility mass 
spectrometry for non-hypothesis driven discovery-based metabolomic study. 
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5 CHAPTER FIVE:  
CONCLUSIONS AND FURTHER WORK 
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5.1 THESIS OVERVIEW 
This thesis describes analytical methods for the detection of metabolic biomarkers of 
disease and physiological change. The research was directed towards the development 
and application of novel analytical techniques, based on mass spectrometry and ion 
mobility spectrometry, and bioinformatics strategies for the identification of 
diagnostic/prognostic biomarkers. Methods have been developed based on UHPLC-MS 
alone and in combination with ion mobility spectrometry (UHPLC-IM-MS) for 
untargeted metabolite profiling of biofluids such as saliva and mouse plasma. The 
applications of these methods include investigations on biomarkers of the efficacy of 
colorectal cancer preventative treatment, diagnostic biomarkers of asthma and 
physiological stress. 
The individual chapters are summarised in the following sections and directions for 
further work are proposed. 
5.1.1 Summary of chapter one 
Chapter one covers the theoretical principles of ion mobility spectrometry (IMS), mass 
spectrometry (MS) and multivariate statistical analysis (MVA) techniques. An account of 
modern day metabolomics, physiology and the application of saliva as a diagnostic 
medium is presented. The chapter also provides a review of analytical techniques used in 
metabolite profiling of biofluids with particular emphasis on salivary metabolite 
profiling. 
5.1.2 Summary of chapter two 
Chapter two demonstrates the potential of tri-wave ion mobility spectrometry in 
combination with ultra-high performance liquid chromatography and mass spectrometry 
for the metabolic analysis of mouse plasma. Untargeted metabolite profiling analysis of 
mouse plasma was carried out with minimal sample pre-treatment, involving only 
protein precipitation, to assess the chemopreventive efficacy of rice bran in colorectal 
cancer. Plasma derived from APC
min
 mice, a well-established model for colon 
carcinogenesis, was used for untargeted metabolite profiling and potential biomarker 
discovery. The UHPLC-IM-MS method was shown to yield improvements compared to 
conventional metabolite profiling methods based on HPLC-MS in the following manner: 
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 The UHPLC-IM-MS method offered increased analytical space for untargeted 
metabolite profiling of mice plasma. This was achieved by a multi-dimensional 
separation of analytes based on UHPLC retention times, ion mobility and mass-
to-charge ratios in a single 10 minute chromatographic run.  
 The cycle time for the analysis of samples was 15 minutes with column clean-up 
and conditioning phases built into the UHPLC gradient method, which is ideal for 
high throughput analysis of metabolomic samples. 
 The improvement of mass spectral data quality obtained by the removal of 
polyethylene glycol (PEG) contamination from the samples using post-
acquisition processing was successfully demonstrated.  
 Potential biomarker ions of efficacy of rice bran supplementation in colorectal 
cancer were identified. 
5.1.3 Summary of chapter three 
Chapter three presents the development and application of a robust methodology based 
on UHPLC-MS for salivary metabolite profiling and the discovery of potential 
biomarkers of asthma. The specific outcomes from this study are: 
 A method has been developed and established for metabolite profiling of saliva 
using UHPLC-MS. 
 The analytical method has been characterised (i.e. validated) on the basis of the 
reproducibility and dynamic range of the method. 
 Unsupervised multivariate data analysis methods have been utilised after logical 
data reduction procedures to reduce the complexity of the very large dataset 
obtained from untargeted metabolite profiling studies. 
 Ten potential metabolite biomarker ions of asthma have been identified from the 
moderate asthmatics in the study with their tentative elemental composition 
assignments. 
 A predictive model based on partial least squares – discriminant analysis (PLS-
DA) has been constructed using the ten discriminant ions, which shows good 
predictive capability for moderate asthmatics and controls. The predictive model 
was used to test its ability to classify mild asthmatic population. 
 155 
 
 Current methods for diagnosis of asthma - FEV1%, methacholine challenge and 
blood eosinophil level - all use invasive sample collection methods and thus 
cause patient discomfort. The developed method has been proposed to be used in 
conjunction with existing methods or as a preliminary screen for the diagnosis of 
asthma as passive drool sampling of saliva is carried out non-invasively.  
5.1.4 Summary of chapter four 
The potential of ion mobility in combination with existing ultra-high performance liquid 
chromatography and mass spectrometry methods for the untargeted metabolite profiling 
of saliva is demonstrated in Chapter four. The method developed is based on protein 
precipitation and UHPLC-IM-MS, along with multivariate data processing strategies for 
global metabolite profiling of saliva. The specific outcomes from the study were: 
 The developed method utilises <1 mL volume of saliva (i.e. 500 µL), which is 
easily obtainable by passive drool method. The sample pre-treatment involves 
only protein precipitation as a clean-up stage. 
 The chromatographic gradient for UHPLC-IM-MS analysis of saliva was 
optimised while maintaining the analysis cycle time at 15 minutes, which is 
advantageous for high throughput metabolite profiling analyses. 
 Ion mobility (IM) separation was optimised for untargeted salivary metabolite 
profiling by UHPLC-IM-MS. 
 The developed UHPLC-IM-MS method was characterised (i.e. validated) by 
assessing the reproducibility and dynamic range of the analytical method using 
endogenous metabolite ions thus accounting for matrix effects. These factors are 
important considerations for identification of up-regulated or down-regulated 
metabolite ions. 
 The advantages of using ion mobility for targeted analysis and its advantages for 
enhancing the selectivity of target metabolites have been illustrated. 
 The developed method has been successfully applied to a metabolite profiling 
study to discover potential biomarker ions of physiological stress. 
 Valerolactam has been identified as a potential biomarker of physiological stress 
from saliva by comparison of retention time (tR), ion mobility drift time and 
MS/MS spectra with purchased standard of δ-valerolactam.  
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5.2 FUTURE DIRECTIONS 
5.2.1 Validation of biomarkers 
Studies described in this thesis have been of pilot study nature with relatively small 
number of participants/patients as compared to large scale metabolomic studies. This has 
been the case as the research described focuses more on method development for 
profiling of biofluids. Although the analytical methods described in this research have 
been validated, the output, which is the identified potential biomarker ions, is yet to be 
validated. 
Many studies in metabolomics suffer similar problems with relatively small number of 
samples and thus await validation of the outputs, the accepted strategy for validation 
being to analyse a larger sample set and to use quantitative MS methods. All but one of 
the potential biomarker ions identified from the three studies (colorectal cancer, asthma 
and physiological stress) described in this thesis need to be identified by comparison 
with analytical standards using criteria such as UHPLC retention time, accurate mass, 
MS/MS spectrum and ion mobility drift time as illustrated by the example of 
valerolactam in Chapter Four. 
It is proposed that the quantification of the identified metabolites such as valerolactam be 
carried out using a multiple reaction monitoring (MRM) method by using UHPLC-
MS/MS with an internal standard with a larger cohort of samples. The internal standard 
in this case ideally would be deuterated-valerolactam or a molecule/derivative from 
piperidine family such as Methimazole (Anon 2013). 
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5.2.2 Combined metabolomics and proteomics sample pre-treatment 
The integration of all ‘–omics’ sciences under the umbrella of systems biology is gaining 
interest worldwide. Metabolomic and proteomic studies, however, typically involve 
different sample preparation steps. This is a significant roadblock in combined 
metabolomic and proteomic studies especially where sample quantity is limited or 
precious. 
The sample pre-treatment by protein precipitation employed in this research is a 
straightforward process which removes proteins from saliva by a simple acetonitrile 
crash method. The interference or contamination of the sample with external reagents or 
compounds is minimal as only an organic solvent – acetonitrile is used during sample 
pre-treatment. A major potential advantage offered by this method is, it can facilitate 
designing of metabolomic and proteomic studies from the same sample, as the 
metabolomics part of the project will utilise the supernatant obtained from the sample 
pre-treatment whereas the precipitated proteins pellet remaining behind can be digested 
and utilised for proteomic studies. Protein precipitation employed during this research is 
capable of extracting polar and non-polar metabolites with minimal degradation and 
efficiently extract proteins from complex biofluid such as saliva for both metabolomic 
and proteomic studies. This presents a viable opportunity to combine sample preparation 
for integrated metabolomic and proteomic studies. 
 
Figure 5.1 Combined sample pre-treatment strategy for metabolomics and 
proteomics. 
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5.2.3 FAIMS for metabolomics 
Field asymmetric waveform ion-mobility spectrometry (FAIMS), which is also known as 
differential mobility spectrometry (DMS), is an ion mobility based electrophoretic 
technique (Kolakowski & Mester 2007; Nazarov 2012). High-Field Asymmetric 
Waveform Ion Mobility Spectrometry (FAIMS) is a gas phase separation technique that 
exploits the difference in the mobility of an ion in low and high electric fields to separate 
ions in mixture. FAIMS has previously been demonstrated to be a highly effective 
separation step prior to mass spectral analysis (Brown et al. 2010). This technique is yet 
to be used for global metabolic profiling analysis. With instrumental developments and 
data collection strategies in FAIMS, there is a potential for this technology to be used for 
metabolite profiling analysis.  
Preliminary work was carried out on method development for metabolite profiling of 
saliva by UHPLC-FAIMS-MS. Sample collection and pre-treatment of saliva was carried 
out according to the established methods described in this thesis. Analysis was carried 
out using a prototype miniaturised ultra-FAIMS device (Owlstone, Cambridge, UK) 
combined with a UHPLC-MS setup. The UHPLC-MS setup consisted of an Agilent 1200 
series HPLC system interfaced with an Agilent 6230 time-of-flight mass spectrometer 
(Agilent Technologies, Santa Clara, CA, USA). 
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Figure 5.2 UHPLC-FAIMS-MS analysis of saliva extract. Black trace denotes 
UHPLC-MS analysis of saliva extract and green trace denotes the analysis of saliva 
using UHPLC-FAIMS-MS. 
Figure 5.2 shows the comparison between analysis of saliva extract using UHPLC-MS 
and UHPLC-FAIMS-MS. The miniaturised ultra-FAIMS device used enables FAIMS 
scan rates of <2 seconds which enable c.a. 4 scans within a UHPLC chromatographic 
peak (assuming ~8 second peak width). However, since the miniaturised ultra-FAIMS 
device and mass spectrometric data acquisition software were controlled by separate 
software, the start points of the analysis by the FAIMS module and the mass 
spectrometer module could not be synchronised over multiple runs. As a result due to 
these limitations of the software, the analysis of saliva extract by UHPLC-FAIMS-MS 
could not be further investigated. However, with future software developments, the 
utility of FAIMS in conjunction with UHPLC-MS in metabolic profiling studies could be 
explored. 
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5.3 SUMMARY OF THESIS 
The research presented in this thesis has shown the potential of the use of a non-
invasively obtained biofluid – saliva- in disease diagnosis by discovery of potential 
biomarkers from metabolite profiling studies. 
The research has also sought to explore the analytical potential of the use of ion mobility 
spectrometry in combination with existing UHPLC-MS based techniques for targeted 
and untargeted metabolite profiling studies on biofluids. The additional dimension of 
separation offered by IM has demonstrated improvement in mass spectral data quality, 
enhancement in selectivity for targeted metabolite analysis as well as has aided in 
identification of potential biomarker molecules.  
The field of metabolomics and untargeted metabolite profiling in particular is expected 
to continue to grow in the upcoming decade with applications in fields as varied as 
cancer research, food science and nutritional research, personalised medicine, drug 
toxicity, drug discovery, drug metabolism and pharmacokinetic (DMPK) studies. These 
studies will provide new insights into integrated systems biology. Metabolomics being a 
technologically driven science, developments in instrumentation such as ion mobility and 
field asymmetric waveform ion mobility spectrometry along with new data analysis 
strategies are expected  become valuable tools in the future development of metabolic 
profiling. 
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7 Appendix 2 – Workflows 
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7.1 SALIVA SAMPLING PROTOCOL 
Requirements: 
 Chromacol® Universal glass vials with screw caps (30mL) will be used for 
the collection of whole saliva from the participant. 
 Eppendorf® LoBind microcentrifuge tubes 2.0mL will be used for aliquoting 
and storage of saliva samples. 
 Micropipette (1000μL volume) and pipette tips for aliquoting the saliva and 
plasma samples. 
 BD Vacutainer® LH (10.0mL) blood collection vial for blood plasma. 
Setup: 
 Centrifuge set up at 4oC and 1500g, timed for required duration (15 minutes) 
for processing blood into plasma. 
 Ice box with dry ice for storing of aliquoted samples prior to transport to -
80
o
C freezer. 
Things to Avoid Prior to Sampling: 
The participant should be asked NOT to: 
 Consume alcohol 24 hours prior to the sample collection. 
 Brush their teeth 1 hour prior to sampling. 
 Have a large meal, dairy products, tea/coffee or salivary stimulants such as 
lemon-drops, chewing gum etc. within 1 hour prior to sample collection. 
Things to Document Prior to Sampling: 
 Date and time of the sample collection should be noted. 
 Prescription and over-the-counter medication taken should be documented. 
 Caffeine and Nicotine consumption/habits should be noted. 
 Participants should be scanned for oral health problems or injuries. 
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Protocol: 
The participant will be briefed about the sampling procedures. 
The participant will be asked to drink approximately half a glass of unflavoured 
drinking water 10 minutes prior to the beginning of saliva sampling by passive 
drool method. This aids in stimulating saliva production. 
Blood sampling will be carried out during these 10 minutes before the start of 
passive drool sampling. 10mL of blood will be collected which corresponds to 
approximately 5mL of plasma. 
BD Vacutainer
®
 LH vial with the collected blood, will be placed in centrifuge for 
processing blood into plasma. 
At the end of 10 minutes, participant will be issued with a saliva collection vial 
i.e. universal glass vial (30mL) 
The participant will be asked to sit comfortably with their head tilted forward; 
this should allow saliva to pool in front of the mouth. 
The participant should be encouraged to avoid the instinct to swallow as well as 
roll the tongue around in mouth as this stimulates saliva production. 
After about 1 minute, there should be enough saliva pooled in front of the mouth 
such that the participant will be able to dribble it in the collection vial. This 
process should be continued for a total of 10 minutes. 
At the end of which the collection vial will be handed back to the investigator for 
aliquoting and storage. 
Sputum sampling will be carried out next for participants willing to continue. 
Aliquoting and Storage: 
Whole saliva will be kept cold (4
o
C i.e. on ice) immediately after collection. 
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The investigator will then aliquot the saliva from collection vial in 600μL 
aliquots in Eppendorf
® 
LoBind microcentrifuge tubes (2.0 mL) with the help of 
micropipette. 
Care should be taken to avoid the foam part of the saliva while aliquoting. 
Saliva being a viscous fluid, slow aspiring with the micropipette is important for 
accurately transferring the desired amount for aliquoting. 
Aliquoted saliva samples should be immediately transferred to the ice box 
containing dry ice. 
Plasma should be aliquoted as 1mL aliquots in 3 Eppendord LoBind
®
 
microcentrifuge tubes (total 3mL plasma). 
Plasma samples should be transferred to the ice box containing dry ice 
immediately after aliquoting. 
At the end of sampling, all the samples should be transferred to the -80
o
C freezer 
as soon as possible for storage.  
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7.2 SALIVA SAMPLE COLLECTION WORKFLOW 
  
Rinse mouth 10 minutes prior to sample collection 
Issue saliva sample collection vial 
Sit comfortably with head titled forward 
Allow saliva to pool in front of the mouth 
Dribble pooled saliva in the collection vial every 1 to 2 
minutes 
Stop when required amount i.e. ~ 2 mL is obtained 
 x 
 
7.3 ALIQUOTING AND STORAGE PROTOCOL 
 
  
Keep collected whole saliva cold (~4oC 
i.e. on ice) 
Divide the whole saliva into aliquots in 
Eppendorf LoBind tubes 
Avoid foam part of saliva while 
aliquoting 
Ensure slow aspiration of saliva while 
using micropipettes for optimum 
accuracy 
Label aliquoted samples 
Freeze at -80oC as soon as possible 
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7.4 SALIVA SAMPLE PRE-TREATMENT WORKFLOW 
  
500 μl Saliva in Eppendorf LoBind 2.0ml 
Ultrasonication 
10 minutes 
Acetonitrile Addition (1 ml) 
Vortex 
30 Sec 
Ultrasonication 
10 minutes 
Centrifugation 
10 minute, 10,000 g, Ambient Temp. 
Transfer 
Supernatant to Eppendorf LoBind 2ml 
Evaporation/Concentration 
Turbovap,  45 min 
Making up sample 
Reconstitute the dried extract in 50 μl in 95:05 Water/ACN 
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7.5 COLORECTAL CANCER – RUN ORDER 
 
  
Run No. Sample No. Description Run No. Sample No. Description
2 CONDITIONING 49 19 C3
3 CONDITIONING 50 Blank
4 CONDITIONING 51 20 B2
5 CONDITIONING 52 Blank
6 Blank 53 QC
7 1 A5 54 Blank
8 Blank 55 21 C4
9 2 D2 56 Blank
10 Blank 57 22 B1
11 3 B4 58 Blank
12 Blank 59 23 C2
13 4 C15 60 Blank
14 Blank 61 24 A4
15 5 C7 62 Blank
16 Blank 63 25 C6
17 QC 64 Blank
18 Blank 65 QC
19 6 C1 66 Blank
20 Blank 67 26 C13
21 7 C10 68 Blank
22 Blank 69 27 C11
23 8 D7 70 Blank
24 Blank 71 28 D8
25 9 D1 72 Blank
26 Blank 73 29 C16
27 10 A7 74 Blank
28 Blank 75 30 C9
29 QC 76 Blank
30 Blank 77 QC
31 11 C12 78 Blank
32 Blank 79 31 D4
33 12 D3 80 Blank
34 Blank 81 32 C14
35 13 A6 82 Blank
36 Blank 83 33 A2
37 14 C8 84 Blank
38 Blank 85 34 C5
39 15 D6 86 Blank
40 Blank 87 35 A1
41 QC 88 Blank
42 Blank 89 QC
43 16 B3
44 Blank
45 17 A3
46 Blank
47 18 D5
48 Blank
 xiii 
 
7.6 ASTHMA PATIENT INFORMATION 
Column Explanations: 
 Patient ID 
 BDP equivalent: How much inhaler steroid a patient is taking each day (e.g. 
200mcg perday) 
 Gender: 0=male 1=female 
 When diagnosed: 0=<1 year 1= 1-5 years 
 Rhinitis 0=no 1=yes 
 GO reflux 0=no 1=yes 
 Oral contraceptive pill 0=no 1=yes 
 Ezcema 0=no 1=yes 
 Non-steroidal anti-inflammatory allergy 0=no 1=yes 
 Family history of allergy 0=no 1=yes 
 JACQ: symptom questionnaire: higher the number the worse the symptoms 
 V1IGE: Blood IGE level 
 V1SRMEOS: Blood eosinophil level 
 NO values: 10,30,50,100,200 
 FEV1 
 FEV1% pred: >80% = less likely to have asthma <80% more likely to have 
asthma (all patients with a value <80% are highlighted in red). 
 FVC 
 FVC%pred 
 FEV1/FVC ratio 
 V1eos: sputum eosinophil count: >3% =more likely to have asthma (all patients 
with a value >3% are highlighted in red). 
 Neutrophils 
 Macrophages 
 Lymphocytes 
 Epithelial 
 SPT: skin prick test 0=no 1=yes 
 Aspergillus 
 Number of + spt each patient had 
 PC20 = methacholine challenge (<8mg/ml = more likely to have asthma all 
patients with a value of less than 8 are highlighted in red). 
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PatientID BDP Equiv V1 BDP Daily Gender DOB WhenDiagnosed Height Weight BMI Rhinitis GOReflux OralCon Eczema NSAID Family
(cm) (kg)
1 Female 19/04/1966 167 47.6
2 Male 10/06/1986 181 75.4
3 Female 26/12/1948 NR NR
4 200 200 Male 28/12/1941 1 171 78.1 26.70907288 0 0 0 0 0 0
5 1000 1000 Female 18/04/1953 1 162 58 22.10028959 0 0 0 0 0 1
6 800 800 Male 15/03/1937 1 172 74.9 25.31773932 0 0 0 0 0 0
7 400 400 Female 08/02/1943 1 153 62 26.48553975 0 0 0 0 0 0
8 400 400 Female 05/03/1947 1 158 62.3 24.95593655 0 0 0 1 0 1
9 400 400 Male 26/02/1952 1 181 86 26.25072495 0 0 0 0 0 0
10 200 200 Male 21/09/1953 1 174.5 90.5 29.72060985 1 0 0 0 0 0
11 800 800 Male 04/11/1959 1 179 96 29.96161169 0 0 0 0 0 1
12 400 400 Male 27/09/1942 1 168 76 26.92743764 0 0 0 0 0 0
13 400 400 Female 04/08/1985 1 171 81 27.70083102 0 0 1 1 0 1
14 Male 17/05/1992 184 69
15 Female 04/07/1992 166 87.3
16 400 400 Female 25/07/1954 1 170 65.5 22.66435986 0 0 0 1 0 0
17 Female 11/04/1989 158 67.9
18 400 400 Male 25/04/1961 1 163 63 23.71184463 0 0 0 1 0 0
19 800 800 Female 16/05/1940 1 170 88 30.44982699 0 1 0 1 0 1
20 400 400 Female 08/11/1971 1 149 69.2 31.16976713 0 0 0 1 1 1
21 400 400 Male 03/05/1938 1 170 80 27.6816609 1 1 0 0 0 0
22 400 400 Female 14/02/1951 1 173 80.6 26.93040195 0 0 0 1 0 1
23 800 800 Male 17/10/1960 1 178 107.6 33.96035854 1 1 0 0 0 0
24 800 800 Female 26/07/1959 1 177 89.3 28.50394203 0 1 0 0 0 0
25 400 400 Female 11/01/1945 1 156 55.2 22.68244576 0 1 0 0 0 0
28 800 800 Female 12/06/1972 1 171 146.4 50.06668719 0 1 0 1 0 0
29 400 400 Female 04/01/1945 1 162 73 27.81588173 1 1 0 1 1 0
30 800 800 Female 24/06/1943 1 155 70 29.13631634 1 1 0 1 0 0
31 400 400 Male 28/06/1970 1 168 90.6 32.10034014 0 0 0 0 0 0
32 200 200 Male 01/07/1943 1 182 72.9 22.00821157 0 0 0 0 0 0
33 2000 2000 Male 03/05/1947 1 173 101 33.74653346 0 0 0 0 0 0
34 Female 10/03/1976 NR NR
35 50 50 Male 22/02/1974 1 183 99.7 29.77096957 1 1 0 0 0 0
36 800 800 Male 03/10/1956 0 173 82.3 27.49841291 0 0 0 0 0 0
37 2400 2400 Male 17/12/1949 1 174.5 91.7 30.11469528 0 0 0 0 0 1
38 Female 26/04/1959 158 48
39 Female NR NR NR
40 Female 22/07/1990 170 78.2
41 Female 17/02/1992 167 62.4
42 Female 03/12/1990 159 55.7
43 Female 05/02/1992 172 53.3
44 800 800 Female 15/06/1945 1 166 57.1 20.72143998 0 0 0 0 0 0
45 400 400 Female 23/03/1941 1 161 66 25.46198063 0 0 0 1 0 1
46 100 100 Female 31/03/1978 0 167 56 20.07960128 0 0 0 1 0 1
47 Female NR NR NR
48 Male 05/05/1985 163 60
49 Male NR NR NR
50 Female 12/12/1987 178 63
51 Male 17/01/1952 185 95
52 Male 31/10/1988 173 95
53 Female 31/12/1952 165 90
54 Male 13/09/1984 185 79
55 Male 12/08/1992 NR NR
56 400 400 Male 11/06/1943 1 173 76.4 25.52708076 0 0 0 0 0 0
57 400 400 Female 16/05/1980 1 170 63.6 22.00692042 0 0 1 0 1 1
58 1000 1000 Female 24/06/1973 1 167 87 31.19509484 0 0 0 0 0 1
59 400 400 Female 18/01/1963 1 169 67 23.45856238 0 0 0 1 0 1
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PatientID V1JACQ1-5 V1JACQ1-6 V1JACQ1-7 V1IGE V1SRMEOS MEANV1NO10 MEANV1NO30 MEANV1NO50 MEANV1NO100 MEANV1NO200 V1Alv V1Bronch V1DNO V1FEV1
1
2
3
4 0.8 0.67 1 222 0.2 33.6 23.7 11.9 7.25 2.1 61.2 0.8 2.35
5 1.4 1.33 1.8 1160 0.4 163.3 121.9 57.8 29.4 0.9 340.2 0 1.5
6 0.2 0.17 0.43 324 0.4 135.7 56.25 38.6 21.7 13.25 6.2 89.1 0.9 2.27
7 0.6 0.67 0.57 4 0.1 19.8 14.35 7.15 5.45 2.8 31.3 0.7 1.85
8 0.2 0.17 0.71 184 0.1 73.1 24.4 15.65 10.2 5.9 2.5 41.5 0.8 1.38
9 0.2 0.3 1 91 0.1 18.55 12.55 7.8 5.45 3.1 28.3 1 1.9
10 1 0.83 1.29 91 0.6 56.25 51.55 26.05 15.55 6.5 112.9 0.7 2.26
11 1 0.8 1 98 0.5 30 20.75 12.7 7.7 3.6 51.1 0.9 3.08
12 0.5 0.33 0.57 3 0.5 59.95 39.75 21.85 5.2 101.1 0.8 2.4
13 0 0 0.57 109 0.4 115.65 44.15 29.2 15.2 8.3 2.3 74.9 0.8 2.32
14
15
16 0 0.17 0.71 10200 0.2 204.8 91.3 64.35 36.35 18.65 6.4 160.5 0.6 1.97
17
18 0 0 0.57 22610 0.5 77.15 34.85 26.3 13.95 8.65 4.4 54.5 0.8 2.02
19 0.6 0.5 1.14 382 0.1 36 33.65 17.45 7.7 1.1 89.1 0.1 1.35
20 0 0 0.29 114 0.3 26.8 17.8 10.35 7.75 4.3 39.6 0.9 2.07
21 0.8 0.7 0.6 133 0 26.1 21.95 11.8 7.95 4.2 46 0.8 3.15
22 0.2 0.17 0.71 303 0.3 82.4 32.6 25.2 15.1 7.7 3.5 57.1 0.6 1.65
23 1.6 1.67 1.43 93 0.2 44.15 27.35 15.2 9.05 6.5 3.8 32.9 0.8 3.58
24 0.8 1 1.14 0.4 34.65 19 12.95 8.05 3.7 52.6 0.7 2.4
25 0 0 0.29 28 0.3 75.6 29.8 15.55 10 5.25 1.4 47.3 0.4 1.72
28 0.4 0.33 0.86 75 0.2 13.3 9.35 6.2 2.35 -0.2 32.6 0 2.3
29 0 0 0.43 101 0.3 88.7 39.3 20.95 12.5 8.5 3.6 56.7 0.6 1.63
30 1 1 1.57 126 0.6 20.7 13.4 8.05 3.7 54.3 0.8 1.32
31 0 0 0 38 0.1 22.7 17.1 9.8 4.65 1.1 45.4 0.2 4.25
32 0 0.16 0.57 315 0.1 116.6 59.65 42.15 23.15 12.75 5.1 98.6 0.7 2.53
33 1 1 1.57 223 0.7 89.2 61.6 39.25 20.9 8.4 160.8 0.8 1.82
34
35 0.8 0.83 1.29 154 0.1 93.1 38.65 21.95 13.25 8.35 3.6 57.9 0.9 2.6
36 0.2 0.33 0.29 139 0.4 37.6 26.9 14.35 8.45 2.9 67.6 0.5 3.45
37 1 1 0.86 40 0.5 134.05 95.05 55.9 33.55 15 231.1 0.9 3.28
38
39
40
41
42
43
44 1.2 1.17 1 77 0.4 17.3 57.1 119 1 2.55
45 0.2 0.17 0.14 3 0.1 30.45 17.25 11 6.95 3 46.8 0.8 2.01
46 0 0 0 22 0.1 12.2 10.25 6.1 2.9 1 25.4 0.4 2.6
47
48
49
50
51
52
53
54
55
56 0.4 0.33 0.57 62.1 36.25 28.95 15.35 8.65 4.7 55.2 0.6 2.8
57 1 0.83 0.71 0.1 12.25 7.45 2.75 3.8 2.4 13.3 0.5 3.4
58 1 1 1.14 149 0.3 22.2 15.6 9.5 5.45 2.4 39.1 0.9 2.45
59 0.8 0.67 0.57 36 0.2 7.8 4.3 1.95 0.5 -0.8 15.6 0.5 3.4
 xvi 
 
 
  
PatientID V1FEV1%PRED V1FVC V1FVC%PRED V1FEV1/FVC V1EOS V1NEUTS V1MACROS V1LYMPH V1EPITH V1SPTDONE V1HIST V1SAL V1PC20 NO category
1
2
3
4 79 3.05 75 0.77 0.5 88.5 10.75 0 0.25 1 1 0 2.99 0
5 59 2.8 100 0.5 10.75 16 68.5 0 4.75 1 1 0 0.03 2
6 81 3.35 91 0.68 20.75 67.75 11 0 0.5 1 1 0 32 1
7 105 2.4 112 0.77 0 47 40.75 0.25 12 1 1 0 32 0
8 67 2.55 103 0.54 1 1 0 2.3 0
9 54 3.5 74 0.54 0.5 63.5 34.75 0 1.25 1 1 0 7.56 0
10 67 3.45 82 0.66 6 26.5 40 1 26.5 1 1 0 2.52 2
11 82 4.48 96 0.69 1.75 72.82 22.44 0.25 2.74 1 1 0 6.63 0
12 87 4.15 116 0.58 19 49.75 24.75 0.25 6.25 1 1 0 32 1
13 66 3.15 78 0.74 1 1 0 0.5 1
14
15
16 67 3.4 90 0.58 0.25 46 51.75 0.25 1.75 1 1 0 1.17 2
17
18 65 3.63 96 0.56 4.75 41.75 53.5 0 0 0 0 0 0.59 1
19 53 2 63 0.68 0.75 63.5 24.5 1 10.25 1 1 0 8 1
20 88 2.65 97 0.78 1.5 46.25 51 0.25 1 1 1 0 2 0
21 99 4.45 106 0.71 0 38.5 60.75 0.25 0.5 1 1 0 32 0
22 63 2.2 66 0.75 0.75 41 57 0.25 1 1 1 0 1 1
23 97 5 107 0.72 0.5 78 17.75 1.75 2 1 1 0 0.03 0
24 80 3.2 88 0.75 0.25 99.5 0 0 0.25 1 1 0 0 0
25 81.1 3 107.5 0.57 1 1 0 7.16 0
28 68 3.15 76 0.73 0.8 91.4 7.4 0.4 0.2 1 1 0 6.35 0
29 76 2.6 101 0.63 0.75 91.25 7.75 0 0.25 1 1 0 32 0
30 57 2 64 0.66 9.5 32 54.25 0 4.25 1 1 0 8 0
31 107 5.3 109 0.8 1 64 31 2 2.5 1 1 0 32 0
32 73 4.6 103 0.55 0 100 0 0 0 1 1 0 32 1
33 58 2.85 71 0.64 19.5 29.75 29.5 0 21.25 1 1 0 2 2
34
35 60 3.95 75 0.66 1 1 0 16 0
36 97 4.5 97 0.77 1 1 0 32 1
37 101 4.25 102 0.77 11 74.5 13.75 0 0.25 1 1 0 15.79 2
38
39
40
41
42
43
44 116 3.33 115 0.77 1 0 0 32 0
45 100 2.65 110 0.76 0.25 83.75 13.5 2.5 0.25 0 0 0 1 0
46 82 3 82 0.87 1 1 0 0
47
48
49
50
51
52
53
54
55
56 87 3.8 93 0.74 1 1 0 32 1
57 102 4 104 0.85 1 1 0 32 0
58 88 3.1 88 0.79 1 1 0 0
59 118 4.6 137 0.76 1 1 0 32 0
 xvii 
 
7.7 ASTHMA SCHEME OF ANALYSIS (RUN ORDER) 
Serial 
No. 
Participant 
Sample 
Code 
Vial 
Code 
Asthmatic Control Gender Run Number 
1 Blank - - - - - AM_Saliva_001 
2 Standard - - - - - AM_Saliva_002 
3 Blank - - - - - AM_Saliva_003 
4 CR1 QC 1 - - - - AM_Saliva_004 
5 CR2 QC1 - - - - AM_Saliva_005 
6 CR3 QC1 - - - - AM_Saliva_006 
7 CR4 QC1 - - - - AM_Saliva_007 
8 CR5 QC1 - - - - AM_Saliva_008 
9 QC1 QC1 - - - - AM_Saliva_009 
10 54 MAA054 70406 1 
 
M AM_Saliva_010 
11 28 MAA028 65609 1 
 
F AM_Saliva_011 
12 55 MAA055 70773 
 
1 M AM_Saliva_012 
13 3 MAA003 54386 
 
1 F AM_Saliva_013 
14 56 MAA056 70788 1 
 
M AM_Saliva_014 
15 QC2 QC2 - - - - AM_Saliva_015 
16 51 MAA051 70376 
 
1 M AM_Saliva_016 
17 49 MAA049 70170 
 
1 M AM_Saliva_017 
18 1 MAA001 52276 
 
1 F AM_Saliva_018 
19 21 MAA021 58279 1 
 
M AM_Saliva_019 
20 10 MAA010 55501 1 
 
M AM_Saliva_020 
21 QC3 QC3 - - 
 
- AM_Saliva_021 
22 58 MAA058 71210 1 
 
F AM_Saliva_022 
23 16 MAA016 56563 1 
 
F AM_Saliva_023 
24 36 MAA036 67893 1 
 
M AM_Saliva_024 
25 7 MAA007 55231 1 
 
F AM_Saliva_025 
26 47 MAA047 70153 
 
1 F AM_Saliva_026 
27 QC4 QC4 - - - - AM_Saliva_027 
28 38 MAA038 67911 
 
1 F AM_Saliva_028 
29 11 MAA011 55510 1 
 
M AM_Saliva_029 
30 20 MAA020 58219 1 
 
F AM_Saliva_030 
31 44 MAA044 68771 1 
 
F AM_Saliva_031 
32 18 MAA018 57366 1 
 
M AM_Saliva_032 
33 QC5 QC5 - - - - AM_Saliva_033 
34 30 MAA030 65801 1 
 
F AM_Saliva_034 
35 12 MAA012 55606 1 
 
M AM_Saliva_035 
36 48 MAA048 70161 
 
1 M AM_Saliva_036 
37 15 MAA015 56191 
 
1 F AM_Saliva_037 
38 19 MAA019 57613 1 
 
F AM_Saliva_038 
39 QC6 QC6 - - - - AM_Saliva_039 
1 
QC 6 DAY 
2 
QC 6 DAY 2 - - - - AM_Saliva_040 
2 6 MAA006 55141 1 
 
M AM_Saliva_041 
3 32 MAA032 66163 1 
 
M AM_Saliva_042 
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4 13 MAA013 56113 1 
 
F AM_Saliva_043 
5 35 MAA035 67776 1 
 
M AM_Saliva_044 
6 25 MAA025 64761 1 
 
F AM_Saliva_045 
7 QC7 QC7 - - - - AM_Saliva_046 
8 41 MAA041 68019 
 
1 F AM_Saliva_047 
9 17 MAA017 57025 
 
1 F AM_Saliva_048 
10 9 MAA009 55492 1 
 
M AM_Saliva_049 
11 33 MAA033 67074 1 
 
M AM_Saliva_050 
12 53 MAA053 70394 
 
1 F AM_Saliva_051 
13 QC8 QC8 - - - - AM_Saliva_052 
14 24 MAA024 64753 1 
 
F AM_Saliva_053 
15 37 MAA037 67903 1 
 
M AM_Saliva_054 
16 23 MAA023 64768 1 
 
M AM_Saliva_055 
17 8 MAA008 55421 1 
 
F AM_Saliva_056 
18 34 MAA034 67637 
 
1 F AM_Saliva_057 
19 QC9 QC9 - - - - AM_Saliva_058 
20 57 MAA057 71207 1 
 
F AM_Saliva_059 
21 5 MAA005 54872 1 
 
F AM_Saliva_060 
22 29 MAA029 65675 1 
 
F AM_Saliva_061 
23 4 MAA004 54737 1 
 
M AM_Saliva_062 
24 43 MAA043 68038 
 
1 F AM_Saliva_063 
25 QC10 QC10 - - - - AM_Saliva_064 
26 2 MAA002 52294 
 
1 M AM_Saliva_065 
27 39 MAA039 67920 
 
1 F AM_Saliva_066 
28 22 MAA022 60258 1 
 
F AM_Saliva_067 
29 40 MAA040 68010 
 
1 F AM_Saliva_068 
30 45 MAA045 68997 1 
 
F AM_Saliva_069 
31 QC11 QC11 - - - - AM_Saliva_070 
32 46 MAA046 70055 1 
 
F AM_Saliva_071 
33 31 MAA031 65811 1 
 
M AM_Saliva_072 
34 52 MAA052 70385 
 
1 M AM_Saliva_073 
35 42 MAA042 68028 
 
1 F AM_Saliva_074 
36 50 MAA050 70182 
 
1 F AM_Saliva_075 
37 QC12 QC12 - - - - AM_Saliva_076 
38 59 MAA059 71230 1 
 
F AM_Saliva_077 
39 14 MAA014 56181 
 
1 M AM_Saliva_078 
40 QC13 QC13 - - - - AM_Saliva_079 
41 BLANK - - - - - AM_Saliva_080 
42 STANDARD - - - - - AM_Saliva_081 
43 BLANK - - - - - AM_Saliva_082 
 
